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Receptor Tyrosine kinases (RTKs) are a family of membrane proteins with extracellular 
ligand-binding domains, single transmembrane domains, and intracellular kinase 
domains. RTKs conduct biochemical signals upon lateral dimerization in the plasma 
membrane.  While RTK activation is postulated to occur in response to ligand binding, 
recent work suggests that some RTKs are capable of forming ligand-independent dimers. 
However, the biological significance of RTK unliganded dimers is not well established, 
and the mechanistic knowledge of RTK signal transduction is incomplete. Here we use a 
methodology that has been specifically developed to study unliganded dimers, in order to 
further our understanding of RTK signal transduction across the plasma membrane.  
We show that the Fibroblast growth factor receptors, FGFRs,  and Vascular endothelial 
growth factor receptor 2, VEGFR2, form dimers in the absence of their ligands, and we 
measure the unliganded dimer stabilities. We show that the transmembrane and 
intracellular domains favor dimerization, while the extracellular domains inhibit 
dimerization. We demonstrate that the unliganded dimers are phosphorylated. We further 
show that the unliganded dimers undergo structural changes in response to ligand 
binding, and this response depends on the identity of the ligand. Such structural changes 
appear to be a critical aspect of FGFR and VEGFR2 signal transduction across the 
plasma membrane. 
The FGF receptors and VEGF receptor 2 harbor many pathogenic mutations, but the 
effects of these mutations on signal transduction are not well understood. Here we study 
five different pathogenic mutations, linked to cancers and growth disorders, and show 
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that these different mutations alter the mechanism of signal transduction in profoundly 
different ways. Thus, our results provide new basic knowledge about RTK signal 
transduction across the plasma membrane in health and disease. 
Thesis advisor and reader: Dr.Kalina Hristova 
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1. Literature review 
1. 1.The plasma membrane. The cell plasma membrane is a bilayer consisting of lipids 
(phospholipids and glycolipids), cholesterol, and proteins in the form of integral and 
peripheral membrane proteins, channels and transporters. The plasma membrane of 
mammals contains five major phospholipids; phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and sphingomyelin. 
The lipid bilayer is critical for membrane protein function.  It also imposes a barrier 
which prevents the passage of ions and water-soluble molecules through the plasma 
membrane (136, 137). 
1.2. Membrane proteins. An estimated 30-40% of mammalian cellular proteins are 
membrane proteins. Proteins are responsible for carrying out specific functions. 
According to the fluid mosaic model of the plasma membrane (137), membrane proteins 
are categorized into two classes: peripheral and integral. Peripheral membrane proteins 
may dissociate from the membrane without disruption of the lipid bilayer. However, 
integral membrane proteins are stably inserted into the bilayer. Most of the integral 
membrane proteins are transmembrane proteins. Examples are the 58 Receptors Tyrosine 
Kinases, and Glycophorin, the integral membrane protein of the red blood cells. In 
mammalian cells, transmembrane proteins span the lipid bilayer as α-helices of 20-27 
hydrophobic amino acids.  The structures of many transmembrane proteins are unknown, 
as they cannot be overexpressed and crystallized. Thus, a variety of other biochemical 
and biophysical methods have been developed over the past few decades to decipher the 
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structural and functional properties of these proteins. Yet, many questions about the 
function of membrane proteins remain unanswered.  
1.3. Receptor Tyrosine Kinases (RTKs). RTKs, first discovered in 1980s, comprise a 
superfamily of 58 single pass transmembrane proteins which are subclassified into 20 
families. RTKs are essential for many aspects of cell life including proliferation, 
metabolism, migration, differentiation and survival (7, 39, 76, 126). All the receptors 
possess a single pass transmembrane domain (TMD), ligand binding extracellular domain 
(ECD), intracellular juxtamembrane domain (JMD), tyrosine kinase domain (TKD) and a 
C-terminus tail (Figure 1). The complex RTK signaling output results from receptor 
dimerization in the two dimensional plane of the plasma membrane. However the 
mechanistic principles and the propensity of receptor dimerization and activation are only 
minimally/partially understood. It is now known that dysregulated RTK signaling results 
in pathologies. RTKs are implicated in initiation and progression of many forms of 
cancers and skeletal disorders either through point mutations or receptor and or ligand 
overexpression (7). Numerous approved therapeutics target various domains of these 






Figure 1. Schematic diagram of Fibroblast growth factor receptor and Vascular 
endothelial growth factor receptor 2 (VEGFR2) and ligands. 
 
1.3.1 Fibroblast Growth Factor Receptors (FGFRs). FGFR1, FGFR2, FGFR3 and 
FGFR4 are involved in embryonic and adult skeletal development. The FGFR 
extracellular domain consists of three Immunoglobulin like (Ig-like) domains, D1, D2 
and D3 with ~ 9-20 amino acid linker regions in between the domains. 18 ligands (FGFs) 
bind to and activate FGFR family members. Human fgfs are 150-300 amino acids long 
and share 30-60% sequence identity. Human fgfs play diverse functions throughout 
embryonic and adult development (29, 30, 40, 145). In adults fgfs play critical roles in 
tissue homeostasis, wound healing and angiogenesis (32, 62). Binding of fgfs to FGFRs 
stabilizes FGFR dimers and is hypothesized (but not proven) to induce a structural 
change of the receptor leading to phosphorylation of key tyrosine residues (including 
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tyrosines located in the activation loop). As many as 20 isoforms in some cases have been 
identified for the FGF receptors. The isoforms are mainly either different at their D3-Ig 
like domain or the length of their C-terminus tail due to alternative splicing. Crystal 
structures of FGF receptor ectodomains have revealed that Domain 2 and 3 (D2-D3) and 
the linker in between are indispensible for ligand (fgf) binding to the receptor (115). The 
mode of ligand binding to FGFRs is bivalent, with two fgfs and two heparin sulphate 
proteoglycans (HSPG) forming a complex with two fgf receptors (128). Moreover 
structural studies have revealed that the two receptors contact each other and HSPG 
molecules at D2. Domain 1 (D1) and the acid box region of FGFRs has been shown to 
play an autoinhibitory role in FGFR ligand induced dimerization (47, 68, 97). FGF 
receptors have been the subject of intense crystallographic studies; however questions 
remain unanswered regarding the unliganded dimerization of these receptors, the role of 
the intracellular domain in FGFR dimerization and the role of various fgfs in receptors 
dimerization and activation.  
FGF/FGFR signaling is involved in an array of biological events inside the cell, however 
the origins of biological specificity largely remain unknown.  FGF/FGFR signaling is a 
major therapeutic target, but only a few strategies have shown promise. Thus, elucidating 
the exact biophysical/biochemical mechanism of FGFR dimerization and activation will 
greatly enhance the drug design for these receptors. In Chapter 1, we study the ligand 
independent and ligand dependent homodimerization of FGFR1, FGFR2 and FGFR3. We 
investigat the role of various domains in FGFR dimerization. Finally we study the effect 




1.3.2 Vascular Endothelial Growth Factor Receptors (VEGFRs). VEGFRs play a 
crucial role in the development of the blood and lymphatic vessels. VEGF ligands 
(VEGFA/B/C/D and PlGF) selectively bind to and activate VEGFRs on endothelial cells. 
Upon ligand binding, VEGFR 1, 2 and 3 are activated by trans-phosphorylation of the 
tyrosines located in the kinase domain and C-terminus tail of these receptors. This 
regulates the formation, growth and stabilization of blood vessels in cancer, diabetes and 
cardiovascular disorders.  
The VEGF receptor extracellular domain is large and consists of seven Ig-like domains 
(D1-D7). Crystal structures of VEGFR2 extracellular domain in the presence of VEGF 
have revealed that ligand binds between D2 and D3 (78). Further biophysical and 
biochemical studies have shown that receptor contacts exist between D4 domains (D4-
D4) and D7 domains (D7-D7) in the liganded receptor structure (65, 120). However, the 
contribution of these contacts to receptor stability remains unknown. VEGFR 
dimerization in the presence and absence of ligands is poorly quantified. It is only known 
that the three VEGF receptors (VEGFR1/FLT1, VEGFR2/FLK1/KDR & 
VEGFR3/FLT4) homo- and heterodimerize in the presence of ligands such as 
VEGFA/B/C/D and PlGF. The receptors are also known to form complexes with the 
VEGF co-receptors (Neuropilins). However, all the possible homo- and heterodimer 
complexes and their interaction propensities are uncharacterized. In particular, there are 
no studies of VEGFR homo-dimerization and activation in the presence and absence of 
ligands. There are no structures for full length VEGFR dimers and the existance of 
VEGFR unliganded dimers has not been addressed by research in the field so far. In this 
dissertation, we have investigated these questions for VEGFR2, the major receptor 
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involved in angiogenesis. In Chapter 2, we study the ligand independent and ligand 
dependent homodimerization of VEGFR2, the role of various domains in receptor 
dimerization, and the effect of various VEGFs on receptor dimerization and structure. We 
also study the effect of four mutations on VEGFR2 dimerization and activation.  
1.4. A Physical-chemical model for FGFR and VEGFR dimerization and activation. 
RTKs transduce signals via lateral dimerization in the plane of the plasma membrane. We 
used a thermodynamic description of receptor dimerization where receptors exist in a 
monomer-dimer equilibrium in the absence of ligands. When ligand binds, the 
unliganded dimers are converted to liganded dimers with different structure. The total 
receptor concentration is [T]=2[d]+[M]. The dimerization constant (k) is defined for the 
following model as: 
       
(1) 
          (2) 
        
 
1.5. Quantitative Imaging FRET (QI-FRET) as a direct dimerization assay.  
Fӧrster resonance energy transfer (FRET) occurs as a result of non-radiative energy 
transfer between a donor fluorophore and an acceptor fluorophore (44). The requirement 
for successful FRET is for the emission spectrum of the donor fluorophore to overlap 
with the excitation spectrum of the acceptor. When the donor and acceptor are at a close 









The QI-FRET method has been described previously (22, 23), but it applied here for the 
first time to full-length RTKs. Soluble YFP and mCherry were produced in E.coli and 
were purified as described previously and in chapter 6  (125).  Purified solutions of YFP 
and mCherry of known concentration were imaged in the donor, FRET and acceptor 
scans, to obtain the calibration constants for the donor and the acceptor, iD and iA, as well 
the bleed-through coefficients for the donor and the acceptor, βD and βA  (81).  A soluble 
linked YFP-mCherry protein was also imaged in the three channels to obtain the gauge 
factor GF as described by Li et al (81). 
Each vesicle co-expressing FGFR-YFP and FGFR-mCherry was imaged in the donor, 
acceptor and FRET channels (Figure S3). The  fluorescence intensities across the plasma 
membrane, ID, IFRET, and IA, in the three channels, were determined as described in detail 
elsewhere (22).  The acceptor concentration in each vesicle, CA , was calculated according 
to (22): 






C      (3) 
 
The sensitized emission of the acceptor in each vesicle was determined as (81): 
DDAAFRETSEN IIII            (4) 
The donor intensity in the absence of the acceptor ID,corr , and the donor concentrations 
(CD) were calculated as: 








      (6) 
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From equations (1) and (4), the total concentration, T, and the acceptor fraction, xA, are 
calculated according to:  








                 (8)
 
The FRET efficiency, E, was calculated using eq.6: 







1       (9)
 
The FRET efficiency was corrected for the so-called “proximity FRET” contribution 
which describes the  close approach of  donors and acceptors  (within distances of 100 Å 
or so) in the membrane without specific interactions  (70, 140, 163). The dimeric fraction 
is determined from the corrected FRET efficiency according to:  
                   
             
                           (10) 
The constant E
~
in equation (8) is the “Intrinsic FRET”, the FRET efficiency in a dimer 
containing a donor and an acceptor. This is a structural parameter, a constant for each 
receptor dimer, which depends only on the separation and the orientation of the two 
fluorescent proteins in the dimer, not on the dimerization propensity. 
       (11) 
 

















Based on the law of mass action, the dimeric fraction can be written as a function of the 














fD                 (12) 
Equations (10) and (11) are used to fit the dimerization model to the data while 
optimizing for two adjustable parameters: the dimerization constant K, and the intrinsic 
FRET, Ẽ.   
The free energy of dimerization is calculated according to: 
)ln(KRTG                                  (13) 
with the standard state defined as 1 receptor/nm
2
. The dissociation constant is 1/K, and is 
reported in units of m
-2
 in Table 1. 






                   (14) 
Thus, measurements of E and xA for each vesicle in this case allows us to directly 
determine the value of the Intrinsic FRET, Ẽ, in each vesicle. Histograms of the measured 
Ẽ are shown throughout the manuscript, such as in Figure 3 in Chapter 1, for example. 
1.6. Significance of RTK measurements in this thesis. 
The work presented in this thesis provides the first thermodynamic measurements of 
intact RTKs in plasma membrane derived from mammalian cells. FGFR1, FGFR2, 
FGFR3, and VEGFR2 were characterized here. Prior to this work, intact RTK 
thermodynamics and ligand induced structural studies have not been possible in native 
mammalian membranes. The QI-FRET method, which was utilizaed here in conjuction 
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with plasma membrane derived vesicles, makes biophysical characterization of RTKs 
possible. 
The achievements in this thesis are as follows: 
We quantified sequence specific interactions of four different RTKs, and a number of 
mutants in the plasma membrane over a wide range of concentrations, using RTKs tagged 
with fluorophores. These donor and acceptor concentrations were determined along with 
FRET efficiency  in order to obtain the donor to acceptor ratio and the total 
concentrations, dimeric fractions, intrinsic FRET (a structural parameter) and free energy 
of dimerization. This is the first measurement of the thermodynamics of RTK 
dimerization. 
 We extensively characterized the plasma membrane-derived vesicles in terms of their 
phospholipid content and their utility for study of RTK interactions. Transient 
transfection in cell based FRET invesitigations results in a large numbers of misfolded 
fluorescent receptors in inner compartments of mammalian cells. This fluorescence 
interferes with plasma membrane measurements. Hence, vesicles are ideal for 
fluorescence based biophysical characterization studies as they are native like and lack 
cytoplasmic content. Additionaly, using plasma membrane-derived vesicles allowed us to 
bypass the need for receptor reconstitution in synthetic vesicles. Reconstitution of full 
lenght RTKs has proved to be extremely challengining and results in improper orientation 
of the receptors inserted in the bilayer.  
All the measrurements performed here accounted for and corrected for proximity FRET 
or stochastic FRET, which has been previousely verified experimentally. This is in 
contrasct to previous studies performed in intact cellular membranes, which do not 
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distinguish beween stochastic and sequence specific FRET for membrane protein 
interactions.  
1.7. Dissertation Objectives.  
The major objective of this thesis project is to enhance our understanding of RTK 
function by employing novel FRET-based experimental methods. These methods yield 
quantitative information about RTK interaction propensities and allow us to monitor 
structural changes that occur due to ligand binding or due to pathogenic mutations. With 
this novel methodology, here we investigate if FGF and VEGF receptors can form dimers 
in the absence of ligand. We study the thermodynamic contributions of the different 
FGFR and VEGFR domains to dimerization. We investigate the effect of pathogenic 
mutations on receptor interactions and structure. We characterize the response of the 
unliganded dimers to ligand binding. The FRET-based measurements are supplemented 
with biochemical activity assays, to establish a link between RTK dimer stability, RTK 
dimer structure, and function. 
The interactions between the receptors are studied in plasma membrane derived vesicles. 
Such vesicles are beginning to be used in biophysical research, but have not been 
characterized thus far. A second objective of this dissertation, therefore, is their 
characterization. A third objective is to optimize the production of fluorescent proteins, as 











Here we demonstrate that the FGF receptors form dimers in the absence of ligand at 
physiological concentrations, and that the unliganded dimers are phosphorylated.  We 
further demonstrate that the unliganded FGFR dimers undergo structural changes upon 
ligand binding, The structural changes in response to fgf1 and fgf2 binding are very 
different, resulting in different phosphorylation of the fgf1 and fgf2-bound dimers. Thus, 
there exist multiple active ligand-bound states for the FGF receptors. We further show 
that, upon fgf1 binding, the TM domains in the FGFR3 dimer engage in helix-helix 
interactions that involve GxxxG-like motifs. Binding of fgf2, however, results in a very 
different TM structure which is closely packed. This structure ensures the smallest 
separation between the TM domains and the highest possible FGFR3 phosphorylation, a 
conclusion which is supported by a strong correlation between TM domain dimer 
structure and kinase phosphorylation, for wild-type FGFR3 and three FGFR3 mutants. 
Furthermore, we show that the pathogenic A391E mutation emulates the structural effects 
of fgf2, trapping FGFR3 in its most active state. This study reveals unexpectedly high 
structural plasticity of the FGF receptor dimer structure, which enables different 
biological responses to different ligands. It also uncovers a novel molecular mecahnsim 




Keywords: Receptor tyrosine kinases, dimerization, intracellular domain, dimer stability 
2.1. Introduction 
The fibroblast growth factor receptor  (FGFR) family includes four receptors that bind 18 
ligands called fibroblast growth factors, using heparin as a co-factor (37, 104, 105, 162). 
The FGF receptors are single-pass membrane proteins, with N-terminal extracellular 
(EC) domains consisting of three imminoglobulin-like subdomains (D1, D2, and D3), a 
transmembrane (TM) domain, and an intracellular (IC) domain with tyrosine kinase 
activity (39, 74, 85). FGFRs transduce biochemical signals via lateral dimerization in the 
plasma membrane. Although not sufficient, receptor dimerization is required for 
activation, as it brings the two catalytic domains in close proximity, allowing them to 
cross-phosphorylate each other on tyrosines in the activation loop (37, 127). This process 
activates the kinases, which now bind adaptor proteins and phosphorylate cytoplasmic 
substrates, thus triggering downstream signaling cascades that control cell growth and 
differentiation (95, 141, 142). The FGF receptors play important roles in all cell types, 
but are most well known for the critical role that they play in the development of the 
skeletal system (35). Their many pathogenic mutations are linked to skeletal, cranial, and 
other developmental abnormalities (74, 151, 161, 162).   
Research over the last decade has brought substantial progress in our understanding of 
FGFR activation, fueled by high resolution structures of isolated FGFR domains (47, 96-
98, 102, 115). Yet, while the general principles of FGFR activation are now known, 
mechanistic knowledge of how the signal is transmitted from the extracellular domains in 
response to ligand binding to the kinases in the FGFR dimers is incomplete, despite very 
active research in the field. To gain insight into the process, here we study the 
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dimerization of FGFR1, FGFR2, and FGFR3, as well as the response of these receptors 
to the ligands fgf1 and fgf2.  
2.2. ABREVIATED METHODS 
Experiments were performed with CHO cells, cultured as described below. For the FRET 
experiments, the receptors were tagged with YFP and mCherry on their C-termini. 
Vesicles were produced from CHO cells using an osmotic stress buffer as previously 
described (33, 123). Vesicles containing donor and acceptor-labeled receptors were 
imaged in the confocal microscope, and analyzed with the QI-FRET method, described as 
a step-by-step protocol in reference (22). The FRET efficiency, the donor concentration 
and the acceptor concentration were determined using equations (1) through (7) in 
Supplementary Material. The dimeric fraction, the dimerization constant and the Intrinsic 
FRET were calculated as decribed in Supplementary Materials, following equations (7) 
through (10). In the case of 100% dimeric receptors, the experiments yield directy the 
Intrinsic FRET in each vesicle (see equation 11 in Supplementary Material).  
Phosphorylation was studied using Western blotting, following protocols given in 
previous publications (54, 56, 57, 59).  
2.2.1. Materials and Methods 
The YFP plasmid was received from Dr. M. Betenbaugh (Johns Hopkins University, 
Baltimore, MD) and the pRSET-mCherry plasmid was obtained from Dr. R.Tsien 
(University of California, San Diego). The plasmids encoding human wild-type FGFR1 
and FGFR2 in the pRK5 vector were received from Dr.M.Mohammadi, NYU. The 
plasmid encoding human wild-type FGFR3 in the pcDNA3.1(+) vector was a gift from 
Dr. D. J. Donoghue, UCSD. All primers were purchased from Invitrogen. 
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For this work, the full length FGFR1 and FGFR2 genes were cloned into the pcDNA 
3.1(+) vector. To accomplish this, the genes were first amplified using Polymerase Chain 
Reaction (PCR) and then each gene was double digested using Hind III and XhoI 
restriction enzymes and ligated into the pcDNA3.1(+) vector. YFP or mCherry genes 
were subsequently fused to the C-terminal tail of each receptor via a 3 amino acid (GGS) 
linker (Figure S1) between the XhoI and XbaI restriction sites in the vector. 
Details about the cloning of FGFR3 EC-TM-(GGS)5-YFP and FGFR3 EC-TM-(GGS)5-
mCherry into the pcDNA 3.1(+) vector are given elsewhere (Chen et al 2010).  For this 
work, the sequences encoding for the EC and TM domains of FGFR1 and FGFR2 were 
amplified by PCR, double digested using HindIII and EcoRI restriction enzymes and 
inserted in place of the FGFR3 EC-TM gene in the FGFR3 EC-TM-(GGS)5-YFP and 
FGFR3 EC-TM-(GGS)5-mCherry plasmid constructs, to produce the FGFR1 EC-TM-
(GGS)5-YFP, FGFR1 EC-TM-(GGS)5-mCherry, FGFR2 EC-TM-(GGS)5-YFP, and 
FGFR2 EC-TM-(GGS)5-mCherry plasmids.  
All the mutant full length FGFR3 constructs were created from the wild-type using 
QuickChange ® II XL Site-Directed Mutagenesis Kit (Stratagene, CA). These constructs 
are shown in Figure S2, and are used in the Western blotting experiments. 
The A374I-G375I-S378I EC+TM FGFR3 mutant and the L377I-G380I-A391 EC+TM 
FGFR3 mutant used in the FRET studies were generated from the full-length mutants. 
The complementary DNA (cDNA) encoding the EC and mutant TM domains was 
amplified using PCR and was double digested with HindIII and EcoRI. The FGFR2 EC-
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TM-(GGS)5-YFP and FGFR2 EC-TM-(GGS)5-mCherry plasmid constructs were also 
double digested with HindIII and EcoRI enzymes, and ligated with the  PCR products. 
2.2.2. Cell culture and transfection for FRET experiments 
 Chinese Hamster Ovary cell (CHO) cells were cultures at 37 ˚C with 5% CO2 for 24h. 
Transfection was carried out using Fugene HD transfection reagent (Roche Applied 
Science), following the manufacturer’s protocol. Cells were co-transfected with 3-7 ug of 
DNA encoding receptors tagged with either YFP or mCherry.  
2.2.3. Production of mammalian plasma membrane vesicles 
Vesiculation was performed using a chloride salt vesiculation buffer consisting of 200 
mM NaCl, 5 mM KCl, 0.5 mM MgSO4, 0.75 mM CaCl2, 100 mM bicine and protease 
inhibitor cocktail (Complete mini EDTA-free tabs, Roche Applied Science) adjusted to 
PH of 8.5 (33). CHO cells were rinsed twice with 30% PBS (pH 7.4), and incubated with 
1 mL of chloride salt vesiculation buffer overnight at 37 °C.  A large number of vesicles 
were produced after 12 h, and the vesicles were transferred into 4-well Nunc Lab-Tek II 
chambered coverslips for imaging. Images of vesicles with labeled FGF receptors are 
shown in Figure S3.  Most of the cytoplasm in the vesicles is lost during vesicle 
production, as attested by the fact that soluble proteins of molecular weight up to 200 
kDa are not retained inside the vesicles (paper in preparation). 
2.2.4. QI-FRET Image Acquisition 
Vesicles were imaged using a Nikon Eclipse confocal laser scanning microscope using a 
60× water immersion objective. All the images were collected and stored at a 512 × 512 
resolution. Three different scans were performed for each vesicle: (1) excitation at 488 
17 
 
nm, with a 500-530 nm emission filter (donor scan); (2) excitation at 488 nm, with a 565-
615 nm emission filter (FRET scan); and (3) excitation at 543 nm, with a 650 nm 
longpass filter (acceptor scan). Gains of 8.0 were used for all the three scans. The 
bleaching of the fluorescent proteins was minimized through the use of ND8 filters when 
excitating with the 488 nm laser, and low pixel dwell time (1.68 μs). 
2.2.5. Western blots 
CHO cells were cultured in serum-free medium for 24 h following transfection and then 
treated with lysis buffer (25 mM Tris-HCl, 0.5% Triton X-100, 20mM NaCl, 2 mM 
EDTA, phosphatase inhibitor and protease inhibitor, Roche Applied Science). Lysates 
were collected following centrifugation at 15,000 g for 15 min at 4 °C and loaded onto 3–
8%NuPAGE®Novex®Tris–Acetatemini gels (Invitrogen, CA). The proteins were 
transferred onto a nitrocellulose membrane, and blocked using 5% milk in TBS. FGFR 
total protein levels were assessed using antibodies against FGFR3 (H-100; sc-9007), 
FGFR2 (H-80; sc-20735) and FGFR1 (H-76; sc-7945) from Santa Cruz Biotechnology. 
The phosphorylation of the tyrosines in the activation loop of the FGFR kinases was 
assessed using specific anti-phospho-Tyr antibodies (Tyr653/654; #3471, Cell Signaling 
Technologies). These antibodies are raised against Tyr653/654 in the activation loop of 
FGFR1, but are reactive to all FGFR receptors because of their identical activation loop 
sequences. Anti-phospho-Tyr766 (1E5); (#2544; Cell Signaling Technology) was used to 
asses FGFR1 phosphorylation at Tyr766. Anti-phospho-Tyr724 (sc-33041; Santa Cruz 
Biotechnology) was used to detect the phosphorylation of Tyr724 in FGFR3. These 
antibodies were then followed by anti-rabbit HRP conjugated antibodies (W4011, 
18 
 
Promega). The proteins were detected using the Amersham ECL detection system (GE 
Healthcare). 
2.2.6. Activation with fgf1 and fgf2. CHO cells were cultured in normal medium for 24 
h following transfection and then starved in serum-free medium for 24 h. 5000 ng/mL of 
fgf1 or fgf2 (Millipore, MA), were added to the serum-free medium. After incubating for 
10 min at 37˚C with ligand, cells were lysed as described above and analyzed using 
Western blotting. 
2.3. Results 
2.3.1. Full-length FGF receptors dimerize in the absence of ligand, and unliganded 
FGFR2 and FGFR3 dimers exist at physiological concentrations.  
Unliganded FGFR dimers have been reported in the literature (84). However, the 
propensities for unliganded dimerization of the FGF receptors have not been measured 
and are unknown.  To fill this knowledge gap, here we characterized the dimerization of 
full length FGFR1, FGFR2, and FGFR3 in plasma membrane derived vesicles using a 
FRET-based technique termed “quantitative imaging FRET (QI-FRET)” (22, 23, 114). 
To allow FRET detection, the monomeric fluorescent proteins YFP and mCherry (a 
FRET) pair were attached to the C-termini of full-length FGFR1, FGFR2, and FGFR3 via 
flexible GGS linkers (see Figure S1). CHO cells were co-transfected with plasmids 
encoding FGFR1-YFP and FGFR1-mCherry, FGFR2-YFP and FGFR2-mCherry, or 
FGFR3-YFP and FGFR3-mCherry.  After the receptors were expressed on the plasma 
membrane, the cells were vesiculated  using an osmotic stress vesiculation buffer (33, 
123).  The vesicles were imaged as described previously (23, 122) (see also Figure S3). 
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The donor concentration, the acceptor concentration, the total receptor concentration, the 
FRET efficiency, and the receptor dimeric fraction were determined for each vesicle 
(Figures 1A and B). Eight hundred to 1200 individual plasma membrane-derived vesicles 
were analyzed for each FGF receptor, and the data for all the vesicles expressing one 
receptor type were combined to yield dimerization curves for the receptor (Figure 1C).  
From the data, we determine:  (1) the dimeric receptor fractions for a given receptor 
concentration (Figure 1C), (2) the dimerization constant K for each receptor (Table 1), 
and (3) the intrinsic FRET, Ẽ, for each receptor (Table 1), a structural parameter that 
depends only on the separation and the orientation of the two fluorescent proteins in the 
dimer.  The dimerization free energies are -4.3 ± 0.2 and -5.4 ± 0.2 kcal/mole and -6.3 ± 
0.2 kcal/mole for FGFR1, FGFR2, and FGFR3, respectively, corresponding to two 
dimensional dissociation constants of 240 to 710 m
-2
.  The intrinsic FRET values vary 
between 0.43 and 0.66, corresponding to 48 to 56 Å separation between the fluorescent 
proteins in the dimers.  
The dimerization curves for the three full-length receptors are shown in Figure 1C with 
the solid lines. To evaluate the biological significance of FGFR unliganded dimerization, 
we note that typical RTK physiological expression levels are below 100 receptors/μm
2
. 
For these receptor expressions, the binding curves for both FGFR2 and FGFR3 in Figure 
1C show substantial dimeric populations. Thus, FGFR unliganded dimers exist in cells 
under physiological conditions.  Furthermore, measurements of phosphorylation in 
Figure S4 as a function of expression demonstrate that the phosphorylated fraction 




2.3.2. Thermodynamic contributions of FGFR domains to unliganded dimerization 
To gain mechanistic knowledge about unliganded dimerization, we investigated how 
different FGFR domains contribute to the energetics of the process. We created two 
truncated versions of the receptors. In the first version, the intracellular domains were 
removed, and the FPs were attached to the TM domains via a (GGS)5 flexible linker 
(Figure S1).  These constructs (termed EC+TM) therefore consisted of the EC domains, 
the TM domains, flexible linkers, and fluorescent proteins (Figure S1). In the second 
truncated version, both the IC and EC domains were removed, such that these constructs 
had the TM domains attached to the fluorescent proteins via flexible (GGS)5 linkers 
(Figure S1). We then characterized the dimerization of the truncated constructs in plasma 
membrane derived vesicle using the QI-FRET method. The dimerization curves for the 
truncated receptors are shown in Figure 2, along with the results for the full-length 
receptors for comparison. The optimal values for the dimerization constants and the 
Intrinsic FRET for all the variants are shown in Table 1. 
 First, we observe that the TM domains have a strong propensity for dimerization, with 
dimerization free energies varying between -5.2 to -6 kcal/mole (Kdiss varying between 40 
and 156 m
-2
). Second, by comparing the stabilities of the two types of truncated 
receptors (EC+TM and TM), we obtain directly the thermodynamic contribution of the 
EC domain to FGFR unliganded dimerization,GEC. For all three FGFRs, the addition 
of the EC domain decreases the dimerization propensity (GEC ranging from 1.4 to 2.3 
kcal/mole), and thus the contribution of the EC domain to dimerization is inhibitory.  
Third, by comparing the stabilities of the full-length receptors and the truncated receptors 
without the IC domains, we obtain directly and for the first time the thermodynamic 
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contribution of the IC domain to FGFR unliganded dimerization,GIC. (Table 1). 
Surprisingly, we see large differences in GIC, ranging from zero to ~ -3 kcal/mole.  
While the contributions of FGFR2 and FGFR3 IC domains are -2.0 and -2.9 kcal/mole, 
respectively, the contribution of FGFR1 IC domain is practically zero, suggesting that 
either FGFR1 IC domain does not make contacts that stabilize the full-length FGFR1 
dimer, or that the stabilizing contacts are balanced by repulsive ones.  We thus conclude 
that the IC domain contribution is stabilizing, not inhibitory, and it varies substantially 
for the three receptors 
An important finding of this work is that FGFRs form dimers in the absence of the IC 
domains. It has been proposed previously that the IC domain is required for FGFR 
dimerization in the absence of ligand (3, 84). Our results directly demonstrate, however, 
that the IC domain is not necessary for FGF dimerization, but its stabilizing effect is 
significant for FGFR2 and FGFR3.  
2.3.3. Structural changes in FGFR dimers upon fgf1 and fgf2 binding 
In the experiments described above, we determined the Intrinsic FRET for all studied 
dimers, along with the dimerization propensities (Table 1). The value of the Intrinsic 
FRET contributes to the measured FRET efficiencies, and thus it needs to be determined 
and accounted for in order to correctly measure the dimerization propensities. 
Furthermore, the value of the Intrinsic FRET yields information about the distance 
between the fluorescent proteins in the dimer, thus providing insight into dimer structure. 
We therefore sought to compare the Intrinsic FRET in the presence and absence of 
ligand, as a means to follow structural changes on the cytoplasmic side of the receptor 
upon ligand binding to the extracellular domains. Since the TM domains have been 
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proposed to play a role in FGFR activation (8, 80), we first worked with the truncated 
EC+TM FGFR constructs, in which the fluorescent proteins were attached to the TM 
domains via flexible linkers. This way, we could directly monitor possible changes in the 
structure of the TM domains in the receptor dimers in response to ligand binding. 
Experiments were performed at, saturating ligand concentration (5,000 ng/ml), under 
conditions when the ligand amounts exceed total FGFR amounts by at least two orders of 
magnitude as previously described (19, 21, 53)), to ensure that all receptor are in the 
ligand-bound dimeric state (see references  (19, 21, 53) for details). In the case of 100% 
dimeric receptors, the FRET signal depends on (i) the Intrinsic FRET, i.e. the distance 
and orientation of the fluorescent proteins in the ligand-bound dimers, and (ii) the 
acceptor fraction, which is measured in each vesicle.  The dimerization constant cannot 
be determined, but the measurements of the Intrinsic FRET at saturating ligand 
concentrations, allow us to assess structural changes that occur in response to ligand 
binding.  
FRET experiments were performed in the presence of two different ligands, fgf1 and 
fgf2. For each receptor/ligand pair, 300 to 500 individual plasma membrane-derived 
vesicles were imaged, one hour after adding 5 g/ml ligand to the vesicles. Results are 
shown in Figure S5. The Intrinsic FRET for each vesicle was measured according to 
equation (11) in Supplementary data, and histograms for these values for each 
receptor/ligand pair are shown in Figure 3A.  
In Figure 3A, we see significant differences between the Intrinsic FRET values measured 
for fgf1-bound and fgf2-bound FGFR dimers (p<0.01).  The Intrinsic FRET value in the 
fgf1-bound state is ~0.55, while the Intrinsic FRET value in the fgf2-bound state is ~0.73.  
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Assuming random orientation of the fluorophores (justified because they are attached via 
long linkers), we calculate the distances between the fluorescent proteins (Table 1). In the 
presence of fgf1, the distance between the fluorescent proteins is about 52 Å (similar to 
the unliganded case). In the case of fgf2, the distance between the fluorescent proteins is 
about 44 Å. Since in all cases the attachment of the fluorescent proteins to the TM 
domain is the same, these differences indicate differences in the separation of the C-
termini of the TM domains in the two ligand-bound states. Thus, these experiments yield 
a direct demonstration of structural differences in FGFR3 TM domain structure in the 
fgf1- and fgf2- bound cases.   
The Intrinsic FRET values in the presence of fgf1 and fgf2 are shown in Table 2, such 
that these values can be directly compared to the Intrinsic FRET in absence of ligand 
shown in Table 1. We see that fgf2 binding causes a statistically significant change in 
Intrinsic FRET, while the change upon fgf1 binding is not statistically significant. 
2.3.4. Structural differences in the fgf1 and fgf2 states correlate with 
phosphorylation levels 
To investigate the biological significance of the different structures that we observe in the 
FRET experiments in the presence of fgf1 and fgf2, we compared the phosphorylation of 
full-length FGFR1, FGFR2, and FGFR3 at saturating fgf1 and fgf2 concentrations (5 
g/ml) using Western blotting. The architecture of the full-length receptors used in the 
Western blot experiments is shown in Figure S2. For detection, we used specific anti-
FGFR antibodies against the extracellular domains of FGFR1, FGFR2, and FGFR3, as 
well as anti-phospho-Tyr antibodies that are reactive to phosphorylated tyrosines in the 
activation loop of the three receptors (anti-phospho-Y653/4) or other tyrosines in the 
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kinase domain.  Results are shown in Figures S6 and 3B. We see that tyrosine 
phosphorylation is higher in the fgf2 bound state for both FGFR1 and FGFR3, as 
compared to the fgf1 bound state. Interestingly, the Western blot results for FGFR2 
reveal the same FGFR2 phosphorylation in the presence and fgf1 and fgf2 (as well as in 
the absence of ligand, see Figure S6). This finding is surprising, but not entirely 
unexpected as FGFR2 has been previously described to interact with soluble adaptor 
proteins which regulate its dimerization and activity (3, 84). The Western blot results are 
therefore consistent with the findings of two distinct ligand-bound active states, and 
directly demonstrate that these distinct states exhibit different phosphorylation levels for 
FGFR1 and FGFR3. 
2.3.5. Insights from a high-resolution NMR structure of the isolated FGFR3 TM 
dimer 
The only FGFR TM domain high-resolution dimer structure reported thus far is the 
FGFR3 TM domain dimer structure (8).  In this structure, solved by NMR in micelles, the 
FGFR3 TM helices form a left-handed dimer, with helix-helix interactions occurring 
along the entire TM domain. The TM helices are almost parallel to each other, and wrap 
around each other in a tight closed-packed configuration (see Figure S7).  
It can be argued that the TM dimer structure in Figure S7, observed in micelles by NMR, 
should give the highest intrinsic FRET possible in the FRET experiments, as the two C-
termini are tightly packed against each other. The highest Intrinsic FRET observed in our 
experiments was recorded in the presence of fgf2. These arguments lead us to 
hypothesize that the isolated FGFR3 TM domain dimer structure in micelles is the same 
as (or is very similar to) the fgf2-dound dimer structure in plasma membranes.  
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2.3.6. FGFR3 domain dimer structure in the fgf2 state 
To test the hypothesis that the isolated FGFR3 TM domain dimer structure in micelles is 
the same as (or very similar to) the fgf2-bound dimer structure in plasma membranes, we 
mutated amino acid residues 377, 380 and 391. These residues were shown to mediate 
interactions between the TM helices in the NMR structure, based on the recorded inter-
helical NOEs (8).  The mutations were engineered in the truncated EC+TM construct 
used in the FRET studies (Figure S1) and in the full-length FGFR3 receptor (Figure S2).  
The comprehensive FRET characterization of the dimerization of this truncated mutant, 
in the absence and presence of fgf1 and fgf2, is shown in Figure S8. The Intrinsic FRET 
values for the truncated mutant, as well as the Western blots that assess the 
phosphorylation of the full-length mutant are shown in Figure 4, I (in the presence of fgf1 
and fgf2), and Figure 5, I (in the absence of ligand). We see that this mutant behaves very 
differently in the presence of fgf2, as compared to the WT. In particular, the Intrinsic 
FRET values in the fgf1 and fgf2 states are identical for this mutant, and are the same as 
the I-FRET value for the WT fgf1 case. Furthermore, the phosphorylation of this mutant 
in the presence of saturating fgf1 and fgf2 concentrations is also the same, and lower than 
the phosphorylation of the wild-type in the fgf2 state (see Figure S13). Thus, the 
engineered mutations in the NMR interface destabilize and abolish the FGFR3 fgf2-
bound state, and induce a structural transition to the fgf1 state when fgf2 is bound. This 
finding is consistent with the hypothesis that the NMR structure and the fgf2-bound TM 
dimer structures are the same. 
FGFR3 TM domain has multiple GxxxG-like motifs that do not participate in the NMR 
interface, but are believed to be capable of forming a putative alternative dimer interface 
26 
 
(8) in the TM domain dimer. Such GxxxG-like motifs, sometimes called 
SMALLxxxSMALL motifs, have small amino acids such as Gly, Ala, Thr and Ser in i, 
i+4  positions, and are believed to mediate interactions between hydrophobic helices in 
membranes. To investigate if this GxxxG-like interface pays a role in FGFR3 
dimerization, we mutated three glycines in this GxxxG-like interface to virtually 
eliminate all GxxxG-like motifs (Figure S). The mutations were engineered in the 
truncated EC+TM construct used in the FRET studies (Figure S7) and in the full-length 
FGFR3 receptor (Figure S2). The comprehensive characterization of the dimerization of 
this mutant, in the absence and presence of the fgf ligands, is shown in Figure S9. The 
Intrinsic FRET values, as well as the measured phosphorylation levels of the full-length 
mutant from Western blots are shown in Figure 4B, II (in the presence of fgf1 and fgf2), 
and Figure 5B, II (in the absence of ligand); see also Figure S10. We see that these 
mutations, which are not expected to impact the NMR structure, do not impact the fgf2 
state either.  Indeed, both the Intrinsic FRET and the phosphprylation of the GxxxG-like 
mutants and the wild-type at saturating fgf2 concentrations are the same. This finding 
lends further support to the hypothesis that the NMR and the fgf2-bound TM dimer 
structure are similar. 
2.3.7. FGFR3 TM domain dimer structure in the fgf1 state 
The mutagenesis described above revealed that mutations in the NMR interface have no 
effect on the Intrinsic FRET value, the distance between fluorescent proteins,  and on the 
phosphorylation in the fgf1-bound state of FGFR3. Thus, the structure of the FGFR3 TM 
domain dimer in the fgf1-bound state is different from the fgf2-bound state structure, as 
well as from the NMR TM domain structure. On the other hand, the Intrinsic FRET 
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measured in the fgf1 state is altered when the GxxxG-like interface is mutated (Figure 4), 
suggesting that these mutations perturb the fgf1 bound structure. Therefore, the FGFR3 
TM dimer in the fgf1 state is likely stabilized by helix-helix interactions that involve the 
GxxxG-like interface.  
2.3.8. FGFR3 TM domain dimer structure in the unliganded state 
Mutations in both the NMR interface and the GxxxG interface altered the Intrinsic FRET 
measured in the unliganded state (Figure 5). One way to interpret this unexpected finding 
is to assume that the TM domain in the unliganded state explores both the fgf1 and fgf2-
bound structures. If this is the case, the Intrinsic FRET must be a weighted average of the 
Intrinsic FRETs between the fgf1 and fgf2-bound states.  While we cannot completely 
exclude this possibility, we note that there are no statistically significant differences in 
Intrinsic FRET in the unliganded and in the fgf1-bound states (Tables 1 and 2). 
A second way to interpret our findings is to postulate that the TM domains can interact 
through a third helix-helix interface, which involves at least one amino acid from each 
the two separate sets of mutations. While the mutagenesis could not provide specific 
structural insights into the unliganded dimer structure, the results strongly suggest that 
the unliganded dimer structure is different from the fgf1-bound structure, despite having 
the same Intrinsic FRET, as well as from the fgf2-bound dimer structures. Thus, FGFR3 
TM domain dimer can adopt (at least) three structural configurations.  Fgf1 binding to the 
unliganded dimers induces structural changes which do not alter significantly the 
separation of the fluorescent proteins in the dimer. Fgf2 binding, on the other hand, 
brings the fluorescent proteins in EC+TM FGFR3 construct closer together. 
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Our results further suggest that the FGFR3 TM domain may adopt yet another dimer 
structure in the absence of the EC domain. Indeed, the Intrinsic FRET measured for the 
EC+TM and TM dimers in the absence of ligand are significantly different for FGFR3, 
but are the same for FGFR1 and FGFR2 (Table 1). In FGFR3, the fluorescent proteins 
are closer to each other when the EC domain is deleted, suggesting that the EC domain 
may push the TM helices apart and thus may interfere with the sequence-encoded 
interactions between the TM domains.  
Next, we performed FRET experiments at saturating ligand concentrations with the three 
full-length FGF receptors, linked to fluorescent proteins. The values of the Intrinsic 
FRET measured in the presence of fgf1 and fgf2 are shown in Table S1, together with the 
values measured in the absence of ligand (i.e. from the experiment in Figure 1). In this 
case, the structural interpretation of the data is not straight-forward because the 
fluorescent proteins are attached to the long flexible C-terminal tails (> 50 amino acids) 
of the full-length receptors. Yet, we see significant changes in Intrinsic FRET upon 
ligand binding in the case of FGFR1 and FGFR2, consistent with the idea that both fgf1 
and fgf2 binding leads to structural changes in the receptor dimers. 
2.3.9. Effect of a pathogenic mutation of FGFR3 
To further investigate the biological significance of our observations, we studied the 
pathogenic A391E mutation in the TM domain of FGFR3, a mutation linked to Crouzon 
syndrome with acanthosis nigricans (94). Previous QI-FRET studies have shown that this 
mutation stabilizes the unliganded EC+TM FGFR3 dimer by -1.4kcal/mole (122). 
Intriguingly, the two-parameter fit of the QI-FRET data in the absence of ligand for this 
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mutant yielded a value of 0.70 ± 0.02, the same as the value measured in the fgf2-state 
for the wild-type (0.72 ± 0.01). 
This fact prompted us to investigate further the behavior of the mutant. Using QI-FRET, 
we characterized the Intrinsic FRET of the A391E EC+TM FGFR3 construct in the 
presence of saturating fgf1 and fgf2 concentrations. We also characterized the 
phosphorylation of the full-length mutant in the presence of saturating fgf1 and fgf2 
concentrations.  
The comprehensive characterization of the dimerization of the A391E pathogenic mutant, 
in the absence and presence of fgf1 and fgf2, is shown in Figures S11. The Intrinsic 
FRET values as well as the Western blots that assess the phosphorylation of the mutants 
in the presence of fgf1 and fgf2 are shown in Figure 6.  We see that the Intrinsic FRET 
values in the fgf1 and fgf2 states are identical for this mutant, and are the same as the I-
FRET value for the wild-type fgf2 case (Figure 6A, I). The phosphorylation of the full-
length A391E mutant in the presence of saturating fgf1 and fgf2 concentrations are also 
the same (Figure 6 B, II), and are the same as in the wild-type fgf2-bound state (Figure 
S13). Thus, the A391E mutation abolishes the fgf1 state, and forces the dimer into the 
fgf2 state when fgf1 was bound.   The mutation also increased the phosphorylation in the 
presence of fgf1, up to fgf2 levels.  
Taken together, published and new data demonstrate that the A391E mutation traps the 
FGFR3 dimer in the fgf2 state even in the absence of ligand. We thus find that the fgf2 
state is stabilized (rather than destabilized) when A391, an amino acid that likely 
participates in helix-helix contacts in the fgf2 state, is mutated to Glu. This finding can be 
explained by the formation of a stabilizing hydrogen bond between the mutant Glu and 
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the neighboring helix, an idea which is supported by molecular modeling (82).  Once 
formed, this structure does not change significantly upon binding fgf1 or fgf2.  The 
A391E mutation therefore mimics the action of fgf2 in enforcing a particular dimer 
structure. Since the fgf2-bound state is the most active one, the A391E mutation leads to 
increased phosphorylation and thus disregulated signaling and disease.  
2.3.10. Correlation between TM dimer structure and receptor phosphorylation 
Figures 3 through 6 above show multiple examples of correlations between Intrinsic 
FRET and phosphorylation levels. In Figure 7A we show the global correlation for wild-
type FGFR3 and the three FGFR3 mutants studied here.  We see a very strong correlation 
between Intrinsic FRET and phosphorylation, as measured in our experiments. In Figure 
7B we show the correlation between (i) the calculated distance between fluorescent 
proteins in the dimer and (ii) phosphorylation of the full-length receptor, calculated under 
the assumption of free fluorescence protein rotation. Again, we see a strong correlation 
between (i) distance between the fluorescent proteins and (ii) phosphorylation. 
2.4. Discussion 
2.4.1. Mechanism of FGFR activation. 
Here we demonstrate that the FGF receptors form dimers in the absence of ligand at 
physiological concentrations, and that the unliganded dimers are phosphorylated.  We 
further demonstrate that the unliganded FGFR dimers undergo structural changes upon 
ligand binding, the structural changes in response to fgf1 and fgf2 binding are very 
different, resulting in different phosphorylation of the fgf1 and fgf2-bound dimers. These 
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results establish the existence of multiple active ligand-bound states for the FGF 
receptors. 
Upon fgf1 binding, FGFR3 TM domains engage in interactions that involve GxxxG 
motif. Binding of fgf2, however, results in a very different TM structure which is closely 
packed. This structure ensures the smallest separation between the TM domains and the 
highest possible FGFR3 phosphorylation. Thus, fgf2 binding bring the TM domains 
closer together, as compared to the fgf1 case, and induces maximum kinase 
phosphorylation.  This conclusion is supported by a strong correlation between TM 
domain dimer structure and kinase phosphorylation, for wild-type FGFR3 and three 
FGFR3 mutants (Figure 7).  
2.4.2. A unified model of RTK activation 
Since the discovery of RTKs in the 70s, researchers have been searching for a model that 
captures the essence of RTK signal transduction across the plasma membrane. The first 
proposed model was the “diffusion-based” or “canonical” model of RTK activation (39). 
It postulates that RTKs are monomers in the absence of ligand, but dimerize and cross-
phosphorylate/activate each other upon ligand binding. However, recent work has 
identified unliganded RTK dimers, and thus an alternative model was proposed, the so-
called “pre-formed dimer model” (6, 12, 14, 84). In this model, the RTKs are dimeric in 
the absence of ligand, and ligand binding induces a structural change in the receptor that 
reorients the catalytic domains for efficient activation. Here we find that FGFR1, FGFR2, 
and FGFR3 dimerize in the absence of ligand, and they undergo structural changes in 
response to ligand binding. Thus, they all follow the pre-formed dimer model.  
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We also see that the dimerization propensities of FGFR1, FGFR2, and FGFR3, are very 
different (Table 1). This difference is obvious in the dimerization curves in Figure 1 C, 
which show levels of pre-formed dimers. While significant populations of FGFR2 and 
particularly FGFR3 exist for receptors concentrations < 100 receptors per micron 
squared, FGFR1 is predominantly monomeric. Thus, FGFR1 appears to follow the 
canonical model of activation.  Taken together, these results suggest the possibility that 
the difference between the “canonical” and the “pre-dimerized” mode of activation is not 
fundamental, but may simply lay in the magnitude of the unliganded dimerization 
constant.  We thus propose that all RTKs may follow a single model of activation, which 
includes unliganded dimers as intermediates. However, the stability of the unliganded 
dimers vary significantly and, thus not all receptors exist at pre-formed dimer under 
physiological conditions.   
2.4.3. Interplay of different FGFR domains in dimerization. 
Here we measured directly the thermodynamic contributions of the different FGFR 
domains to unliganded dimerization (Figure 2). These results demonstrate that the 
deletion of the IC domains decreases the dimerization propensity, with effects varying 
from negligible to strong (-3 kcal/mole).  On the other hand, the deletion of the EC 
domain increases the dimerization propensity by 1.4 to 2.3 kcal/mole.  Thus, the 
contribution of the IC domain to unliganded dimer stability is generally stabilizing, while 
the contribution of the EC domain is destabilizing. However, our results further suggest 
that, at least in the case of FGFR3, these thermodynamic contributions are not completely 
additive. Indeed, the change in the Intrinsic FRET upon the deletion of the EC domain 
(Table 1) suggests that the EC domain affects the behavior of the TM domain. Although 
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FGFR3 TM domains form dimers by themselves, the TM dimer structure and stability 
may be altered by the presence of the EC domain.  
2.4.4. Multiple active RTK dimers 
Within the pre-formed dimer model, ligand binding to the extracellular domains induces 
structural changes that propagate to the kinase domains (4, 6, 36). It has been 
hypothesized that these structural changes must involve the TM domains, as they connect 
the two large soluble domains across the membrane. In particular, a change in the 
separation between the C-termini of the TM domains of about 10 Å has been proposed to 
occur upon ligand binding for some receptors (8, 9, 42, 67), which in turn is believed to 
change the distance between the kinase domains, and/or their orientation, and allow for 
efficient cross-phosphorylation.  The experiments presented here provide a direct 
demonstration that such a structural change occurs in the FGF receptors within the 
plasma membrane (Tables 1, 2, and S1). Our data demonstrate further that two different 
structures are adopted by the FGFR TM domain dimers in the fgf1 and fgf2 bound states, 
and these structures have different biological activities.  
Previously, differences in binding strengths for different FGF receptor/ligand pairs have 
been reported, and these differences have been suggested to underlie the specificity of the 
biological response of a receptor to a particular ligand (97, 106, 167). Here we further 
demonstrate differences in structure when different ligands are bound. These structural 





2.4.5. Phosphorylation is correlated with distance between the TM domains.  
We discovered here a strong correlation between the Intrinsic FRET (and the distance 
between the fluorescent proteins in the EC+TM FGFR3 dimer) and the phosphorylation 
of the receptors (Figure 7). It can be argued that the distance between the fluorescent 
proteins in our experiments must correlate with the distance between the C-terminal ends 
of the TM domains in the dimer, at these are the points of attachment of the (GGS)5 
linkers.  Such a correlation is consistent with our findings that the closed packed NMR 
structure corresponds to the highest phosphorylation fgf2-bound state.  Thus, the activity 
of the receptor is controlled by the structure of the TM domains. Since the kinase 
domains are attached to the TM domains in the full-length receptors, our results suggest a 
correlation between the separation of the kinase domains in the dimer and their 
phosphorylation. Indeed, fgf2 binding leads to increase in activity over fgf1 by bringing 
the TM helices closer together in the dimer.  However, the receptor itself is not a passive 
player in the process, as mutations in the receptors can over-ride the effect of the ligand 
and force it into an alternative structure with aberrant activity.  
2.4.6. A new molecular mechanism behind FGFR-linked pathologies 
There are many known pathogenic mutations in the FGF receptors, most of them linked 
to different bone growth disorders (26, 28, 119, 151, 158). Here we uncovered a new 
mechanism through which FGFR-linked pathologies can arise. In particular, we showed 
that the A391E mutation mimics the structural effects of fgf2 binding, preventing the 
dimer from exploring the unliganded and fgf1-bound conformation, and traps it in the 
most active fgf2 state. This is possible because of the structural plasticity of the FGF 




 ΔG (kcal/mol) Kdiss (μm
-2
) Intrinsic FRET d(Å) 
Full FGFR1 -4.3 (-4.0 to -4.5) 710 ± 420  0.66 (0.64 to 0.69) 48 ± 1 
Full FGFR2 -5.4 (-5.2 to -5.7) 111 ± 44 0.43 (0.41 to 0.44) 56 ± 1 
Full FGFR3 -6.3 (-6.0 to -6.8) 24 ± 15 0.55 (0.53 to 0.57) 51 ± 1 
ECTM FGFR1 -4.6 (-4.4 to -4.8) 428 ± 145  0.50 (0.46 to 0.55) 53 ± 2 
ECTM FGFR2 -3.4 (-3.2 to -3.6) 3235 ± 1100  0.57 (0.51 to 0.64) 51 ± 2 
ECTM FGFR3 -3.4 (-3.2 to -3.6) 3235 ± 1100  0.52 (0.46 to 0.57) 52 ± 2 
TM FGFR1 -6.0 (-5.7 to -6.3) 40 ± 26 0.50 (0.46 to 0.52) 53  ± 1 
TM FGFR2 -5.7 (-5.4 to -6.1) 67 ± 37  0.52 (0.5 to 0.54) 52 ± 2 
TM FGFR3 -5.2 (-5.0 to -5.4) 156 ± 54  0.65 (0.64 to 0.67) 48 ± 1 
 
 Table 2-1.  Parameters describing FGFR unliganded dimerization. Dimerization free 
energies (dimer stabilities), ΔG, two-dimensional dissociation constants Kdiss, Intrinsic 
FRET efficiencies Ẽ, and distance between fluorescent proteins, d, in the dimers. These 
parameters are obtained from least-square fits of a dimer model to the FRET data. The 
distance between the fluorescent proteins in the EC+TM FGFR constructs is 51 to 53 Å 









 Intrinsic FRET D(Å) 
ECTM FGFR1+fgf1 0.55±0.01 51 ± 1 
ECTM FGFR1+fgf2 0.73±0.01 45 ± 1 
ECTM FGFR2+fgf1 0.53±0.01 52 ± 1 
ECTM FGFR2+fgf2 0.75±0.01 44 ± 1 
ECTM FGFR3+fgf1 0.55±0.01 51 ± 1 
ECTM FGFR3+fgf2 0.72±0.01 45 ± 1 
377I-380I-391I 0.39±0.01 57 ± 1 
377I-380I-391I+fgf1 0.52±0.01 52 ± 1 
377I-380I-391I+fgf2 0.53±0.01 52 ± 1 
374I-375I-378I 0.43±0.01 56 ± 1 
374I-375I-378I+fgf1 0.63±0.01 49 ± 1 
374I-375I-378I+fgf2 0.74±0.01 45 ± 1 
A391E+fgf1 0.75±0.01 44 ± 1 
A391E+fgf2 0.78±0.01 43 ± 1 
 
Table 2-2.  Intrinsic FRET efficiencies Ẽ, measured in the presence of saturating fgf1 and 
fgf2 concentrations for the truncated EC+TM FGFR constructs. In the fgf1 state, the 
measured distance between the fluorescent proteins is 51 to 52 Å (highlighted in grey). In 
the fgf2 state, the measured distance between the fluorescent proteins is 43 to 45 Å 






Figure 2-1.  (A) Measured FRET as a function of receptor concentration, for the three 
full-length receptors. Every data point represents a single vesicle (B) The donor 
concentration is plotted as a function of the acceptor concentration, for each vesicle. (C) 
Dimeric fraction as a function of total receptor concentrations. The solid line is the 



































































Figure 2-2.  Dimerization curves for the full-length receptors (black), truncated receptors 
that lack the IC domain and thus contain only the EC and TM domains (olive), and the 
TM domains only (red). Data for EC+TM FGFR3 and TM FGFR3 are from (124). The 



















































































standard errors. The solid lines are the best fits of a monomer-dimer equilibrium model to 
the data. These data demonstrate that the TM domains have a very strong propensity for 
dimerization. The EC domains, on the other hand, inhibit dimerization. The contribution 
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Figure 2-3. FRET and Western blot results for wild-type FGFR1, FGFR2, and FGFR3. 
(A). Intrinsic FRET values, measured for the three FGF EC+TM receptors in the 
presence of saturating fgf1 and fgf2 concentrations. The Intrinsic FRET is a measure of 
the separation between the fluorescent proteins in the dimer. Two different Intrinsic 
FRET values were measured for fgf1 and fgf2 (see also Supplementary Figure S5). 
Therefore, the binding of these two ligands to the extracellular domains of the receptors 
leads to different separation of the fluorescent proteins on the cytoplsmic side of the 
membrane. (B). Western blots, reporting on the phosphorylation of the full-length 
receptors in the presence of saturating concentrations of fgf1 and fgf2. Expression of the 
receptors was probed with anti-FGFR1, anti-FGFR2, and anti-FGFR3 antibodies to the 
extracellular domains of the three receptors. Phosphorylation was assays using antibodies 
against phosphorylated tyrosines in the activation loop of the three kinases (anti-phospho-
Y653/4) or other phosphorylated tyrosine residues (Y766 in FGFR1 and Y723 in 
FGFR3). Two bands are observed for all receptors. The top bands are the fully 
glycosylated mature receptors that reside primarily in the plasma membrane. Only the top 
bands are used to quantify phosphorylation. Phosphorylation was calculated by dividing 
the intensities of the anti-phospho-Y bands to the intensities of the anti-receptor bands. 
Relative phosphorylation is reported with respect to the fgf2 case. There is a statistically 
significant difference between the phosphorylation in response to fgf1 and fgf2 for 
FGFR1 and FGFR3. (D) Graphical representation of the findings that the fgf1-bound and 
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Figure 2-4. Insights into the fgf1-bound and fgf2-bound FGFR3 dimer structures in the 
plasma membrane, based on mutagenesis that is guided by a high resolution NMR 
structure of the isolated FGFR3 TM domain in micelles ((8), see Figure S7). (I) Data for 
the 377I-380I-391I mutant in the presence of saturating of fgf1 and fgf2 concentrations. 
The 377I-380I-391I mutations were engineered to destabilize the FGFR3 dimer structure, 
solved for the isolated TM domain in micelles (see Figure S7B). (II) Data for the 374I-
375I-378I mutant in the presence of saturating fgf1 and fgf2 concentrations.  The 374I-
375I-338I mutations were engineered to destabilize a putative alternative dimer structure 
not observed in the NMR experiments, mediated by GxxxG-like motifs (see Figures S7C 
and S7D).   (A) Intrinsic FRET values, measured for the truncated EC+TM FGFR3 
mutants. The histograms of measured Intrinsic FRET values in single vesicles for the 
wild-type are shown in grey for the fgf1 case and in green for the fgf2 case. The 
histograms for the mutants are shown in black in the presence of fgf1 and in olive in the 
presence of fgf2. In the presence of the 377I-380I-391I mutations (I), the Intrinsic FRET 
values measured in the presence of fgf2 shift such that they overlap with the fgf1 wild-
type case. In the presence of the 374I-375I-378I  mutations (II), the Intrinsic FRET 
values measured in the presence of fgf1 move towards the fgf1 wild-type case. (B) 
Western blots showing expression of the full length 374I-375I-378I and 374I-375I-378I 
mutants, as assayed by anti-FGFR3 antibodies, and phosphorylation of the tyrosines in 
the activation loop, as assayed by the anti-phospho-Y653/4 antibodies.  The 
quantification of the Western blot results demonstrates the phosphorylation of the two 
mutants is similar in the fgf1 and fgf2-bound case. Thus, the 374I-375I-378I mutations 





Figure 2-5. The unliganded FGFR3 dimer structure, based on mutagenesis, guided by the 
high resolution structure of the isolated FGFR3 TM domain in micelles (8). (I). Data for 
the 377I-380I-391I mutant in the absence of ligand. The 377I-380I-391I mutations were 
engineered to destabilize the FGFR3 dimer structure, solved for the isolated TM domain 
in micelles. (II) Data for the 374I-375I-378I mutant in the absence of ligand. The 374I-
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mediated by GxxxG motifs. (A). Blue Gaussian: Intrinsic FRET measured for the 
constitutively dimeric EC+TM 377I-380I-391I (I) and 374I-375I-338I (II) mutants in the 
absence of ligand (see Supplemental Figures S8 and S9).  Cyan bar: Intrinsic FRET for 
the wild-type, obtained by fitting the FRET data to a dimerization model (Table 1). The 
Intrinsic FRET decreases due to both mutations, suggesting that the fluorescent proteins 
in the dimer move way from each other due to the mutations. (B) Western blot data, 
reporting on the phosphorylation of the full-length mutants as compared to the wild-type. 
The phosphorylation of the wild-type and the mutants is the same, despite the increased 






Figure 2-6. Effect of the pathogenic A391E FGFR3 mutation on dimer structures in the 
fgf1 and fgf2 states. The A391E mutation is the genetic cause for Crouzon syndrome 
with acanthosis  nigricans, a cranial abnormality. (A) Intrinsic FRET values, measured 
for the A391E EC+TM mutant in the presence of saturating concentrations of fgf1 and 
fgf2. The histograms for the wild-type are shown in grey in the presence of fgf1 and 
green in the presence of fgf2. The histograms for the mutants are shown in black in the 






























































mutations, the Intrinsic FRET values measured in the presence of fgf1 shift such that they 
overlap with the fgf2 wild-type case. Thus, the A391E mutation abolished the fgf1 state. 
(B) Western blots showing expression, as assayed by anti-FGFR3 antibodies, and 
phosphorylation of the tyrosines in the activation loop, as assayed by anti-phospho-
Y653/4 antibodies. Also shown is the quantification of the Western blot results; only the 
top bands of fully-glycosylated receptors are quantified. The phosphorylation of the 
A391E mutant is identical in the fgf1 and fgf2 states, and is the same as the 
phosphorylation of the wild-type in the fgf2 state (see Figure S13). The A391E mutation 
increases the phosphorylation in the fgf1 state to fgf2-state levels. 
 
 
Figure 2-7.   Correlation between Intrinsic FRET and phosphorylation, for FGFR3 and 
the three studied FGFR3 mutants. Only results for constitutive dimer are included. The 























































phosphorylation of the wild-type in the fgf2-bound state is assigned a value of 1, and all 
other measured phosphorylation levels are scaled accordingly using the data in Figure 
S13. There is a strong correlation between the two measured quantities (p<0.0001). (B) 
Strong correlation between the distance between fluorescent proteins in the EC+TM 
FGFR3 constructs and full-length FGFR3 phosphorylation. 
 
 
 Intrinsic FRET D(Å) 
FGFR1 0.66 ± 0.03 48 ± 1 
FGFR1+fgf1 0.57 ± 0.01 51 ± 1 
FGFR1+fgf2 0.58 ± 0.01 50 ± 1 
FGFR2 0.43 ± 0.02 56 ± 1 
FGFR2+fgf1 0.55 ± 0.01 51 ± 1 
FGFR2+fgf2 0.69 ± 0.01 46 ± 1 
FGFR3 0.55 ± 0.02 51 ± 1 
FGFR3+fgf1 0.59 ± 0.01 50 ± 1 
FGFR3+fgf2 0.59 ± 0.01 50 ± 1 
 
Table S1(2-3). Intrinsic FRET, measured for the full-length receptors in the absence and 
presence of ligand. In this case, the fluorescent proteins are attached to the long flexible 
C-terminal tails of the full-length receptors (which vary in sequence and length), 
complicating direct structural interpretation of the data. Yet, we see significant changes in 
Intrinsic FRET upon ligand binding for FGFR1 and FGFR2, consistent with the idea that 






Figure S1(2-8). The plasmid constructs used in the FRET experiments. SP: signal 
peptide, EC: extracellular domain, FGFR3 TM domain: (DEAGSVYAG 
ILSYGVGFFLFILVVAAVTLCRLR ), IC: intracellular domain, FP: Fluorescent protein, 
either YFP or mCherry (a FRET pair). The full-length receptors had fluorescent proteins 
attached to their C-termini via a flexible GGS linker. The truncated receptors had the 
intracellular domain substituted with a fluorescent protein, which was attached to the TM 
domain via a longer flexible (GGS)5 linker.  
23 367 399
L377I-G380I-A391I (GGS)5 Fluorescent proteinEC TM(L377I-G380I-A391I)SP
23 367 399
A374I-G375I-S378I (GGS)5 Fluorescent proteinEC TM(A374I-G375I-S378I)SP
23 367 399
A391E (GGS)5 Fluorescent proteinEC TM(A391E)SP
23 367 399
FGFR3 EC+TM (GGS)5 Fluorescent proteinEC TMSP
22 369 403
FGFR2 EC+TM (GGS)5 Fluorescent proteinEC TMSP
21 376 402
FGFR1 EC+TM (GGS)5 Fluorescent proteinEC TMSP
23 367 399
FGFR3 
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Figure S3 (2-10). One vesicle, imaged in the FRET, acceptor, and donor channels. A 
Gaussian function (black line) was fitted to the fluorescence intensity across the 
membrane (blue symbols) after correcting for background fluorescence.   The residuals 




Figure S4 (2-11).  Relative phosphorylation of mature FGFR1 in the absence of ligand, 
as a function of FGFR1 expression.  (A) Western blot results. Varying levels of receptor 
expression were achieved by varying the amount of plasmid used for transfection from 
0.25 µg to 2 µg.  (B) The ratios of phospho-staining to receptor staining intensities were 
calculated and scaled with respect to the results from the first lane (2 µg of DNA).  Only 
the top bands containing the mature fully glycosylated FGFR1 were included in the 
quantification.  The relative phosphorylation increases with receptor expression, as 





Figure S5 (2-12). FRET efficiencies, donor concentrations and acceptor concentrations, 






Figure S6 (2-13). Phosphorylation of FGFR1, FGFR2, and FGFR3, characterized via 
Western blotting.  Lane “CHO”: no transfection; Lane “-“: no ligand; Lane “fgf1”: 5 







Figure S7 (2-14). FGFR3 TM domain structure in micelles, solved by NMR (8). (A) The 
solved structure is tightly packed. (B) The amino acids L377, G380, and A391 mediate 
the helix-helix contacts in the structure, based on inter-helical NOEs that were measured 
experimentally. We mutated these three amino acids to Ile in order to disrupt this “NMR 
interface”. (C) Amino acids A374, G375 and S378 participate in several GxxxG-like 
motifs (also known as SMALLxxxSMALL motifs), known to mediate TM helix 
dimerization, but do not play a role in helix packing in the NMR structure (8). These 
GxxxG motifs have been proposed to stabilize a putative alternative FGFR3 TM dimer 
structure (8). Here we mutated A374, G375 and S378 in order to disrupt this putative 






Figure S8 (2-15). FRET data for the EC+TM FGFR3 (L377I-G380I-A391I) mutant 
 






Figure S10 (2-17). Phosphorylation of the L377I-G380I-A391I and A374I-G375I-S378I 
mutants, characterized via Western blotting. Lane “WT”: wild-type FGFR3, no ligand; 
Lane “M“: mutant, no ligand; Lane “+fgf1”: mutant + 5 g/ml fgf1; Lane “+fgf2”: 




Figure S11 (2-18). FRET data for the A391E EC+TM FGFR3 mutant. The A391E 
mutation is the genetic cause for Crouzon syndrome with acanthosis nigricans.  Data in 























































































































Figure S12 (2-19). Phosphorylation of the pathogenic A391E mutant, characterized via 
Western blotting. Lane “CHO”: no transfection; Lane “WT”: wild-type FGFR3, no 
ligand; Lane “M“: mutant, no ligand; Lane “+fgf1”: mutant + 5 g/ml fgf1; Lane 






Figure S13 (2-20). Relative phosphorylation of wild-type FGFR3 and the FGFR3 
mutants studied here, in the presence of saturating fgf2 concentrations. The relative 
phosphorylation was calculated as the ratio of anti-phospho band staining intensity 
divided by the anti-receptor staining intensity. Only the fully glycosylated mature FGFR3 
top bands are included in the calculation. Shown are pair-wise comparisons for receptors 






















































































Chapter 3. Mechanism of VEGFR2 signal transduction across 




Here we demonstrate that VEGFR2 forms dimers in the absence of ligand, and that these 
dimers undergo a structural change upon binding the ligands VEGF-A121, VEGF-A165, 
VEGF-C and VEGF-D. The structural change entails a movement of the transmembrane 
domain C-termini away from each other, and correlates with receptor activation. 
Furthermore, we show that the pathogenic C482R mutation resembles the structural 
effects of the ligand, trapping VEGFR2 in its most active state.  Investigations with three 
other VEGFR mutants reveal that mutations can easily alter the structures and stabilities 
of both unliganded and liganded VEGFR2 dimers, sometimes with profound functional 
consequences. Our results challenge the current paradigm that VEGFR dimerization and 
activation occur only in response to ligand binding. They establish that unliganded 
VEGFR2 dimers are an important intermediate in the process of VEGF signal 
transduction across the plasma membrane. 
Keywords: VEGFR, vegf, angiogenesis, receptor tyrosine kinase, unliganded 





Angiogenesis, the development of new blood vessels from pre-existing ones, is critically 
important for embryogenesis, organ development, and wound healing (100, 116) (1).  
Angiogenesis is also tightly linked to cancer, as the growth of all solid tumors require the 
recruitment of new blood vessels to supply nutrients (87, 150). Thus, a therapy that 
inhibits angiogenesis would be applicable to many human cancers. In addition, a therapy 
that promotes angiogenesis could be used to restore blood supply to ischemic tissues in 
heart disease and in stroke. 
Angiogenesis is predominantly regulated by the ligands and receptors of the vascular 
endothelial growth factor (VEGF) signaling network (41, 72, 92, 103, 135). Of the three 
receptors, VEGFR2 is the primary regulator of endothelial cell proliferation and 
migration (46, 146), VEGFR-2 is expressed in virtually all human vascular endothelial 
cells, and is overexpressed in many solid tumors (139, 164). There is a correlation 
between cancer survival and VEGFR-2 signaling, as aggressive cancerous phenotypes 
correlate with enhanced signaling (18). Thus, VEGFR2 is recognized as an attractive 
therapeutic target.  
VEGFR2 is a receptor tyrosine kinase (RTK), and conducts biochemical signals via 
lateral dimerization in the membrane.  Like all RTKs, VEGFR has four domains: an 
extracellular (EC), a transmembrane (TM) domain, and an intracellular (IC) domain 
composed of a juxtamembrane (JM) domain, a kinase domain, and a tail (Figure 1) and 
an intracellular catalytic (IC) domain.  The EC domain of VEGFR is large, consisting of 
seven immuloglobulin-like (Ig-like) domain, termed D1 (at the N-terminus) to D7 
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(closest to the membrane). VEGFR2 binds to, and is activated by the ligand VEGF-A, as 
well as the processed forms of VEGF-C and VEGF-D.  The binding affinity of VEGFR2 
is highest  for VEGF-A, and the signaling through the VEGF-A/VEGFR2 complex is 
considered the most angiogenic signaling pathway (41, 72, 92, 103, 135).  
Many aspects of VEGFR2 dimerization and activation are not well understood, and this 
lack of knowledge is one bottleneck in the development of targeted VEGFR2 therapies. 
In the RTK field, currently is no consensus model of RTK signal transduction across the 
plasma membrane. Instead, two models are most often discussed in the literature. The 
first is the “diffusion-based” or “canonical” model, in which RTKs are monomers in the 
absence of ligand, and dimerize only upon ligand binding. Ligand-driven dimerization 
brings the two catalytic domains into close proximity, allowing for their efficient cross-
phosphorylation. The second model is the “pre-formed dimer model”, in which the 
receptors are dimeric in the absence of ligand, and ligand binding induces a structural 
change that reorients the catalytic domain to allow for efficient cross-phosphorylation. 
The difference between the two models lies in the absence and presence of unliganded 
dimers. High resolution structures for VEGF/VEGFR complexes revealed that 
extracellular D2 and D3 are involved as ligand binding pocket (13, 78). 
While unliganded dimers have been described for some RTKs, it not known which model 
adequately describes the activation of most RTKs.  The “diffusion-based” or “canonical” 
model of RTK activation, is the model used in textbooks and in highlighting drug 
development efforts by pharmaceutical companies. Unliganded VEGFR dimers have not 
been reported in the literature, and thus (by default) their activation is assumed to follow 
the canonical model.  Though various domains in the extracellular region have been 
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investigated for their role in ligand-dependent and ligand-independent VEGFR2 
dimerization. Domains 4 and 7 of VEGFR2 are implicated in homotypic contacts of the 
receptor in the presence of ligand (65, 71, 120). 
Here we study the behavior of the VEGFR2 receptor in the absence of ligand, and the 
response of the receptor to VEGFA121, VEGFA165, VEGF C and VEGF D, in the 
presence of missense and domain replacement mutations in order to gain insights into the 
mechanism of VEGFR2 activation. 
3.2. Materials and Methods 
The YFP plasmid was received from Dr. M. Betenbaugh (Johns Hopkins University, 
Baltimore, MD) and the pRSET-mCherry plasmid was obtained from Dr. R.Tsien 
(University of California, San Diego). All of the truncated plasmid constructs used for 
mammalian expression were constructed with pcDNA 3.1(+) vector (Invitrogen). The full 
length VEGFR2 (KDR) and V769E and C342R mutants were constructed in pBE vector. 
The full length (D4D5) and (D7D6) were constructed in pLib and pc5Frt vectors 
respectively. All primers were purchased from Invitrogen. 
To generate VEGFR2-(GGS)-mCherry and VEGFR2-(GGS)-YFP, MluI restriction site 
was created in the multiple cloning site of the pBE vector which had full length human 
VEGFR2 (KDR) insert. The cDNAs encoding YFP and mCherry were then amplified 
using Polymerase Chain Reaction (PCR) and double digested with MluI and XhoI. The 
double digested YFP and mCherry cDNAs were then ligated to the C-terminus of 
digested pBE-VEGFR cDNA.  
The sequence encoding for the EC and TM domains of VEGFR2 were amplified by PCR, 
double digested using HindIII and EcoRI restriction enzymes and inserted into (GGS)5-
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YFP and (GGS)5-mCherry pcDNA3.1(+) vectors containing a flexible 15 amino acids 
GGS linker and YFP or mCherry fluorophores, to produce VEGFR2 EC-TM-(GGS)5-
YFP, VEGFR2 EC-TM-(GGS)5-mCherry plasmids.  
The V769E and C482R mutant full length VEGFR2 constructs (VEGFR2V769E, 
VEGFR2C482R), VEGFR2 EC-TMV769E-(GGS)5-YFP, VEGFR2 EC-TMV769E-(GGS)5-
mCherry, VEGFR2 EC-TMC482R-(GGS)5-YFP, VEGFR2 EC-TMC482R-(GGS)5-mCherry 




D5 was generated by replacing domain 4 of VEGFR2 with domain 5 of 
VEGFR1. The VEGFR2D7

D6 construct was created by replacing domain 7 of VEGFR2 
with domain 6 of VEGFR1 (detailed in (65)). 
The VEGFR2D7

D6 was generated by replacing domain 7 of VEGFR2 with domain 6 of 
VEGFR1. The VEGFR2D7

D6 construct was created by replacing domain 7 of VEGFR2 
with domain 6 of VEGFR1 (detailed in (65)).  
To construct VEGFR2 EC-TMD4

D5-(GGS)5-YFP and VEGFR2 EC-TMD4

D5-(GGS)5-
mCherry plasmids, cDNA encoding  EC-TMD4

D5 was amplified from VEGFR2D4

D5 
plasmid construct. This cDNA was then double digested with HinIII and EcoRI. The 
digested cDNA was then ligated with pcDNA3.1(+)-(GGS)5-YFP or  pcDNA3.1(+)-
(GGS)5-mCherry double digested with Hind III and EcoRI. 
To construct VEGFR2 EC-TMD7

D6-(GGS)5-YFP and VEGFR2 EC-TMD7

D6-(GGS)5-
mCherry plasmids, cDNA encoding  EC-TMD7

D6 was amplified from VEGFR2D7

D6 
plasmid construct. This cDNA was then double digested with HinIII and EcoRI. The 
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digested cDNA was then ligated with pcDNA3.1(+)-(GGS)5-YFP or  pcDNA3.1(+)-
(GGS)5-mCherry double digested with Hind III and EcorI. 
To generate VEGFR2 TM-(GGS)5-YFP, VEGFR2 TM-(GGS)5-mCherry plasmids, the 
sequence encoding the TM domain of VEGFR2 
(GAQEKTNLEIIILVGTAVIAMFFWLLLVIILRTVKR) was amplified using PCR. 
This cDNA was then double digested with HindIII and EcoRI and ligated with digested 
pcDNA3.1(+)-(GGS)5-YFP or pcDNA3.1(+)-(GGS)5-mCherry. 
3.2.1. Cell culture and transfection 
 Chinese Hamster Ovary cell (CHO) cells were cultures at 37 ˚C with 5% CO2 for 24h. 
Transfection was carried out using Fugene HD transfection reagent (Roche Applied 
Science), following the manufacturer’s protocol. Cells were cotransfected with 3-7 ug of 
DNA encoding   VEGFR2-YFP and VEGFR2-mCherry constructs. Cells were 
vesiculated 24 h post transfection as described below. We have not observed staining for 
VEGFR2 (via Western blots) in the above cells unless transfected. 
3.2.2. Production of mammalian plasma membrane vesicles 
Vesiculation was performed using a chloride salt vesiculation buffer (33) consisting of of 
200 mM NaCl, 5 mM KCl, 0.5 mM MgSO4, 0.75 mM CaCl2, 100 mM bicine and 
protease inhibitor cocktail (Complete mini EDTA-free tabs, Roche Applied Science) 
adjusted to PH of 8.5. CHO cells were rinsed twice with 30% PBS (pH 7.4), and 
incubated with 1 mL of chloride salt vesiculation buffer overnight at 37 °C.  A large 
number of vesicles were produced after 12 h, and the vesicles were transferred into 4-
well Nunc Lab-Tek II chambered coverslips for imaging.  
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In the past, we have observed that when we express soluble fluorescent proteins in cells 
and we vesiculate with this procedure, the fluorescent proteins are not found within the 
vesicles, suggesting that at least some of the cytoplasmic content is lost during vesicle 
production.  
3.2.3. Treatment with VEGF. CHO cells were cultured in normal medium for 24 h 
following transfection for 24 h. The cells were then vesiculated with osmotic stress buffer 
overnight. The vesicles (1 mL) were collected in one well of a 4 chambered slide and 
treated with 2500 ng/mL of VEGF-A121, VEGF-A165  (Cell Signaling Technologies), 
VEGF-C and VEGF-D (PeproTech, USA) were added to the serum-free medium. After 
incubating for 1 h at room temperature with ligand, the vesicles were imaged using a 
Nikon confocal microscope. 
3.2.4. QI-FRET Image Acquisition 
Vesicles were imaged using a Nikon Eclipse confocal laser scanning microscope using a 
60× water immersion objective. All the images were collected and stored at a 512 × 512 
resolution. Three different scans were performed for each vesicle: (1) excitation at 488 
nm, with a 500-530 nm emission filter (donor scan); (2) excitation at 488 nm, with a 565-
615 nm emission filter (FRET scan); and (3) excitation at 543 nm, with a 650 nm 
longpass filter (acceptor scan). Gains of 8.0 were used for all the three scans. The 
bleaching of the fluorescent proteins was minimized through the use of ND8 filters when 
excitation with the 488 nm laser, and low pixel dwell time (1.68 μs). 
3.2.5. QI-FRET data Analysis: Methodology and Protocol 




3.2.6. Western blots 
CHO cells were starved in serum-free medium for 24 h following transfection and then 
treated with lysis buffer (25 mM Tris-HCl, 0.5% Triton X-100, 20mM NaCl, 2 mM 
EDTA, phosphatase inhibitor and protease inhibitor, Roche Applied Science). Lysates 
were collected following centrifugation at 15,000 g for 15 min at 4 °C and loaded onto 3–
8%NuPAGE®Novex®Tris–Acetatemini gels (Invitrogen, CA). The proteins were 
transferred onto a nitrocellulose membrane, and blocked using 5% milk in TBS. 
VEGFR2 total protein levels were assessed using antibody against VEGFR2 (55B11; 
Cell Signaling Technologies) or anti-HA tag (ab9134; abcam). Phosphotyrosine levels 
were assessed using Phospho-VEGFR2 receptor antibody (Tyr1054/1059; #3817, Cell 
Signaling Technologies). The endogenous VEGF-A levels were detected by staining with 
anti-VEGF-A antibody (PA1080, Boster Biological Technology Co, USA).This was 
followed by anti-rabbit HRP conjugated (W4011, Promega) and Goat anti-rat (sc-2006, 
Santa Cruz Biotechnology)  HRP conjugated antibodies. The proteins were detected 
using the Amersham ECL detection system (GE Healthcare). 
3.2.7. Cross-linking Experiments. Following a 24h starvation, CHO cells expressing 
full length VEGFR2, EC+TM VEGFR2 WT were subjected to cell surface cross-linker 
and lysed for western blotting. The cells transfected with full length VEGFR2, EC+TM 
VEGFR2 WT were incubated with 2 mM membrane impermeable crosslinker BS
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(Pierce) for 30 min at room temperature. The cells transfected with TM VEGFR2 WT 
and TM VEGFR2 V769E were incubated with 2 mM membrane permeable crosslinker 
EGS (Pierce) for 60 min at room temperature. All samples were quenched in 20 mM 
Tris-HCl for 15 min. After one rinse with ice-cold PBS, the cells were lysed and the 
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receptors were detected using Western blotting. Following the cross-linking and PBS 
washes, the cells were then treated with lysis buffer (25 mM Tris-Cl, 0.5% TritonX-100, 
20 mM NaCl, 2 mM EDTA, 2 mM Na3VO4 and protease inhibitor, Roche Applied 
Science). The lysates were collected following centrifugation at 15,000 g for 15 minutes 
at 4
o
C and loaded onto 3–8% NuPAGE® Novex® Tris-Acetate mini gels (Invitrogen, 
CA). The proteins in the gels were transferred simultaneously onto a nitrocellulose 
membrane, and blocked using 5% milk in TBS. VEGFR2 total protein levels were probed 
with antibodies against VEGFR2 (#2479; Cell Signaling Technology) and anti-HA tag 
(ab9134; abcam), followed by HRP conjugated antibodies anti-Rabbit (W4011, Promega) 
and Goat anti-rat (sc-2006, Santa Cruz Biotechnology) respectively. The membranes 
were incubated with substrate (Amersham ECL Plus™ Western Blotting Detection 
Reagent) for 2 minutes. The x-ray film was exposed for 3 minutes. 
3.3. Results 
3.3.1. Full-length VEGFR2 dimerizes in the absence of ligand 
VEGFR2 can dimerize in the absence of ligand. Unliganded dimers have been reported 
for other RTKs (84, 86), and they have been shown to play an important biological role 
by potentiating the response of the receptor to ligand. Unliganded VEGFR dimers has not 
been investigated in the literature, and thus (by default) VEGFR2 activation is assumed to 
be canonical. To characterize the unliganded dimerization of full-length VEGFR2, we 
used a FRET method that gives quantitative dimerization propensities of RTKs (22). 
Measurements were performed in plasma membrane derived vesicles using the QI-FRET 
method as previously described.  These experiments were designed such that receptor 
concentrations varied over one to two orders of magnitude, and the concentrations of the 
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receptors are measured in the plasma membrane-derived vesicles, along with FRET 
efficiencies. Thus, we can assess if the data is described by a dimerization model, 
calculate dimeric fractions, and dimerization free energies.  
Plasmids encoding for full-length VEGFR2 linked to fluorescent proteins at the C-
terminus were constructed as shown in Materials and Methods. CHO cells were co-
transfected with plasmids encoding for VEGFR2-YFP and VEGFR2-mCherry. CHO 
cells do not express VEGFR2 or VEGFA (Figure 3), and thus the CHO cell line is 
appropriate for these experiments. After VEGFR2 was expressed and trafficked to the 
plasma membrane, the cells were vesiculated by applying osmotic stress as described. 
Each vesicle was imaged, and FRET efficiencies, donor concentration, and acceptor 
concentration were determined for each vesicle. The measured FRET efficiency for each 
vesicle is shown as a function of acceptor concentration in Figure 1 (red solid symbols). 
With the solid line, we show the so-called proximity FRET which occurs due to random 
approach of donors and acceptors, in the absence of specific FRET. This contribution has 
been characterized in detail in previous work. We see that FRET significantly exceeds the 
proximity FRET values, indicative of specific interactions. 
The donor versus the acceptor concentration and the corrected FRET as a function of 
total concentration in each vesicle are plotted in Figure 1. The FRET data are then used to 
determine both the dimer stabilities (G) and I-FRET as discussed in Supplemental 
Material.  The dimer stabilities are a quantitative measure of the dimerization propensity.  
The measured I-FRET value depends on the dimer structure, in particular on the distance 
and orientation of the fluorescent proteins in the dimer. The values are given in Table 1. 
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In Figure 1D we show the averaged dimeric fractions as well as the dimerization curve 
for full-length VEGFR2.  
The dimerization free energy is -6.1 kcal/mole. To evaluate the significance of 
dimerization, we examined the dimerization curves for physiological VEGFR2 




 per cell, 
corresponding to 10 to 100 receptors per square microns. We note that over this 
expression range expressions, 30% to 60% of full-length VEGFR2 are predicted to be 
dimeric.  These data demonstrate that VEGFR2 has a strong dimerization propensity and 
thus does not follow the canonical activation model, contrary to popular belief. 
3.3.2. VEGFR2 is autophosphorylated in the absence of ligand 
To further investigate if VEGFR2 can dimerize in the absence of ligand, we performed 
cross-linking experiments as described in Materials and Methods, using Western blotting.  
A cross-linked dimeric band for full-length VEGFR2 was observed in these experiments, 
confirming the FRET results that VEGFR2 can dimerize in the absence of ligand.  
Some RTKs have been shown to form phosphorylated dimers in the absence of ligand. 
To learn if VEGFR can be phosphorylated in the absence of ligand, we measured the 
phosphorylation full-length VEGFR2 receptors in the absence of ligand. We probed the 
phosphorylation of the tyrosines in the activation loop of the VEGFR2 kinase using anti-
P-Y1054/Y1059 antibodies.  Experiments were performed after starving for 24 hours, to 
remove any traces of growth factors. This fact, and the fact that CHO cells do not 
produce VEGF (Figure 3), allowed us to investigate the phosphorylation of unliganded 
VEGFR2 dimers. The blots, shown in Figure 2, demonstrate tyrosine phosphorylation in 
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the absence of ligand. The results in Figure 2 support the idea that VEGFR2 dimerizes 
and is at least partially phosphorylated in the absence of ligand.  
3.3.3. The extracellular domain inhibits VEGFR2 dimerization. The intracellular 
domain is not required for dimerization but significantly stabilizes VEGFR2 dimers. 
To understand how the unliganded dimer is stabilized, we asked how the three different 
VRGFR2 domains (EC, TM, and IC) contribute to the stability of the unliganded dimers.  
To answer this question, we performed experiments with two truncated VEGFR2 
constructs, one lacking the IC domain (a EC+TM construct) and one lacking both the EC 
and IC domains (a TM construct). The TM construct includes the VEGFR2 signal peptide 
(to be cleaved), VEGFR2 TM domain, a (GGS)5 flexible linker, and fluorescent proteins. 
The EC+TM construct also includes the VEGFR2 EC domain (see Figure 1B). The 
results for these two constructs are shown in Figure 1 with the olive and black symbols, 
and in Table 1. 
From Figure 1d, we see that: (i) the isolated TM domain forms dimers (dimer stability 
G = -4.5 kcal/mole). (ii) the EC domain inhibits dimerization (G = +1.1 kcal/mole), 
such that the stability of the EC+TM dimer is reduced to -3.4 kcal/mole. (ii) The IC 
domains stabilize the dimer by -2.7 kcal/mole. Thus, we show that the EC domain 
inhibits unliganded VEGFR2 dimerization, while the TM and IC domains promote 
dimerization (i.e. stabilize unliganded dimers). 
The results show that the TM and EC+TM constructs exhibit the same I-FRET value (I-
FRET  0.61).  The latter finding suggests that the addition of the EC domain does not 
alter the separation of the C-termini of the TM domains in the dimer. On the other hand, 
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the I-FRET values are distinctly different when the kinase domain is present, as expected, 
reflecting the difference in the attachment of the fluorescent proteins to the full-length 
and truncated receptors. 
Previous results (Figure S2A from (90)) agree with our results. These previous findings 
show that phosphorylation of VEGFR dramatically increased upon removal of the EC 
domain (phosphorylation of full VEGFR2 compared to TM+IC). 
3.3.4. Bound ligand causes a structural change in the receptor. VEGF-A121, VEGF-
A165, VEGF-C and VEGF-D induce similar structural change in the VEGFR2 
dimer. 
The idea of a structural change in RTK dimers upon ligand binding is a key concept in 
the pre-formed dimer model.  According to this paradigm, the unliganded dimers lack full 
activity because the kinase domains are not positioned optimally with respect to each 
other. Upon ligand binding, there is a structural change in the extracellular domain that 
propagates to the kinase domain. The TM domain can be expected to play a key role in 
this process, as it mediates the connection between the two soluble domains. However, 
structural changes are very challenging to detect directly in the native plasma membrane 
due to experimental limitations. Experiments in the RTK literature often utilize isolated 
RTK domains, and there are NO high resolution full-length RTK dimer structures. Thus, 
structural changes are difficult to capture experimentally even in model systems. For 
some RTKs, a large change in the separation between the C-termini of the TM domain 
has been proposed to occur upon ligand binding. We therefore asked if the VEGFR 
ligands can induce a change in the separation of the TM domain C-termini. To answer 
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this question, we compared the I-FRET values for the EC+TM constructs in the absence 
of ligand and in the presence of 3 ligands.   
In the absence of ligand, the Intrinsic FRET is obtained via two parameter fits as in 
Figure 1 (solid black squares), and the I-FRET value is 0.61, corresponding to separation 
between the proteins of 49 ± 1Å. In the presence of high ligand concentrations, when all 
receptors become 100% liganded dimers, the measured FRET signal does not depend on 
the concentrations of the receptors. We therefore preformed the FRET experiments in the 
presence of ligands at very high concentrations (2.5g/ml).  The goal here was to ensure 
that the receptors are in the liganded dimeric state, such that the measured FRET signal 
depends only on the distance and orientation of the fluorescent proteins and on the donor-
to-acceptor ratio (and not on dimerization).    
Data are shown in Figure 4. Consistent with expectation, the FRET efficiency does not 
depend on receptor concentration, suggesting that the dimeric fraction becomes 100% for 
all receptor concentrations. In the case of 100 % (constitutive dimerization) all the FRET 
experiments measure the value of the intrinsic FRET, after correcting for different donor-
to-acceptor ratios.  Figure 5 shows the distribution of the I-FRET values, which is about 
0.42 corresponding to a separation between the proteins of 56 ± 2 Å. 
Thus, we see that ligand binding changes the value of I-FRET for the EC+TM construct 
from 0.61 to 0.42. This change in I-FRET demonstrates that ligand binding leads to a 
structural change, suggesting that the fluorescent proteins become further apart in the 
dimer (illustrated in Figure 5). VEGF-A, VEGF-C and VEGF-D has been shown to 
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induce the same activation which is consistent with the same structural changes we 
observe here. 
3.3.5. The C482R mutation induces ligand-independent constitutive dimerization. 
The mutant unliganded dimer is similar to liganded wild-type dimers.  
The C482R mutation in D5 of VEGFR2 is implicated in infantile hemangiomas, 
characterized by disorganized angiogenesis in infants. It was identified in cultured 
hemangioma endothelial cells from two out of 9 subjects investigated in the study (11).  It 
is believed that this mutation leads to constitutive VEGFR signaling, through a 
mechanism that involved VEGFR2-mediated control over VEGFR1 expression (66). 
However, the effect of the mutation on VEGFR2 dimerization has not been investigated. 
Yet, mutations of Cysteines in RTK extracellular domains have been suggested to affect 
receptor dimerization. Therefore, we asked whether the C482R mutation might affect 
dimerization in the absence of ligand, as well as the dimer structure in the liganded state.  
With this goal in mind, we examined the unliganded dimerization of the mutant. The 
dimeric fraction did not depend on the concentration, similarly to the case when ligand 
was present, suggesting a constitutive dimer (Figure 6). Furthermore, the I-FRET value is 
exactly the same as measured in the presence of ligand. Thus, this mutation leads to 
constitutive dimerization of the VEGFR2 receptor, and the unliganded mutant dimer has 
the same structure as the liganded wild-type dimer. Thus, this mutation seems to emulate 
the effect of ligand. Further proof for this behavior comes from the fact that the addition 
of ligand does not alter dimerization (Figure 6). This finding is consistent with the idea 
that the mutant is dimeric, and that the unliganded mutant dimer adopts the liganded 
wild-type structure, prior to ligand binding. Importantly, Western blots under reducing 
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and non-reducing conditions, shown in Supplementary data, show that disulfide bond 
formation does not play a role in dimer stabilization. 
To investigate if VEGFR2 C482R is capable of ligand binding, we added saturating 
amount of VEGF121-Alexa Fluor to CHO vesicles expressing EC-TM-VEGFR2C482R-
(GGS)5-YFP. As Figure 6 (right) demonstrates, the mutant receptor was fully capable of 
binding VEGF. 
3.3.6. The V769E mutation causes a structural change in the isolated TM domain 
dimer, but stabilizes the dimer when the EC domain is present. 
The phosphorylation of VEGFR2 increases upon ligand binding. We found that the 
liganded VEGFR2 structure is characterized by larger separation between the C-termini 
of the TM domains. Thus, it appears that kinase auto-phosphorylation activity is higher 
for larger separation between these C-termini. To further examine this relationship, we 
characterized mutants with different phosphor-tyrosine activities as compared to wild-
type in the presence of ligand, and investigate if these mutants will give different I-FRET 
as compared to the wild-type. One such mutant is the V769E mutant, carrying a valine to 
glutamic acid substitution in its TM domain. The phosphorylation of the V769E mutant 
in the presence of VEGF121 is decreased when compared to wild type VEGFR2 (Figure 
S3 from (90)), however the activity of the V769E mutant is not different from VEGFR2 
in the absence of ligand.  
We performed experiments with the EC+TM and TM VEGFR2 constructs that carry the 
V769E mutation in the TM domain. In the absence of ligand, the dimer was more stable 
than the wild-type.  Such dimer stabilization has been observed for other glutamic acid 
76 
 
mutants in RTK TM domains, and can be interpreted as dimer stabilization die to the 
formation of E-mediated hydrogen bonds. The I- FRET value that we obtained is similar, 
suggesting that this hydrogen bond does not perturb the structure of the unliganded 
dimer. The I-FRET value in the presence of ligand, however, is distinctly different, and 
has a value of 0.54 (Figure 7). This is smaller than in the case of the liganded wild-type 
dimer, consistent with the connection between (i) distance between C-termini of the TM 
domains and (2) phosphorylation.   
3.3.7. The D7(VEGFR2)D6(VEGFR1) mutation affects ligand-independent and 
ligand-dependent dimerization, yet VEGFR2 is capable of binding to VEGFA121. 
The D4(VEGFR2)D5(VEGFR1) mutation completely inactivates VEGFR.  
Studies in the literature have focused on mapping out possible contacts that stabilize the 
active ligand-bound state of the receptor.  Electron microscopy (120) and small-angle 
solution scattering (71) studies of ECD of VEGFR2 in the presence of VEGF 
demonstrated that contacts occur between D7 and D4 subunits predominantly. 
Furthermore, a crystal structure of the D7 VEGFR2 dimer rvealed direct D7-D7 contacts 
(165). Thus, the current structural model postulates that the ligand-bound EC domain 
dimer is stabilized by ligand binding to D2 and D3, as well direct receptor-receptor 
contacts, specifically D4-D4 and D7-D7 contacts (120). These D4-D4 and D7-D7 
contacts are believed to be essential as they establish the relative positioning of the 
receptors in the dimer, and ultimately affect the positioning of the kinase domains with 
respect to each other.  Consistent with this view, changes in sequence within the putative 
contacts regions have been linked to decrease in receptor activity. 
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Here we sought to directly investigate if the liganded dimer is affected if the D4-D4 and 
D7-D7 contacts are disturbed. With this goal in mind, we examined two mutants in which 
D4 and D7 are not present. We reasoned that if the contacts between these domains 
indeed establish the active structure, we will obtain a value for I-FRET that is different 
from the wild-type. We therefore created EC+TM constructs that had the following 
substitutions D7(VEGFR2)D6(VEGFR1) and  D4(VEGFR2)D5(VEGFR1). 
 We characterized the dimerization of the mutants in the presence and absence of ligand. 
The results are shown in Figures 8 and 9. Figure 8 demonstrates that the replacement of 
D7 of VEGFR2 with D6 of VEGFR1 affects both unliganded and liganded dimerization 
(data in open magenta and solid blue respectively). The measured FRET was not 
consistent with the dimerization model, suggesting the possibility of formation of higher 
order oligomers for this mutant.  
Upon ligand addition, the FRET data overlapped with measurements in the absence of 
ligand. Thus, the dimerization was not changed in the presence of ligand. We therefore 
assessed the ligand binding capability of the mutant in the plasma membrane derived 
vesicles. As shown in figure 8 (right), VEGFA121 binds to VEGFRD7

D6, as observed in 
fluorescent microscopy experiments. This work suggests that ligand binds to the mutant 
oligomers, but does not stabilize these oligomers. The ligand does not induce a transition 
to a liganded dimer, either.  
The results for ECTM VEGFR2D4

D5 construct are shown in Figure 9. This mutant forms 
dimers with slightly higher propensity compared to wild type VEGFR2. However, the 
dimer structure appears to be quite different from the wild-type, as suggested by the very 
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high I-FRET observed for this mutant. Furthermore, upon ligand addition, we observed 
no change in the FRET data for this mutant, either. Unlike the D7 mutant, this mutant did 
not bind ligand (see Figure 9).  We interpret this finding as a demonstration that the 
D4D5 mutation induced a transition to a completely different dimer structure that is not 
observed for the wild-type. This novel structure does not bind ligand and does respond to 
it, and can be considered analogous to the “inactivated” third state of channels. This view 
is consistent with prior results of (65), which showed that this mutation of domain 4 
completely inactivates the receptor. 
3.4. Discussion 
VEGFR2 is believed to exist in a monomeric form in the absence of ligand, and to follow 
the canonical model of ligand-induced dimerization and activation.  Using a quantitative 
FRET-based assay that is specifically designed to probe receptor dimerization in the 
plasma membrane, we demonstrated that full-length VEGFR2 forms dimers in the 
absence of ligand.  We further showed that VEGFR2 unliganded dimers are partially 
phosphorylated, using Western blotting. Both dimerization and phosphorylation increase 
with receptor expression, suggesting that they are correlated. Unliganded dimers have 
been previously observed for other RTKs, such as EGFR and FGFR.  Thus, VEGFR2 
shares a mode of activation with RTKs from different families. 
The QI-FRET methodology can monitor structural changes in the cytoplasmic portion of 
the dimer in response to ligand binding to the extracellular domain.  Here, the QI-FRET 
experiments directly demonstrated that ligand binding induces a structural change in the 
VEGFR2 dimer, in the plasma membrane.  Since VEGFR2 TM domain has been 
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previously suggested to play an active role in establishing the ligand-bound dimer 
structure, the experiments were performed with a truncated VEGFR2 construct in which 
the FPs were attached via a flexible (GGS)5 linker directly to the C-termini of the TM 
domain. Upon ligand binding, the Intrinsic FRET decreased from 0.61 to 0.42, 
corresponding to an increase in separation between the fluorescent proteins in the dimer 
from 49 to 56 Å. Thus, ligand binding increased the separation between the C-termini of 
VEGFR2 TM domains.  
The phosphorylation of all VEGFR2 tyrosines is known to increase upon ligand addition. 
Therefore, the increase in separation between the C-termini of the TM domains correlates 
with an increase in phosphorylation. A similar mechanism of activation has been 
proposed for EGFR; the large separation between EGFR TM C-termini in the ligand-
bound state is believed to create the space needed for the assembly of the active kinase 
dimer. However, the structural change observed for VEGFR2 upon VEGF binding is the 
opposite to the one observed for FGFR upon fgf2 binding.  Thus, while a ligand-induced 
structural change seems to be a general principle of RTK activation, the exact nature of 
the change can be quite different for different receptors.  
The significance of the ligand-bound state is highlighted by our results for the C482R 
VEGFR mutant, identified in infant hemangiomas. We showed that this mutant forms a 
constitutive dimer even in the absence of ligand. Since this mutation eliminates a cysteine 
and thus results in an unpaired cysteine, we expected that the mutant dimer is stabilized 
by a disulfide bond. The comparison of the Western blot results under reducing and non-
reducing conditions, however, were identical, suggesting that this is not the case.  The 
Intrinsic FRET measured for the mutant in the absence of ligand was the same as the 
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Intrinsic FRET measured for the WT in the presence of ligand. Thus, the C482R mutation 
forced the unliganded dimer into the WT liganded state, mimicking the effect of ligand. 
Questions arise as to whether VEGFR2 dimers can exist in other configurations that are 
different from the unliganded and liganded states observed for the WT.  Insights came 
from studies of the V769E mutant. The Intrinsic FRET for the mutant dimer in the 
presence of ligand is 0.54, a value that is not observed for the WT. The V769E mutation 
therefore destabilized the liganded state and induced a transition to a new dimer 
configuration. Thus, the VEGFR2 dimer exhibits a high degree of plasticity.  
The plasticity of the VEGFR2 dimer is further confirmed by our results for the D4 and 
D7 mutants. The D4 mutant formed a dimer with very high intrinsic FRET, 0.82, 
corresponding to tightly packed TM C-termini.  This state is structurally different from 
both the unliganded and liganded WT states, and is not capable of binding ligands. The 
D7 substitution induced a transition into yet another structural state. This mutant formed 
an oligomer, not a dimer, even in the absence of ligand. Unlike the D4 dimer, the D7 
oligomer was capable of binding VEGFR. Yet, ligand binding neither stabilizes the D7 
oligomer, nor altered its structure.  
Previously, the decreased activation of D4 and D7 mutants upon ligand addition was 
interpreted as an indication that D4-D4 and D7-D7 contacts position the two receptors in 
the dimer correctly with respect to each other in the ligand-bound state. With the help of 
the QI-FRET methodology we demonstrated that, in fact, the D4 and D7 domain 
substitutions affected the unliganded state. VEGF either failed to bind to the altered 
structure (in the case of the D4 mutant), or failed to induce a transition to the liganded 
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state (in the case of the D7 mutant). Thus, our work highlights the importance of the 
unliganded state as an intermediate in VEGFR2 signal transduction. 
Based on our results, it can be argued that the inhibition of unliganded VEGFR2 dimers, 
in parallel to VEGFR2 liganded dimers, may be a new useful therapeutic strategy.  With 
such future applications in mind, we sought new insight into the unliganded VEGFR2 
dimer state. Here we measured the contributions of the different VEGFR2 domains to 
unliganded dimerization. First, we showed that VEGFR2 intracellular domain has a large 
favorable contribution to unliganded dimerization. Thus, targeting the interactions 
between VEGFR2 intracellular domains can significantly decrease unliganded VEGFR2 
dimer populations. Second, we demonstrated that the contribution of the entire VEGFR2 
EC domain to unliganded dimerization is inhibitory.  One way to interpret this finding is 
to assume that the EC domains do not interact, and inhibit unliganded dimerization due to 
steric hindrance.  This interpretation, however, is difficult to rationalize in view of our 
finding that the substitution of D4 and D7 significantly alters the unliganded state. It is 
thus possible that D4-D4 and D7-D7 interactions stabilize the unliganded VEGFR2 
dimers, while other domains in the extracellular portion of the receptor have inhibitory 
contributions to unliganded dimerization.  
Over-all, this work establishes the existence and the significance of VEGFR2 unliganded 
dimers. Very little is known about these dimers, and their high resolution structures are 
unknown.  Future studies of these dimers will be required in order to arrive at complete 



























































































Figure 3-1. FRET data describing VEGFR2 dimerization. (A) FRET efficiencies as a 
function of acceptor concentration for full length VEGFR2 (solid red diamonds), EC-TM 
VEGFR2 (solid black diamonds), and TM VEGFR2 (open olive circles). A schematic of 
these receptor constructs is shown in Figure S1.  (B) FRET efficiencies corrected for 
stochastic FRET. (C) Donor to acceptor values plotted for the three constructs. (D). 
Dimeric fractions versus total receptor concentrations, for the full-length VEGFR2 (red 
solid diamonds), EC+TM VEGFR2 (black solid diamonds), and the TM domains only 
(olive, open circles). The measured dimeric fractions are binned and are shown with the 
symbols, along with the standard errors. The solid lines are the best fits of a monomer-
dimer equilibrium model to the data. These data demonstrate that the TM domains have a 
very strong propensity for dimerization. The EC domains, on the other hand, inhibit 











Variant ΔG (kcal/mol) Ẽ Distance between 
fluorophores (Å) 
Full length VEGFR2 -6.1 ± 0. 4 0.82 ± 0.06 41 ± 3 
Wild Type  EC+TM VEGFR2 -3.4 ± 0. 2 0.61 ± 0.05 49 ± 1 
WT+VEGF A 121 - 0.45 ± 0.08 56 ± 2 
WT+VEGF A 165 - 0.43 ± 0.09 56 ± 2 
WT+VEGF C - 0.43 ± 0.09 56 ± 2 
WT+VEGF D - 0.43 ± 0.09 56 ± 2 
WT TM -4.8 ± 0. 2 0.61 ± 0.05 49 ± 1 
V769E TM -4.8 ± 0. 2 0.78 ± 0.02 43 ± 1 
D7 MUT - - - 
D7 MUT+VEGF 121 - - - 
D4 MUT -4.7(+0.5,-0.3) 0.82 (+0.1, -0.08) 41(+4,-3) 
D4 MUT+VEGF 121 -4.7(+0.5,-0.3) 0.82 (+0.1, -0.08) 41(+4,-3) 
C482R MUT - 0.45 ± 0.08 56 ± 2 
C482R MUT+VEGF 121 - 0.45 ± 0.08 56 ± 2 
V769E ECTM MUT -4.2 ± 0. 2 0.61 ± 0.05 49 ± 1 
V769E ECTM MUT+VEGF 121 - 0.54±0.05 52± 1 
 
 
Domain ΔΔG IC ΔΔG EC 





Table 3-1.  Dimerization free energies (dimer stabilities) ΔG and Intrinsic FRET 
efficiencies Ẽ, obtained from least-square parameter fits to the FRET data for full-length 
and truncated constructs that lack the IC domain (EC+TM) and both EC and IC (TM 
only). 
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Figure 3-2. VEGFR2 cross-linking and phosphorylation in CHO cells. (A) BS3 cross-
linking of CHO cells expressing VEGFR2.  Cells were starved for 24 hours to ensure 
there was no ligand present. Staining with anti-VEGFR2 antibodies shows the presence 
of a glycosylated monomer band at MW ~ 240 kDa and glycosylated dimer band at MW 
~ 480 kDa. These results support the FRET results in Fig. 1 that VEGFR2 forms ligand-
independent dimers in the plasma membrane. (B) Western blots showing the expression 
and activation of full-length VEGFR2 in CHO cells in the absence of ligand, when a 
range of μg of DNA was used for transfection (Lane 2). The expression of the three 
receptors is probed with anti-VEGFR2 antibody. The phosphorylation of tyrosines in the 
activation loop of the three receptors is probed with anti-p-1054/1059 antibodies. We see 
antibody staining in all cases, suggesting that the probed tyrosines are phosphorylated in 
the absence of ligand. We did not observe VEGFR2 staining in CHO cells unless 




















Figure 3-3. CHO, HEK293T and MEC (microvascular endothelial) cells stained for 

















Figure 3-4. Left: (A) FRET efficiency measured as a function of acceptor concentration 
for EC+TM VEGFR2, in the absence of ligand and in the presence of VEGF-A121, 
VEGFA-165, VEGF C or VEGF D. The proximity FRET contribution is shown as solid 
line. (B) FRET values, were corrected for stochastic FRET contributions. (C) Donor 
concentrations plotted against acceptor concentrations for unliganded and liganded 
EC+TM VEGFR2. (D) Intrinsic FRET values, measured for the three EC+TM receptors 
in the presence of saturating concentrations of VEGF-A121, VEGF-A165, VEGF-C and 
VEGF-D. Right: confocal images showing VEGF-A121-Alexa Fluor 594 binding to EC-





















Figure 3-6. Left: FRET data comparing the dimerization of wild-type in the absence of 
ligand (black), the C482R mutant in the absence of ligand (blue) and the C482R mutant 
in the presence of ligand (dark yellow). (A) Measured FRET efficiencies in single plasma 
membrane derived vesicles. (B) Corrected FRET. (C) Measured donor versus acceptor 
concentrations in each vesicle. The measured FRET for the mutant does not depend on 
concentration, demonstrating that the mutant is a constitutive dimer in the presence and 
absence of ligand (D) Histograms of measured FRET efficiencies for the mutant, 
revealing Intrinsic FRET values of ~ 0.42. Right: Confocal images of VEGF-A121-Alexa 



















































Figure 3-7. Results for the V769E mutant. (A) Dimeric Fractions in the absence of 
ligand. The solid line is the fit of the dimerization model to the data. The dimerization 
constant and the Intrinsic FRET values, obtained in the fit, are shown in Table 1. (B) 
Histograms of I-FRET values measured in single vesicles in the presence of ligand. The 



















Figure3- 8. Left: (A) FRET efficiency plotted as a function of acceptor concentration for 
WT EC+TM and D7D6 ECTM VEGFR2. (B) Donor concentration plotted against 
acceptor concentration for each vesicle. (C) Raw FRET was corrected for random FRET 
contribution. The FRET dta do not fit the dimerization model, suggesting that the 
D7D6 (VEGFR1) substitution results in the formation of an oligomeric complex. 





 Figure 3-9. Left:  (A) FRET efficiency plotted as a function of acceptor concentration 
for WT EC+TM and D4D5 ECTM VEGFR2. (B) Donor concentration plotted against 
acceptor concentration for each vesicle. (C) Raw FRET was corrected for random FRET 
contribution. D4D5 (VEGFR1) mutation results in formation of a slightly more stable 
dimer than wild type VEGFR2. (D) Dimeric fraction versus receptor concentration for 
the wild-type and the mutant (E).  Dimeric fraction versus receptor concentration for the 
wild-type and the mutant in the presence of ligand.  Right:  the mutant VEGFR2 is not 
capable of ligand binding, as evident from the lack of binding of VEGF121-Alexa Fluor 








Figure 3-10. Our proposed dimerization model for VEGFR, based on our experiments 
only the above scenarios are possible on the plasma membrane. This corrects/refines 
models offered by previous studies based on VEGFR2 TM domain or EC domain 






Figure S1(3-11). The constructs used in the FRET experiments. The full-length receptors 
had fluorescent proteins attached to their C-termini via a flexible GGS linker. The 
truncated receptors had the intracellular domain substituted with a fluorescent protein, 
which was attached to the TM domain via a longer flexible (GGS)5 linker. SP: signal 
peptide, EC: extracellular domain, TM: transmembrane domain. Fluorescent protein was 




















Figure S3(3-13). Left: reduced SDS PAGE and Right: Non-reduced SDS PAGE for WT 
and C482R VEGFR2 followed by western blot staining demonstrates that the constitutive 
dimerization as a result of C342R mutation is not due to cysteine linked disulfide bonds. 
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Receptor Tyrosine Kinases (RTKs) conduct biochemical signals upon dimerization in the 
membrane plane. While RTKs are generally known to be activated in response to ligand 
binding, many of these receptors are capable of forming unliganded dimers that are likely 
important intermediates in the signaling process. All 58 RTKs consist of an extracellular 
domain, a transmembrane (TM) domain, and an intracellular domain which includes a 
juxtamembrane (JM) sequence and a kinase domain. Here we investigate directly the 
effect of the JM domain on unliganded dimer stability of FGFR3, a receptor that is 
critically important for skeletal development.  The data suggest that FGFR3 unliganded 
dimers are stabilized by receptor-receptor contacts that involve the JM domains. The 
contribution is significant, as it is similar in magnitude to the stabilizing contribution of a 
pathogenic mutation and the repulsive contribution of the extracellular domain. 
Furthermore, we show that the effects of the JM domain and a TM pathogenic mutation 
on unliganded FGFR3 dimer stability are additive. We observe that the JM-mediated 
dimer stabilization occurs when the JM domain is linked to FGFR3 TM domain and not 
simply anchored to the plasma membrane. These results point to a coordinated 
stabilization of the unliganded dimeric state of FGFR3 by its JM and TM domains via a 





Receptor tyrosine kinases (RTKs) are membrane proteins that control cell proliferation, 
differentiation, survival and migration (85, 159). They are thus implicated in many 
pathologies, including tumorigenesis, cancer progression, and developmental 
abnormalities (48, 159).  The basic architecture of all RTKs consists of a ligand-binding 
extracellular (EC) domain, a single transmembrane domain and an intracellular portion 
composed of a juxtamembrane (JM) sequence, and a kinase domain (39, 76).  The 
activation of RTKs requires that they dimerize in the plasma membrane, an event that 
brings the two kinase domains in close proximity and leads to their phosphorylation 
(126). This is followed by the phosphorylation of additional tyrosine residues in the 
intracellular domains, which triggers the recruitment of adaptor proteins, and the 
initiation of intracellular signaling cascades (37, 127, 168).  
While the general principles of RTK activation are now well established, we still lack 
comprehensive mechanistic understanding of this process, despite very active research in 
the field.  In the “canonical” model of RTK activation (39), RTKs are monomers in the 
absence of ligand, but dimerize and cross-phosphorylate/activate each other upon ligand 
binding. However, recent work has identified unliganded dimers for many RTKs (36, 84, 
86, 91, 134), and thus an alternative “pre-formed dimer” model of RTK activation was 
proposed in which the RTKs are dimeric in the absence of ligand, and ligand binding 
induces a structural change in the dimer that reorients the catalytic domains for efficient 
activation (6, 56, 80). Activation may be therefore viewed as a thermodynamic change of 
state, i.e. a transition from an unliganded dimeric state which lacks full activity, to the 
fully active liganded dimeric state (56).  
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Recent studies of EGFR, the most widely researched RTK, has suggested that its JM 
domain is critical for establishing the distinct structural features of the liganded and 
unliganded states, and for the transition between the two states (4, 36, 67). In particular, 
while the liganded state is stabilized by direct N-terminal JM-JM contacts, in the 
unliganded state the JM domain interacts with membrane lipids and does not engage in 
stabilizing contacts (4, 36). Intriguingly, the behavior of EGFR JM domain appears to be 
impacted by the lateral interactions between the TM domains, via a mechanism that is not 
completely understood (36). 
Here we investigate the role of the JM domain of another RTK, FGFR3, in stabilizing the 
unliganded state. We also study the coordination of FGFR3 JM and TM domains in the 
absence of ligand. Many developmental abnormalities have been linked to disregulated 
unliganded FGFR3 dimerization (20, 53, 58, 64, 83, 94, 151), but the physical 
interactions that stabilize the unliganded FGFR3 dimer are not completely known. Here 
we make direct measurements of the effect of the JM domain on dimer stabilization, 
within and out of the context of the FGFR3 dimer. The results show that the FGFR3 JM 
domain, unlike the EGFR JM domain, plays an active role in stabilizing the unliganded 
FGFR3 dimers, in coordination with FGFR3 TM domain.  
4.2. EXPERIMENTAL METHODS 
The YFP plasmid was a gift from Dr. M. Betenbaugh (Johns Hopkins University, 
Baltimore, MD) and pRSET-mCherry was obtained from Dr. R. Tsien (University of 
California, San Diego). The plasmid encoding human wild-type FGFR3 was a gift from 




22 different gene constructs, inserted into the multiple cloning site of pcDNA3.1(+) 
between HindIII and XbaI (Table 1) were used in this study. The cloning procedures for 
FGFR3 TM-(GGS)5-YFP, FGFR3 TM-(GGS)5-mCherry, FGFR3 EC-TM-(GGS)5-YFP, 
FGFR3 EC-TM-(GGS)5-mCherry, GpA-(GGS)5-YFP and GpA-(GGS)5-mCherry, 
FGFR3 EC-TMA391E-(GGS)5-YFP, and FGFR3 EC-TMA391E-(GGS)5-mCherry have been 
described previously(22, 23, 122). All constructs included the signal peptide of FGFR3 
(MGAPACALALCVAVAIVAGASS) at the N-terminus. 
To create the FGFR3 EC-TM-JM-YFP and FGFR3 EC-TM-JM-mCherry plasmids, the 
AsiSi site before (GGS)5 in FGFR3 EC-TM-(GGS)5-YFP and FGFR3 EC-TM-(GGS)5-
mCherry was mutated to a BsrGI site. The FGFR3 EC-TM-(GGS)5-YFP and FGFR3 EC-
TM-(GGS)5-mCherry plasmid constructs containing the BsrGI site were then double 
digested using BsrGI and AgeI restriction enzymes. The complementary DNA (cDNA) 
encoding the JM domain of FGFR3 was amplified using Polymerase Chain Reaction 
(PCR), double digested with BsrGI and AgeI and ligated with FGFR3 EC-TM-(GGS)5-
YFP and FGFR3 EC-TM-(GGS)5-mCherry that have been digested with the BsrGI and 
AgeI restriction enzymes.  
To create the FGFR3 EC-TM-JM60-YFP and FGFR3 EC-TM-JM60-mCherry plasmid 
constructs, a XhoI site in the JM sequence of FGFR3 was utilized to double digest EC-
TM-JM60 using Hind III and XhoI. This cDNA was then inserted into the multiple 
cloning sites in the pcDNA3.1(+) vector plasmids encoding YFP and mCherry between 
the HindIII and XhoI sites. 
To generate GpA-(GGS)2-JM-YFP and GpA-(GGS)2-JM-mCherry, a BsrGI site was first 
created at the 7
th
 Glycine position in the (GGS)5 linker sequence in the GpA-(GGS)5-YFP 
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and GpA-(GGS)5-mCherry sequences. The cDNA encoding the JM domain of FGFR3 
together with YFP or mCherry was then amplified from FGFR3 EC-TM-JM-YFP and 
FGFR3 EC-TM-JM-mCherry using PCR, and double digested with the BsrGI and XbaI 
restriction enzymes. The JM-YFP/mCherry digested cDNA was then ligated into the 
pCDNA-GpA-TM-(GGS)5 vector which has been double digested with BsrGI and XbaI. 
The A391E mutation was generated in the FGFR3 EC-TM-JM60-YFP and FGFR3 EC-
TM-JM60-mCherry plasmid sequences using a QuickChange ® II XL Site-Directed 
Mutagenesis Kit (Strategene, CA). 
The GpA-(GGS)2-YFP/mCherry and GpA-(GGS)3-YFP/mCherry plasmid constructs 
were created from GpA-(GGS)5-YFP/mCherry. The GpA-(GGS)2 and GpA-(GGS)3 
cDNAs were amplified using PCR. The GpA-(GGS)5-YFP/mCherry plasmids were 
double digested with HindIII and AsiSI restriction enzymes. The amplified GpA-(GGS)2 
and GpA-(GGS)3 cDNAs were then double digested with HindIII and AsiSI and ligated 
with the double digested GpA-(GGS)5-YFP/mCherry cDNAs. 
4.2.1. Cell culture and transfection 
Chinease Hamster Ovary (CHO) cells were a kind gift of Dr. M. Betenbaugh (Johns 
Hopkins University, Baltimore, MD). The cells were cultured at 37 C with 5% CO2 for 
24h. Transfection was carried out using Fugene HD transfection reagent (Roche Applied 
Science), following the manufacturer’s protocol. Cells were co-transfected with total of 





4.2.2. Production of mammalian plasma membrane vesicles 
Vesiculation was performed as described previously(33). CHO cells were rinsed twice 
with 30% PBS (pH 7.4), and incubated with 1 mL of chloride salt vesiculation buffer 
overnight at 37 °C.  The vesiculation buffer consisted of 200 mM NaCl, 5 mM KCl, 0.5 
mM MgSO4, 0.75 mM CaCl2, 100 mM bicine and protease inhibitor cocktail (Complete 
mini EDTA-free tabs, Roche Applied Science) adjusted to PH of 8.5. A large number of 
vesicles were produced after 1.5 h, and the vesicles were transferred into 4-well Nunc 
Lab-Tek II chambered coverslips for imaging.  
4.2.3. Fluorescence Image Acquisition. Vesicles were imaged using a Nikon Eclipse 
confocal laser scanning microscope using a 60× water immersion objective. All the 
images were collected and stored at a 512 × 512 resolution. Three different scans were 
performed for each vesicle: (1) excitation at 488 nm, with a 500-530 nm emission filter 
(donor scan); (2) excitation at 488 nm, with a 565-615 nm emission filter (FRET scan); 
and (3) excitation at 543 nm, with a 650 nm longpass filter (acceptor scan). Gains of 8.0 
and pixel dwell time of 1.68 μs were used for the three scans. To minimize the bleaching 
of fluorescent proteins, ND8 filters were used during excitation with the 488 nm laser. 
The imaged vesicles exhibited uniform fluorescence intensities (see Figure 2), which 
allowed us to determine the concentrations of the fluorescent proteins in the membrane 
using solutions of purified YFP and mCherry solutions of known concentration as 
described in(125).  The fluorescent protein solutions were prepared as described in (125). 
They were imaged in the microscope using the same settings used for vesicle imaging, to 
allow direct comparison of solution and vesicle intensities. 
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Each vesicle was analyzed using a Matlab® program to determine the fluorescence 
intensity across the membrane(23, 81), which was fitted to a Gaussian function and the 
background intensity was approximated as an error function (see Figure 2). The donor, 
acceptor, and FRET intensities for each vesicle were used to determine (i) the donor 
concentration, (ii) the acceptor concentration, and (iii) the FRET efficiency in each 
vesicle as described in detail elsewhere (23, 81) and in Supplementary Material.   
4.2.4. QI-FRET DATA ANALYSIS IN BRIEF 
Please refer to ref.(22) for a step-by-step detailed protocol.  
Each vesicle co-expressing FGFR-YFP and FGFR-mCherry was imaged in the donor, 
acceptor and FRET channels, yielding the fluorescence intensities, ID, IFRET, and IA (see 
Figure 2).  The acceptor concentrations in each vesicle, CA , is calculated according to: 






C      (1) 
 
The sensitized emission of the acceptor in each vesicle is determined as: 
DDAAFRETSEN IIII       (2) 
The donor intensity in the absence of the acceptor ID,corr , and the donor concentrations 
(CD) are calculated as: 
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and is corrected for the so-called “by-stander FRET” that one would expect if there were 
no specific protein interactions, but donors and acceptors approached each other by 
chance within distances of 100 Å or so (the reader is referred to a detailed discussion in 
ref.(70)). FRET due to sequence-specific dimerization ED is proportional to the fraction 
of receptors in the dimeric state: 






D ~      (7)
 
xA is the acceptor fraction. The proportionality constant E
~
is the “Intrinsic FRET”, the 
FRET efficiency in a dimer containing a donor and an acceptor. This is a purely structural 
parameter, which depends only on the separation and the orientation of the two 
fluorescent proteins in the dimer, but not on the dimerization propensity. 
Based on the law of mass action, the dimeric fraction can be written as a function of the 














fD       (8) 


















                   (9) 
We use equation (9) to fit the measured ED/xA while optimizing for the two adjustable 
parameters: the dimerization constant K, and the intrinsic FRET Ẽ.  The free energy of 
dimerization (dimer stability) is calculated according to: 
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)ln(KRTG                                             (10) 
 
4.3. SECONDARY STRUCTURE PREDICTIONS 
Secondary structures of FGFR3 and EGFR JM domains were evaluated using the 
program JPRED: http://www.compbio.dundee.ac.uk/www-jpred.  
The underlined amino acids in FGFR3 JM domain are predicted to have -sheet 
propensities. No helical segments are predicted for FGFR3. For EGFR, a helical segment 
is predicted (underlined and bold), which has been shown to interact with lipids in the 






















4.4.1. The substitution of an unstructured linker with the FGFR3 JM domain 
stabilizes FGFR3 dimers in the absence of ligand. 
Previously, we have shown that the FGFR3 construct EC-TM-(GGS)5-YFP/mCherry  
(Table 1), in which the intracellular domain has been substituted with a fluorescent 
protein attached via a (GGS)5 linker, forms dimers in mammalian plasma membrane 
derived vesicles in the absence of ligand (23). The (GGS)5 linker has been shown to be 
unstructured and to behave like a random coil (38). Here we substituted this 15-residue 
flexible linker with the 72 amino acid long JM domain of FGFR3 (see Figure 1) and we 
asked how this substitution affects dimerization. To answer this question we measured 
and compared the dimerization of EC-TM-(GGS)5-YFP/mCherry and  EC-TM-JM-
YFP/mCherry in plasma membrane derived vesicles from CHO cells. 
In these experiments, CHO cells were first co-transfected with plasmids encoding either 
EC-TM-JM-YFP and EC-TM-JM-mCherry or EC-TM-(GGS)5-YFP and EC-TM-
(GGS)5-mCherry. After the receptors were produced and trafficked to the plasma 
membrane, the cells were induced to form plasma membrane derived vesicles using an 
osmotic stress method described recently(33). The dimerization of the two FGFR3 
constructs was characterized with a FRET-based method termed QI-FRET as described 
previously(22). The FRET experiments were performed with a laser-scanning confocal 
microscope, imaging a thin slice through the equator of each vesicle (see Figure 2). For 
each receptor, 600 to 1000 individual plasma membrane-derived vesicles were imaged 
and analyzed with the QI-FRET method which yields (i) the donor concentration, (ii) the 
acceptor concentration, and (iii) the FRET efficiencies in each vesicle. The total receptor 
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concentration and the dimeric receptor fraction were calculated in each vesicle, and data 
from many vesicles were combined to yield dimerization curves (Figure 3).  
The QI-FRET methodology has been published as a detailed step-by-step protocol(22), 
and the reader is referred to this protocol for details. In addition, basic concepts behind 
the QI-FRET method are briefly outlined in Supplemental Material to this manuscript 
(see also Figure 2 for an illustration of vesicle image processing).   
Unique aspects of the methodology are: (i) we design our experiments such that receptor 
concentrations are varied over a wide range, and (ii) we independently measure donor 
and acceptor concentrations in the plasma membranes, along with FRET efficiencies. 
Thus, we can assess if the data is described by a dimerization model, calculate dimeric 
fractions, and predict dimeric fractions for receptor concentrations that are not 
experimentally accessible.  From the data, we determine (i) the dimerization constant, K, 
and the dimer stability, or the dimerization free energy G = -RT lnK and (ii) the purely 
structural parameter "Intrinsic FRET”, Ẽ(22).  The measured Intrinsic FRET value 
depends on the dimer structure, in particular on the distance and orientation of the 
fluorescent proteins in the dimer. Most importantly, this is a parameter that affects the 
measured FRET efficiencies, and it needs to be determined and accounted for in order to 
correctly measure K and the dimer stability G. The Intrinsic FRET value Ẽ is a means to 
compare structures and follow large-scale structural perturbations.  
The FRET efficiencies measured the two FGFR3 constructs are shown in Figure S1, 
where each data point represents a single vesicle. The donor concentration in each vesicle 
is also shown in Figure S1 versus the acceptor concentration in the same vesicle. Thus, 
each vesicle contains different concentrations of donors and acceptors, and different total 
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receptor concentrations. From the FRET efficiencies and the donor to acceptor ratio in 
Figure S1 and following the step-by step QI-FRET protocol (22), we obtain the 
dimerization curves shown in Figure 3, as well as the dimerization constant K and Ẽ 
shown in Table 1. 
In Figure S1, the FRET efficiencies appear higher in the presence of the JM domain, 
suggesting that the dimerization is higher when the JM domain is present. After 
accounting for the effect of Ẽ, in Figure 3 we show that the dimeric fraction is higher in 
the presence of the JM domain. The dimerization free energy changes from -3.4 
kcal/mole to -5.4 kcal/mole upon the substitution of the unstructured linker with the JM 
domain. Thus, this substitution increases the stability of the FGFR3 dimer byGJM = -2 
kcal/mole.  
4.4.2. The interplay of FGFR3 domain interactions 
To understand the interplay of the different domains in FGFR3 unliganded dimerization, 
next we studied how the dimerization of the FGFR3 construct studied above changes 
when the EC domains were deleted. Specifically, we worked with (a) a FGFR3 construct 
containing the TM domain, the JM domain, and fluorescent proteins (TM-JM-
YFP/mCherry) and (b) a FGFR3 construct containing the TM domain, a 15 amino acid 
flexible (GGS)5 linker, and fluorescent proteins  (TM-(GGS)5-YFP/mCherry), see Figure 
1. The dimerization results for the two proteins are shown in Figure S2 and Figure 4.  
For TM-(GGS)5-YFP/mCherry, we measure unliganded dimer stability of -5.2 kcal/mole 
(Figure 4), which is higher than the stability in the presence of FGFR3 EC domain.  
Comparison of the stabilities of the EC+TM and TM dimers (-3.4 and -5.2 kcal/mole, 
respectively), demonstrates that the deletion of the EC domain stabilizes the dimer by 1.8 
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kcal/mole, with the positive sign indicating that the contribution is inhibitory.  This result 
is similar to our previous measurements in vesicles produced via chemical vesiculation 
using formaldehyde and DTT (129-131), which yielded ~1 kcal/mole for the inhibitory 
EC domain contribution(23).   
In Figure S2, the FRET efficiency for TM-JM-YFP/mCherry construct does not depend 
on the concentrations, which suggests that the construct is 100% dimer over the 
concentration range we study.  In this case, the exact values of K and GJM cannot be 
determined. However, the data demonstrate that the stability of the FGFR3 TM dimer is 
increased by at least -1.5 kcal/mol in the presence of the JM domain.   
The data in Figures 3 and 4 suggest that the substitution of the unstructured linker with 
the JM domain stabilizes the FGFR3 dimer by -2 kcal/mole, while the EC domain 
inhibits dimerization by 1.8 kcal/mole. In other words, the stabilizing effect of the JM 
domain cancels the inhibitory contribution of the EC domain in the FGFR3 unliganded 
dimer.  
4.4.3. The (GGS)5  linker does not contribute significantly  to dimerization. 
The (GGS)5 linker has been previously assumed to have a negligible effect on protein 
interactions as it is thought to be long enough to allow for flexibility and to prevent 
significant steric overlap between the fluorescent proteins in the dimer (22, 38). Here, we 
sought experimental support for this assumption.  
We reasoned that if the linker affects dimerization, for instance due to the overlap of the 
random coil radii of the two linkers, or due to the steric clash of the fluorescent proteins, 
its contribution will depend on its length.  We therefore compared the interactions 
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between TM helices when the fluorescent proteins were attached to 6, 9, and 15 amino 
acid long linkers. To address this question in a most general context, we performed the 
experiments with the TM helix of glycophorin A (GpA), a well-characterized sequence 
that is traditionally used as a model in transmembrane helix dimerization studies (63, 77). 
In particular, we characterized the dimerization of GpA TM domain when the fluorescent 
proteins are connected via (GGS)2, (GGS)3, and (GGS)5 linkers (see Figure 1).  
Dimerization results for the three constructs are shown in Figure S7, Figure 5, and in 
Table 1. The length of the linker had no effect on GpA dimer stability. The dimerization 
curves in Figure 5 are essentially identical, as also shown by the resulting dimerization 
free energies in Table 1. Furthermore, the value of the Intrinsic FRET, Ẽ, is the same for 
GpA-(GGS)3-YFP/mCherry and GpA-(GGS)5-YFP/mCherry (0.52).  The value of Ẽ is 
somewhat lower for GpA-(GGS)2-YFP/mCherry (0.41), which may be indicative of 
restrictions in mobility of the fluorescent proteins when attached to the shortest linker.  
Overall, these data support the idea that the (GGS)5 linker does not contribute measurably 
to the stabilization of TM dimers. Thus, the GJM contribution that we measure above 
represents the stabilizing contribution of the JM domain. 
4.4.4. Tethering the JM domain to the membrane does not lead to stabilizing 
interactions 
The behavior of the JM domain of EGFR has been shown to depend on the TM 
domain(4, 36).  To test if the FGFR3 JM domain has inherent stabilizing interactions that 
arise simply from membrane tethering, we attached the JM domain to the unrelated GpA 
TM domain via a short, flexible (GGS)2 linker (GpA-(GGS)2-JM-YFP/mCherry, see 
Figure 1). The role of GpA in this experiment was to anchor the protein to the plasma 
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membrane and bring the two JM domains into close proximity upon dimerization. The 
role of the (GGS)2 linker was to decouple the JM domain from the GpA helices, since the 
GpA and FGFR3 dimer structures are different, and the cytoplasmic ends of the dimeric 
helices have different separations. 
We compared the dimerization of the GpA-(GGS)2-JM-YFP/mCherry and GpA-(GGS)5-
YFP/mCherry constructs. The results for these two constructs are shown in Figure S4, 
Figure 6 and in Table 1.  There is no difference in the dimerization of the two constructs. 
Thus, the effect of the substitution of the (GGS)5 linker with (GGS)2-JM was negligible. 
The JM domains therefore engaged in stabilizing contacts only when attached to the TM 
domain of FGFR3 in the appropriate context, but not when closely tethered to the 
membrane via a short, flexible (GGS)2 linker on a different TM domain. Thus, the 
behavior of FGFR3 JM domain in our experiments depends on the details of the TM 
domain dimer. In FGFR3, the two domains seem to act in synergy to stabilize the dimeric 
form. 
4.4.5. The interactions between the JM domains occur within the N-terminal part of 
the JM sequence. 
In EGFR, direct JM-JM contacts in the liganded state occur in the N-terminal portion of 
the JM domain (4, 67). Here we asked whether, similarly, the N-terminal end of the 
FGFR3 JM domain might be responsible for the JM-mediated stabilization of the FGFR3 
unliganded dimers. In particular, we investigated if the removal of a C-terminal segment 
from the JM segment will decrease FGFR3 dimer stability in the absence of ligand. We 
thus shortened the JM domain by 12 residues, using a convenient restriction site in the 
DNA sequence encoding the JM domain. We then measured the dimerization of the 
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construct EC-TM-JM60-YFP/mCherry containing the shorter 60 amino acid JM sequence. 
Results are shown in Figure S5, Figure 7 and in Table 1. The dimer stabilities for EC-
TM-JM60-FP and EC-TM-JM-FP are the same, demonstrating that the C-terminal 12 
amino acid segment of the JM domain does not participate in JM-JM stabilizing 
interactions. Furthermore, the value of the intrinsic FRET, Ẽ, is somewhat higher in the 
case of the shorter linker (0.7 versus 0.57, see Table 1). This suggests that the distance 
between the FPs may be shorter in the dimer when the JM domain is shorter (46 Å versus 
51 Å, assuming free fluorophore rotation), a finding which is consistent with the idea of 
JM-JM interactions occurring within the N-terminal part of the JM domain, close to the 
membrane.  
4.4.6. FGFR3 JM domain stabilizes the A391E FGFR3 dimer  
Previously, we have characterized the dimerization of FGFR3 in the presence of the 
A391E mutation which causes a craniosynostosis, Crouzon syndrome with acanthosis 
nigricans (94). We have shown that the mutation stabilizes the unliganded FGFR3 dimer 
by -1.4 kcal/mole in plasma membrane derived vesicles produced with the 
DTT/formaldehyde vesiculation buffer (122). Here we asked if the substitution of the 
(GGS)5 linker with the JM domain will alter the stability of the pathogenic A391E dimer. 
We therefore engineered the A391E mutation into the ECTM-JM60-FP sequence and then 
measured and compared the dimerization of EC-TMA391E-(GGS)5-YFP/mCherry and EC-
TMA391E-JM60-FP in vesicles produced with the osmotic stress method. Results are 
shown in Figure S6, Figure 8 and in Table 1. The mutation stabilized the FGFR3 dimer 
by -1.4 kcal/mole, consistent with previous results(122), and the JM domain stabilizes the 
A391E mutant dimer by an additional -1.8 kcal/mole. The latter is within experimental 
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error of the contribution of the JM domain in the wild-type protein. Thus, the 
contributions of the A391E pathogenic mutation in the TM domain and of the JM domain 
to dimer stability are additive. 
4.5. DISCUSSION 
4.5.1. Goals and findings of this study 
Our long term goal is to understand the roles of the different RTK domains in RTK 
unliganded dimerization. Here we focus on FGFR3 JM domain, and we find that it 
stabilizes the unliganded FGFR3 dimer. The contribution is significant, when compared 
to the contribution of other FGFR3 domains. For instance, the JM contribution 
completely cancels the inhibitory contribution of FGFR3 EC domain. Furthermore, the 
magnitude of the stabilizing effect is similar to the effect of a pathogenic FGFR3 
mutation, and the two effects are additive. These comparisons suggest that the stabilizing 
effect that we measure here is likely important for FGFR3 biological function. 
Interestingly, the JM domain stabilizes the dimer only when it is attached to FGFR3 TM 
domain (Figures 3 and 4). On the other hand, simply anchoring of the JM domain to the 
membrane does not potentiate JM-JM interactions (Figure 5). These findings suggest that 
the TM and the JM domains in FGFR3 work synergistically to stabilize the unliganded 
FGFR3 dimer.  
4.5.2. Experimental approach 
Studies of the effect of different RTK domains on RTK dimer stability have been 
challenging, as the interactions of interest occur within the two dimensional space of the 
plasma membrane. Soluble isolated domains are sometimes produced and studied in 
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solution, but results acquired for the three dimensional case cannot be extrapolated to two 
dimensions (49, 147).  This is why, here we used a methodology that allowed us to 
directly explore the thermodynamics of RTK dimerization in plasma membrane derived 
vesicles.  
The QI-FRET method that we use here has been described previously(22). Yet, this work 
required significant improvements in experimental protocols as in this case we compared 
the dimerization of RTK constructs that utilized different attachments of the fluorescent 
proteins. Thus, no a-priori assumptions could be made about changes in dimer structure 
and the Intrinsic FRET, Ẽ, upon the incorporation of the JM domain. Instead, all the data 
were subjected to two parameter fits which yielded the values of Ẽ along with the values 
of the dimerization constant K and the dimer stability G.  These fits were possible 
because the RTK concentrations in our experiments spanned ~ two orders of magnitude, 
an improvement of ~ one order of magnitude over our previous work. In particular, we 
were able to decrease the lowest accessible receptor concentration by a factor of ~5, 
while increasing the maximum expression levels by a factor of ~2.  Additionally, for this 
project we used vesicles that are produced using an osmotic stress method (33), and thus 
were not exposed to DTT and formaldehyde which may introduce perturbations in RTK 
interactions. 
4.5.3. Comparison with EGFR 
Previously, we have shown that the substitution of EGFR JM domain with an 
unstructured  (GGS)10 sequence has no effect on unliganded EGFR dimerization(55).  
Thus, in the EGFR case the JM domain does not stabilize the dimer in the absence of 
ligand, a behavior that is very different from the behavior that we observe here. This 
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prompted us to seek differences in sequence characteristics of the FGFR3 and EGFR JM 
domains. We used the web-based program JPRED to evaluate the propensity of FGFR3 
JM domain for folding into secondary structure (see Supplemental data). The FGFR3 
sequence was predicted to be mainly unstructured, with low beta sheet content but no 
helical content.  On the other hand, EGFR JM domain has a short alpha-helical segment 
close to its N-terminus which has been implicated in the interactions of EGFR JM 
domain with lipids in the absence of ligand(4). Thus, the differences in JM domain 
secondary structures may underlie the difference in behavior. 
The activity of all RTKs is often modeled after the mode of activation of the extensively 
studied EGFR. Yet, it is not clear if the lessons learned about EGFR are directly 
transferable to other RTKs. For instance, there are distinct differences in the activation 
mode of the kinases from different RTK families(76). Here we further show that the 
behavior of FGFR3 JM domain is distinctly different from EGFR JM domain, which 
engages in JM-JM stabilizing contacts only upon ligand binding. These results reinforce 
the idea that different families of RTKs have evolved different mechanisms of 
dimerization and activation, and thus all the 58 RTKs merit in-depth investigation.  
4.5.4. Implications 
There is evidence in the literature that unliganded FGFR dimers are important for FGFR 
biological function(84). Unliganded FGR dimers  are phosphorylated, and this basal 
phosphorylation has been suggested to “prime” the kinases for rapid activation upon 
ligand binding (6, 84). Furthermore, FGFR mutations have been shown to cause disease 
by specifically increasing unliganded dimerization (24, 119, 157). For instance, the 
G380R mutation in FGFR3, which causes the most common form of human dwarfism, 
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increases ligand-independent FGFR3 dimerization and phosphorylation, without having a 
significant effect on FGFR3 phosphorylation in the presence of ligand (55).   
Within the “pre-formed dimer” model of RTK activation, the transition from unliganded 
to liganded dimers can be considered as a thermodynamic change of state (56). Thus, 
unliganded dimers are an intermediate in the activation process. When unliganded dimers 
are present, the response of the pre-formed dimers to ligand is not limited by the diffusion 
of the receptors in the plasma membrane and is thus faster. As a result, there is interest in 
understanding the unliganded dimer state, with the long-term goal of understanding RTK 
activation. 
This work yields new knowledge about the unliganded FGFR3 state by demonstrating 
that FGFR3 JM domain plays an important role in unliganded dimer stabilization. The 
biological significance of our observations comes from the fact that the JM contribution 
is similar in magnitude to the effect of pathogenic mutations that stabilize the FGFR3 
dimers, and is additive. Furthermore, the effect opposes and cancels the inhibitory 
contribution of the EC domain. 
Since RTKs are implicated in many human cancers and developmental abnormalities, 
new strategies are being sought to inhibit their dimerization and activation. And because 
the unliganded FGFR3 dimer is an activation intermediate, its destabilization could be a 
viable therapeutic strategy. The significant stabilization of FGFR3 unliganded dimers by 






 ΔG (kcal/mol) ΔΔGJM 
(kcal/
mol) 
Intrinsic FRET, Ẽ D(Å) 
FGFR3 EC-TM-(GGS)5-FP  -3.4 (-3.2 to -3.6)  0.52(0.46 to 0.57) 52.42 (50.7 to 54.6) 
FGFR3 EC-TM-JM-FP  -5.4 (-5, to -6) -2 0.57(0.53 to 0.61) 50.7 (49.3 to 52.1) 
FGFR3 EC-TM-JM60-FP  -5.3 (-5,-5.9) -1.9 0.7(0.66 to 0.74) 46.1 (44.6 to 47.6) 
FGFR3 TM-(GGS)5-FP  -5.2 (-5.0 to -5.4)  0.65(0.64 to 0.67) 47.9 (47.2 to 48.2) 
FGFR3 TM-JM60-FP  100% dimer- > -
1.5  
0.38±0.01 57.6 (56.6 to 58.6) 
GpA-(GGS)5-FP  -5.3 (-5,-5.4)  0.52(0.5 to 0.54) 52.4 (51.7 to 53.1) 
GpA-(GGS)3-FP  -5.2 (-5,-5.4)  0.53(0.52 to 0.55) 52.0 (51.4 to 52.4) 
GpA-(GGS)2-FP  -5.4 (-5.2,-5.6)  0.41(0.39 to 0.43) 56.5 (55.7 to 57.2) 
GpA-(GGS)2-JM-FP  -5.3 (-5,-5.9) 0 0.54(0.52 to 0.57) 51.7 (50.7 to 52.4) 
FGFR3 EC-TMA391E-(GGS)5-FP  -4.8 (-4.5 to -5.0)  0.72(0.68 to 0.74) 45.4 (44.6 to 46.85) 








Table 4-1. Dimer stabilities and Intrinsic FRET for the proteins studies here. Shown are 
optimal values and 95% confidence intervals.  Ẽ is the value of the Intrinsic FRET, which 
depends on the distance between the fluorescent proteins and on their mobility within the 
dimer. Average distance between the fluorescent proteins (D) is calculated under the 







(GGS)5 Fluorescent proteinEC TMSP
FGFR3 EC-TMA391E-(GGS)5-FP
23 367 399
(GGS)5 Fluorescent proteinEC TM(A391E)SP
FGFR3 EC-TMA391E-JM60-FP
23 367 399
JM60 Fluorescent proteinEC TM(A391E)SP
FGFR3 EC-TM-JM-FP
23 367 400
JM Fluorescent proteinEC TMSP
FGFR3 EC-TM-JM60-FP
23 367 400






















Figure 4-1. The plasmid constructs used in the FRET experiments. SP: FGFR3 signal 
peptide (MGAPACALALCVAVAIVAGASS), EC: extracellular domain, FGFR3 TM 
domain: (DEAGSVYAG ILSYGVGFFLFILVVAAVTLCRLR), GpA TM domain: 
(LIIFGVMAGVIGTILLISYGIRRL), FGFR3 JM domain: (S PPKKGLGSPT 
VHKISRFPLK RQVSLESNAS MSSNTPLVRI ARLSSGEGPT LANVSELELP 
ADPKWELSRAR), FGFR3 JM60 (S PPKKGLGSPT VHKISRFPLK RQVSLESNAS 
MSSNTPLVRI ARLSSGEGPT LANVSELEL), FP: Fluorescent protein, either YFP or 




Figure 4-2. A vesicle, imaged and analyzed in the FRET, acceptor, and donor channels. 
Images were acquired with a Nikon laser scanning confocal microscope. The images are 
analyzed with a Matlab code that has been discussed in detail in a previous publication 
(22). The intensity across the membrane (open blue symbols) is fit to a Gaussian (solid 






Figure 4-3. Dimerization curves for EC-TM-(GGS)5-YFP/mCherry and EC-TM-JM-
YFP/mCherry. The dimer that contains the JM domain is more stable. 
 
 
Figure 4-4. Dimerization curves for TM-(GGS)5-YFP/mCherry and TM-JM-
YFP/mCherry. The dimer that contains the JM domain is more stable. 
 



















































Figure 4-5. Dimerization curves for three Glycophorin A TM helix constructs in which 
the fluorescent proteins are attached to the TM helix via different length linkers. The 
linker length does not affect dimer stability. 
 
Figure 4-6. Dimerization curves for GpA-(GGS)5-YFP/mCherry and GpA-(GGS)2-JM-
YFP/mCherry. The two dimers are equally stable. 
 



























































Figure 4-7. Dimerization curves for EC-TM-(GGS)5-YFP/mCherry and EC-TM-JM60-
YFP/mCherry. The shorter JM domain stabilizes the dimer to the same extent as the full-
length JM domain (see Figure 3 and Table 1). 
 
 
Figure 4-8. Dimerization curves for and EC-TMA391E-(GGS)5-YFP/mCherry and EC-
TMA391E-JM60-YFP/mCherry. The A391E mutation is the genetic cause for Crouzon 
syndrome with acanthosis nigricans. The JM domain stabilizes the mutant dimer. 
 
  

























































Figure S1(4-9).  
  
Figure S2(4-10).  
































































































































































Figure S5 (4-13). 
 
  
Figure S6(4-14).  










































































Chapter 5. Strong inter-molecular disulfide linked dimers 




FGF receptors play crucial roles in embryonic and adult development. Missense 
mutations in FGFR1, 2 and 3 are linked to a wide array of skeletal disorders. Many of 
these mutations are in cysteines of receptor Ig domains, which form intrachain disulfide 
bonds. Here we investigated how pathogenic mutations of key cysteines in FGFR 
structure affect dimerization and activation of the receptors. In particular we quantify the 
effect of the pathogenic cysteine mutations on FGFR1, 2 and 3 dimer stability. We show 
that the FGFR1/C178S, FGFR2/C342R and FGFR3/C228R from disulfide linked dimers 
of various strengths in the absence of ligands even at physiological concentrations. The 
mutations increase dimer stability substantially with FGFR2 C342R and FGFR3 C228R 
forming the strongest (constitutive) dimers. We further show that these mutations induce 
a structural change in unliganded FGF receptor dimer. 
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Fibroblast growth factor receptors (FGFR1-4) comprise a family of transmembrane 
tyrosine kinases which bind with high affinity to 22 distinct FGF ligands in humans. 
FGFRs play a key role in the regulation of cell differentiation, migration, proliferation 
and apoptosis. They are critically required for embryonic development, lung 
morphogenesis, osteogenesis and limb bud development. It has been established that 
FGFRs homodimerize in the absence of ligands (3, 84, 155). This ligand-independent 
dimerization induces receptor phosphorylation at a basal level resulting in low activity of 
the receptor. Mutations in FGFR genes (for example over sixty mutations only in 
FGFR2) are associated with pathologies such as skeletal disorders and various forms of 
cancer (110, 151). Interestingly, somatic mutations found in cancers are identical to 
germline mutations which cause skeletal abnormalities such as Crouzon syndrome (CS), 
Apert syndrome (AS) and Pfieffer syndrome (PS)(153). One example is the A391E 
mutation in FGFR3, identified as a somatic mutation in bladder cancers (152, 153) but 
also found in individuals with CS with Acanthosis nigricans.   Other cases include gain or 
loss of a cysteine residue in FGFR1, FGFR2 and FGFR3. Examples of such mutations are 
Arg248Cys, Ser249Cys, Gly370Cys, Ser371Cys, and Tyr373Cys in FGFR3, associated 
with Thanatophoric dysplasia (TD) where a single amino acid is substituted with a 
cysteine (2, 27, 151). Other examples of pathogenic cysteine mutations are C178S in 
FGFR1, C342R in FGFR2, and C228R in FGFR3. 
The phenotypes due to FGFR cysteine mutations have been linked to high activity or loss 
of activity of the receptors. However, the physico-chemical basis for the behavior of 
these mutants remains unknown. This lack of basic knowledge is a major obstacle for 
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drug discoveries, as the goal is to target specific mutant FGFR complexes and not wild 
type FGFR dimers, in various skeletal diseases and cancers.  
Here we investigate the effect of cysteine mutations in FGFR1 (C178S), FGFR2 (C342R) 
and FGFR3 (C228R) on the dimerization and activation of these receptors. These 
mutations disrupt intramolecular disulfide bonds in Ig domains. We aimed to study the 
effect of these cysteine mutations on the stability and structure of the unliganded dimer. 
We found that mutations of these critical cysteines result in increased propensity for 
dimerization in the absence of fgf ligands, likely due to the formation of disulfide bonds 
between unpaired cysteines in the Ig-like domains. The mutations also induce structural 
changes in the intracellular domains of the receptor dimers and hence, alter the activity of 
the receptors. 
Here we approached the problem using the QI-FRET method, which allowed us to 
measure the dimerization propensity and the Intrinsic FRET for the mutant receptor 
dimers. The measurements were carried out in plasma membrane vesicles derived from 
CHO cells (33). The dimerization constant, K, and the Intrinsic FRET, Ẽ, were 
parameters which were obtained from a two parameter fitting to the measured dimeric 
fractions. The intrinsic FRET monitors structural changes by reporting on the distance 
between the fluorescent proteins (FRET pair). 
5.2. Materials and Methods. The YFP plasmid was received from Dr. M. 
Betenbaugh (Johns Hopkins University, Baltimore, MD) and the pRSET-mCherry 
plasmid was obtained from Dr. R.Tsien (University of California, San Diego). The 
plasmids encoding human wild-type FGFR1 and FGFR2 in the pRK5 vector were 
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received from Dr.M.Mohammadi, NYU. The plasmid encoding human wild-type FGFR3 
was a gift from Dr. D. J. Donoghue, UCSD. All of the plasmids used for mammalian 
expression were constructed with pcDNA 3.1(+) vector (Invitrogen). All primers were 
purchased from Invitrogen. 
The cloning procedure for wild type full length human FGFR1, FGFR2 and FGFR3 in 
pcDNA3.1(+) vector have been described previously (Sarabipour and Hristova FGFR 
2015). Cloning of FGFR1-(GGS)-YFP, FGFR1-(GGS)-mCherry, FGFR2-(GGS)-YFP, 
FGFR2-(GGS)-mCherry, FGFR3-(GGS)-YFP and FGFR3-(GGS)-mCherry is described 
in detail in (Sarabipour et al FGFR 2015). Detailed cloning procedure for FGFR3 EC-
TM-(GGS)5-YFP, FGFR3 EC-TM-(GGS)5-mCherry is described in (Chen et al 2010), 
FGFR1 EC-TM-(GGS)5-YFP, FGFR1 EC-TM-(GGS)5-mCherry, FGFR2 EC-TM-
(GGS)5-YFP, FGFR2 EC-TM-(GGS)5-mCherry is described in (Sarabipour and Hristova 
FGFR 2015). 
 For this work, we created 12 plasmid constructs by creating missense mutations in full 
length and truncated FGFR1, FGFR2 and FGFR3 (Figure 1). We created C228R 
mutation in FGFR3 EC-TM-(GGS)5-YFP, FGFR3 EC-TM-(GGS)5-mCherry, FGFR3-
(GGS)-YFP and FGFR3-(GGS)-mCherry plasmid constructs. We introduced C342R into 
FGFR2 EC-TM-(GGS)5-YFP, FGFR2 EC-TM-(GGS)5-mCherr, FGFR2-(GGS)-YFP and 
FGFR2-(GGS)-mCherry plasmid constructs. Finally we created C178S mutation in 
FGFR1 EC-TM-(GGS)5-YFP, FGFR1 EC-TM-(GGS)5-mCherry, FGFR1-(GGS)-YFP 
and FGFR1-(GGS)-mCherry plasmid constructs using QuickChange ® II XL Site-
Directed Mutagenesis Kit (Stratagene, CA). 
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5.2.1. Cell culture and transfection. Chinese Hamster Ovary cell (CHO) and Human 
Embryonic Kidney (HEK) 293 T cells were cultures at 37 ˚C with 5% CO2 for 24h. 
Transfection was carried out using Fugene HD transfection reagent (Roche Applied 
Science), following the manufacturer’s protocol. Cells were cotransfected with 3-7 ug of 
DNA encoding either (i) pcDNA-FGFR1-YFP and pcDNA-FGFR1-mCherry, (ii) 
pcDNA-FGFR2-YFP and pcDNA-FGFR2-mCherry, or (iii) pcDNA-FGFR3-YFP and 
pcDNA-FGFR3-mCherry. Cells were vesiculated 24 h post transfection as described 
below. We have not observed staining for FGFR1, 2 or 3 (via Western blots) in the CHO 
and HEK293T cells unless transfected. 
5.2.2. Production of mammalian plasma membrane vesicles. Vesiculation was 
performed using a chloride salt vesiculation buffer consisting of of 200 mM NaCl, 5 mM 
KCl, 0.5 mM MgSO4, 0.75 mM CaCl2, 100 mM bicine and protease inhibitor cocktail 
(Complete mini EDTA-free tabs, Roche Applied Science) adjusted to PH of 8.5. (33). 
CHO cells were rinsed twice with 30% PBS (pH 7.4), and incubated with 1 mL of 
chloride salt vesiculation buffer overnight at 37 °C.  A large number of vesicles were 
produced after 12 h, and the vesicles were transferred into 4-well Nunc Lab-Tek II 
chambered coverslips for imaging. Images of vesicles with labeled FGF receptors are 
shown in Figure S1.  Most of the cytoplasm in the vesicles is lost during vesicle 
production, as attested by the fact that soluble fluorescent proteins are not retained inside 
the vesicles (Sarabipour et al 2015, lipids). 
5.2.3. QI-FRET Image Acquisition. Vesicles were imaged using a Nikon Eclipse 
confocal laser scanning microscope using a 60× water immersion objective. All the 
images were collected and stored at a 512 × 512 resolution. Three different scans were 
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performed for each vesicle: (1) excitation at 488 nm, with a 500-530 nm emission filter 
(donor scan); (2) excitation at 488 nm, with a 565-615 nm emission filter (FRET scan); 
and (3) excitation at 543 nm, with a 650 nm longpass filter (acceptor scan). Gains of 8.0 
were used for all the three scans. The bleaching of the fluorescent proteins was 
minimized through the use of ND8 filters when exciting with the 488 nm laser, and low 
pixel dwell time (1.68 μs). 
5.2.4. QI-FRET data Analysis: Methodology and Protocol. The quantitative imaging 
FRET method  
5.2.5. Western blots. CHO and HEK293T cells were starved in serum-free medium for 
24 h following transfection and then treated with lysis buffer (25 mM Tris-HCl, 0.5% 
Triton X-100, 20mM NaCl, 2 mM EDTA, phosphatase inhibitor and protease inhibitor, 
Roche Applied Science). Lysates were collected following centrifugation at 15,000 g for 
15 min at 4 °C and loaded onto 3–8%NuPAGE®Novex®Tris–Acetatemini gels 
(Invitrogen, CA). The proteins were transferred onto a nitrocellulose membrane, and 
blocked using 5% milk in TBS. The expression of the receptors was probed with anti-
FGFR antibodies. FGFR total protein levels were assessed using antibodies against 
FGFR3 (H-100; sc-9007), FGFR2 (H-80; sc-20735) and FGFR1 (H-76; sc-7945) from 
Santa Cruz Biotechnology. Phosphotyrosine levels were assessed using Phospho-FGF 
receptor antibodies (Tyr653/654; #3471, Cell Signaling Technologies) which is raised 
against residues surrounding Tyr653/654 FGFR1 but the corresponding sequence is the 
same for FGFR2 and FGFR3. So this antibody detects endogenous levels of all three FGF 
receptors only when phosphorylated at Tyr653/654. This was followed by anti-rabbit 
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HRP conjugated antibodies (W4011, Promega). The proteins were detected using the 
Amersham ECL detection system (GE Healthcare). 
5.3. Results & Discussion 
Figure 1 shows the general structure of FGF receptors and the location of the cysteine 
mutations investigated in this chapter. 
5.3.1. FGFR1 C178S. The C178S mutation in Ig-like D1 of FGFR1 is associated with 
Kallman syndrome. The pediatric phenotype of this syndrome includes severe ear 
anomalies (hypoplasia or agenesis of the external ear), failure to start puberty, infertility 
and complete lack of sense of smell. It occurs in 1 in 10,000 men and 1 in 50,000 women 
(166). To investigate the effect of this mutation on FGFR1 dimerization, we created the 
C178S mutation in FGFR1, which has been tagged with YFP or mCherry as a FRET pair 
(Figure S1). Dimerization was studied in plasma membrane vesicles using QI-FRET, a 
methodology which allows measurements of dimerization propensities and structural 
changes. The two constructs FGFR1C178S-YFP and FGFR1C178S-mCherry were co-
expressed in CHO cells. Twenty four hours after transfection, the cells were treated with 
chloride salt buffer overnight at 37˚C to induce shedding of plasma membrane vesicles 
bearing the receptors. Vesicles were collected in 4 chambered slides and imaged in a  
confocal laser scanning microscope (22). Each vesicle was imaged in 3 scans: (i) a donor 
scan giving the fluorescence of the FRET donor, YFP, when excited directly (ii) a FRET 
scan giving the fluorescence of the acceptor fluorophore, mCherry, when excited 
indirectly by energy transfer from the donor (iii) an acceptor scan which gives the 
fluorescence of the acceptor when excited directly. The intensity of each vesicle image 
137 
 
was quantified using a Matlab program as described previously (22). Using the intensity 
values and parameters obtained from calibrations performed with purified solutions of 
YFP and mCherry, the donor concentration, the acceptor concentration and the FRET 
efficiencies were obtained for each vesicle. Figure 1 (I) shows (A) the FRET efficiency 
as a function of total receptor (donor labeled + acceptor labeled) concentration, (B) donor 
versus acceptor concentrations and (C) dimeric fractions as a function of total receptor 
concentration for wild type FGFR1 and the C178S FGFR1 mutant. A monomer-dimer 
equilibrium model with two adjustable parameters, the dimerization constant K and the 
intrinsic FRET efficiency Ẽ was fitted to the data in Figure 2 (IA), yielding the optimal K 
and Ẽ values for the receptors. Then, each data set in Figure 2 was divided by the optimal 
Ẽ to obtain the dimeric fraction in each vesicle as a function of the total receptor 
concentration in the vesicles. Then, the dimeric fractions for similar receptor 
concentrations were averaged within bins of width 500 receptors/μm
2
.  Along with these 
data, the theoretical dimeric fraction is plotted for each receptor for the optimal value of 
K determined in the fit. The results demonstrate that the C178S mutation modestly 
increases the dimerization propensity of FGFR1 by -1.2 kcal/mol (Table 1).   
The QI-FRET method allows us to calculate distances between fluorescent proteins and 
thus monitor structural changes which occur within the receptor dimers due to mutations. 
As shown in Table 1, The Intrinsic FRET value for C178S FGFR1 dimers was measured 
as 0.7±0.02 and was the same as the Intrinsic FRET value for the wild-type FGFR1 
dimers (0.66±0.02). Thus, the C178S mutation did not change the distance between the 
fluorescent proteins in the FGFR1 dimer. 
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In the full length receptors, the fluorophores are attached to the C-terminal tail at the end 
of the intracellular domain (plasmid constructs shown in Fig S1), which are flexible. 
Thus, it is possible that structural changes are not detected, although they occur.  We 
have shown in Chapter 1 that the structure of the transmembrane domain can be 
monitored when this domain is directly attached to fluorescent proteins via a flexible 
linker. In order to monitor possible structural changes which may be propagated from the 
extracellular domain to the TM domain, we deleted the intracellular domains of wild-type 
FGFR1 and the C178S mutant and replaced it with a flexible (GGS)5 15 amino acid 
linker attached to YFP or mCherry. The results for EC-TM FGFR1 and EC-TM 
FGFR1C178S are shown in Fig.2 (II). The mutation increases the dimerization propensity 
of truncated FGFR1 by -0.7 kcal/mol, an effect that is even smaller than in the case of the 
full-length receptor. The Intrinsic FRET measured showed that the C178S mutation 
induces a structural change by moving the TM domain C-termini of FGFR1 closer to 
each other (Intrinsic FRET = 0.68) compared to wild-type EC-TM FGFR1 (Intrinsic 
FRET = 0.5).  Over-all, the data show that the effect of this mutation on dimerization is 
modest, and that the mutation induces a structural change in the dimer. 
We probed the nature of the C178S dimer by non-reducing SDS gel followed by Western 
blot staining for FGFR1. The schematic of the plasmid constructs used for western 
blotting experiments is shown in Figure S2. As shown in figure 3, FGFR1C178S and EC-
TM FGFR1C178S form dimers on a non-reducing gel, but not on a reducing gel, 
demonstrating the formation of inter-molecular disulfide bonds by the unpaired cysteines. 
We further probed the activation of the C178S FGFR1 mutant. Figure 3 demonstrates that 
the C178S mutation results in a loss of function in FGFR1, as evident from the reduced 
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intensity of the anti-pY653/654 bands for the C178S FGFR1 mutant compared to wild-
type FGFR1.  
5.3.2. FGFR2 C342R. The C342R mutation in the Ig-like D3 of FGFR2 is observed in 
individuals with Crouzon Syndrome (CS), Jackson-Weiss syndrome (JWS), and Antley-
Bixler-like syndrome (ABS2) (69, 73, 75, 93, 107-110, 117, 118, 121, 149). Crouzon 
syndrome is characterized by premature fusion of one or several skull sutures 
(craniosynostosis), and has an incident rate of 1 in 2500 individuals. If untreated, the 
abnormal skull growth may result in impaired cerebral blood flow, impaired vision, 
impaired hearing and central nervous system problems (60). The JWS phenotype is 
characterized by foot abnormalities, the PS phenotype is characterized by short fingers 
and soft-tissue syndactyly, and the ABS2 phenotype is characterized by craniofacial and 
limb abnormalities (50, 94, 107, 121). The mutation C342R disrupts the C278-C342 
intramolecular disulfide bond. 
We measured the dimerization of wild-type FGFR2 and the C342R FGFR2 mutant in 
CHO cell-derived plasma membrane vesicles. Each data point in Figure 4 represents a 
vesicle. Figure 4 (I) shows the FRET efficiency as a function of total receptors/μm
2
 for 
FGFR2 and FGFRC342R. The dimeric fraction measured for FGFR2C342R is 100%, 
indicative of formation of constitutive dimers. The Intrinsic FRET value for wild-type 
FGFR2 was measured as 0.43±0.02 while the Intrinsic FRET value for the C342R 
FGFR2 mutant was 0.55±0.02. Thus, the C342R mutation is responsible for a 
conformational change in FGFR2 dimers which propagated from the EC domain to the 
tyrosine kinase domain and the C-terminal tail of the receptor. 
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We further measured the dimerization propensity of the EC-TM FGFR2 constructs. 
Figure 4 (II) shows the FRET efficiency and dimeric fractions for ECTM-FGFR2 and 
ECTM-FGFR2C342R as a function of total receptor concentration. The EC-TM FGFR2 
dimer stability was -3.4 kcal/mole while the ECTM-FGFR2C342R formed constitutive 
dimers (Figure 4 II). 
Unlike the C178S mutation in FGFR1, the C342R mutation in FGFR2 strongly stabilized 
the unliganded dimer. The mutation also induces a structural change in FGFR2 dimer by 
shifting the Iintrinsic FRET value from 0.57 to 0.72. 
Consistent with the FRET results, Figure 5 demonstrates that in all cases the mutant 
FGFR2 monomer band completely shifts to a dimer in non-reducing gels, indicating 
strong disulfide bond formation between the mutant receptors. Thus, in conclusion, the 
mutation disrupts the C278-C342 intramolecular disulfide bond and disrupts the structure 
of the FGFR2 dimer, as evident from the change in the Intrinsic FRET value.  The mutant 
favors the formation of an inter molecular disulfide bond as evident from the non-reduced 
SDS PAGE results (Figure 5). 
5.3.3. FGFR3 C228R. Colorectal cancer is the most common type of intestinal cancer 
with 140,000 cases each year in the United States alone, according to the National Cancer 
Institute. The C228R mutation in Ig-like D2 of FGFR3 is a somatic mutation found in 
human colorectal carcinoma (50). The mutation disrupts one of the three intramolecular 
disulfide bonds in D2 (they occur between C61-C109, C176-C228 and C275-C339). To 
investigate the effect of the C228R mutation on FGFR3 dimerization, we generated the 
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mutation in full length FGFR3 tagged with YFP or mCherry, as well as in the truncated 
EC-TM FGFR3 constructs. The results of the FRET experiments are shown in Fig 6.  
We next performed FRET experiments with the full-length and the truncated EC-TM 
FGFR2 constructs. The increase in stability due to the mutation in EC-TM FGFR3 is -2.3 
kcal/mol (Figure 6 II, Table 1). The increase in full length FGFR3 dimerization was even 
higher and the receptor forms constitutive (100%) dimers (Figure 6 I). Similarly to the 
FGFR2 C342R mutation and unlike the FGFR1 C178S mutation, the FGFR3 C228R 
mutation strongly contributes to receptor dimerization. The mutation induced a structural 
change in full-length FGFR3, shown by the Intrinsic FRET value of 0.63 (compared to 
Intrinsic FRET=0.55 for WT FGFR3, Table 1). This structural change was also observed 
for the EC-TM FGFR3 C228R construct with an Intrinsic FRET value of 0.69 (compared 
to Intrinsic FRET of 0.51 for WT EC-TM FGFR3). 
We assessed the dimerization of FGFR3 C228R and EC-TM FGFR3 C228R using 
reducing and non-reducing SDS PAGE. Figure 7 A shows that FGFR3 C228R formed 
disulfide linked dimers in non-reducing SDS, but the receptor migrated as monomer only 
in the reduced SDS PAGE (Figure 7B), suggesting that disulfide bonds stabilize the 
dimers. Similarly, the EC-TM FGFR3 C228R formed cysteine linked dimers in the non-
reducing environment (Figure 7C) but not in reducing one (Figure 7D). 
When assessing phosphorylation of FGFR3 C228R, we found that the mutant receptor 
was mainly expressed in its unglycosylated form in HEK293T cells (Figure 7E). 





Here we measured the difference in dimerization between wild type FGFR1 and C178S 
FGFR1, wild type FGFR2 and C342R FGFR2, wild type FGFR3 and C228R FGFR3 in 
plasma membrane-derived vesicles of CHO cells. We investigated these mutations in full 
length and truncated receptors.  
Cysteine mutations are extremely challenging to study by crystallography due to the 
oxidative conditions required for the formation of disulfide bonds. Here we used a 
quantitative FRET methodology and we observed modest to strong dimer stabilization as 
a result of the FGFR1 C178S, FGFR2 C342R and FGFR3 C228R mutations. We probed 
the nature of dimer formation by non-reducing SDS gels followed by Western blots and 
FGFR staining. The results demonstrated formation of disulfide bonds due to the three 
mutations. Finally, we probed the activation of wild type and mutant FGFRs and we 
found that the FGFR1 C178S mutation results in loss of function and that the FGFR3 
C228R mutant is highly phosphorylated as an unglycosylated receptor inside the cell. 
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Figure 5-2. (I) FRET results for wild type FGFR1 (solid black circles) and C178S 
FGFR1 (open magenta circles). Each data point represents a vesicle. Donor versus 
acceptor concentration in each vesicle. DNA ratios in transfections varied from 1:2 to 
1:5, and the acceptor concentration exceeds the donor concentration in all cases. This 
difference in expression is necessary in our experiments because of the different quantum 
yields of the donor (0.61) and the acceptor (0.22), and is fully accounted for in the data 
analysis. (II) FRET results for EC+TM wild type FGFR1 (open black circles) and C178S 
FGFR1 (solid magenta circles). C178S results in a modest increase ((0.7 kcal/mol for 
EC-TM), (1.2 kcal/mol for full length) higher stability for FGFR dimers). 
(I) (II) 

















































































































Figure 5-3. Anti-FGFR1 staining of (A) non-reducing and (B) reducing western blots for 
wild type and C178S FGFR1. Anti-FGFR1 staining of (C) non-reducing and (D) 
reducing western blots for wild type and C178S EC+TM FGFR1. (E) Anti-pY 653/654 




 ΔG (kcal/mol) ΔΔGMUT(k
cal/mol) 
Ẽ d(Å) 
ECTM FGFR1 WT -4.6(-4.4 to -4.8)  0.5(0.46 to 0.55) 53.1(51.4 to 54.6) 
ECTM FGFR2 WT -3.4(-3.2 to -3.6)  0.57(0.51 to 0.64) 50.68(48.3to 52.8) 
ECTM FGFR3 WT -3.4(-3.2 to -3.6)  0.52(0.46 to 0.57) 52.42(50.7 to 54.6) 
ECTM FGFR1 
C178S 
-5.3(-5.2 to -5.4) -0.7(-0.6 
to -0.8)  
0.68(0.66 to 0.7) 46.8 (46.1 to 47.6) 
ECTM FGFR2 
C342R 
100% dimer - 0.72 (0.71,0.73) 45.4 (45 to 46.1) 
ECTM FGFR3 
C228R 
-5.7(-5.6 to -5.8) -2.3 0.69(0.7 to 0.72) 46.8 (46.1 to 47.6) 
Full FGFR1 WT -4.3 (-4.0 to -4.5)  0.66 (0.64 to 0.69) 47.56 (46.5 to 48.3) 
Full FGFR2 WT -5.4(-5.2 to -5.7)  0.43(0.41 to 0.44) 55.67(55.3 to 56.4) 
Full FGFR3 WT -6.3(-6.0 to -6.8)  0.55(0.53 to 0.57) 51.4(50.7 to 52.1) 
Full FGFR1 C178S -5.5(-5.3 to -5.7) -1.2 (-1.2 
to -1.3) 
0.7(0.68 to 0.72) 46.1 (45.4 to 46.8) 
Full FGFR2 C342R 100% dimer - 0.55(0.54 to 0.56) 51.4 (51 to 51.7) 
Full FGFR3 C228R 100% dimer - 0.63(0.62 to 0.64) 48.6 (48.2 to 48.9) 
 
Table 5-1. Dimerization free energies (dimer stabilities) ΔG and Intrinsic FRET 
efficiencies Ẽ, obtained from least-square parameter fits to the FRET data for wild type 
and mutant full-length and truncated constructs that lack the IC domain (EC+TM). 
a






















Figure 5-4. (I) FRET results for wild type FGFR2 (solid black triangles) and C342R 
FGFR2 (open blue diamonds). Each data point represents a vesicle. (II) FRET results for 
EC+TM wild type FGFR2 (open black triangles) and C342R FGFR2 (solid blue 
diamonds). 






















































































































Figure 5-5. Anti-FGFR2 staining of (A) non-reducing and (B) reducing western blots for 
wild type and C342R FGFR2. Anti-FGFR2 staining of (C) non-reducing and (D) 




















Figure 5-6. (I) FRET results for wild type FGFR3 (solid black diamonds) and C228R 
FGFR3 (open red squares). Each data point represents a vesicle. (II) FRET results for 



















































































































Figure 5-7. Anti-FGFR3 staining of (A) non-reducing and (B) reducing western blots for 
wild type and C228R FGFR3 in HEK293T cells. Anti-FGFR1 staining of (C) non-
reducing and (D) reducing western blots for wild type and C228R  EC+TM FGFR3 in 
CHO cells.(E) A large amount of FGFR3 C228R is unglycosylated (glycosylation 










Figure S1(5-8). Plasmid constructs used for the FRET experiments. The full-length 
receptors had fluorescent proteins attached to their C-termini via a flexible GGS linker. 
The truncated receptors had the intracellular domain substituted with a fluorescent 
protein, which was attached to the TM domain via a longer flexible (GGS)5 linker. SP: 
signal peptide, EC: extracellular domain, TM: transmembrane domain. Fluorescent 




Figure S2(5-9). Plasmid constructs used for the Western blot experiments. Amino acid 






Chapter 6. Analytical characterization of plasma membrane-




Plasma membrane-derived vesicles are being used in biophysical and biochemical 
research as a simple, yet native-like model of the cellular membranes. Here we report on 
the characterization of vesicles produced via two different vesiculation methods.  The 
first one is a recently developed method which utilizes chloride salts to induce osmotic 
vesiculation. The second one is a well established chemical vesiculation method which 
uses DTT and formaldehyde. We show that these two vesiculation methods lead to small 
but statistically significant differences in lipid composition. Highly significant differences 
were observed, however, in the degree of incorporation of a membrane receptor and in 
the degree of retention of soluble cytosolic proteins within the vesicles. Thus, in general, 
vesicles produced via osmotic and chemical means cannot be considered equivalent 
models of the cellular membrane, even when derived from the same cell pool. 
6.1. Introduction 
The cellular plasma membrane,  a complex assembly of lipids and proteins,  plays a 
critical role in cell physiology (31, 88, 143, 148).  The membrane provides the barrier, 
and mediates the communication, between the cell and its environment.  The processes 
that occur in the plasma membrane, such as ion conduction, nutrients uptake, and signal 
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transduction, are critical for cell function (10, 39, 99, 160). It is often difficult, however, 
to study these processes in the plasma membrane of living cells, and thus biophysicist 
and biochemists often rely on model membrane systems. One such model system is 
plasma membrane-derived vesicles, which bud off cells in response to external stress (33, 
129). These vesicles are derived from the native cellular membrane, and are thus more 
native-like than vesicles made of synthetic lipids. They are increasingly used in studies of 
lipid-lipid, lipid-protein and protein-protein interactions, and have yielded  new 
knowledge about lipid domains and receptor interactions in the membrane (22, 34, 79, 
114, 154). Often, however, they are not well characterized in terms of their lipid and 
protein content. 
The most widely used vesiculation method, developed in the 1960s, utilizes the chemicals 
formaldehyde and dithiothreitol  (DTT) to stress the cells and to induce an apoptosis-like 
response (129-131). Vesicles can be produced with this method from a variety of 
mammalian cells including human embryonic kidney (HEK) 293T cells, Chinese hamster 
ovary (CHO) cells, A431 human epidermoid carcinoma cells, 3T3 fibroblasts, endothelial 
cells, a variety of other cancer cells, and macrophages (5, 61, 123, 129-132, 154). These 
vesicles have been used widely in the literature to study lipid domains, but concerns may 
arise in some cases due to the presence of DTT, a reducing agent, as well as 
formaldehyde, a molecular cross-linker. Thus, an alternative vesiculation method, which 
utilizes osmotic stress rather than chemicals, was recently developed (33). In this method, 
vesiculation is induced by incubating cells with a buffer which contains high 
concentration of chloride salts. This osmotic method has been used to produce vesicles 
from CHO and A431 cells, in the absence of DTT and formaldehyde. The overall 
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appearance of the vesicles produced with the osmotic stress method and the 
DTT/formaldehyde method is very similar (33), and both vesicle preparations have been 
used successfully in studies of protein interactions in membranes (123). 
 Here we sought to characterize and compare the vesicles produced by chemical and 
osmotic vesiculation and to identify differences that might exist between the two types of 
vesicles. In particular, we characterized and compared A431 chloride salt vesicles and 
A431 DTT/formaldehyde vesicles. As a control, we also characterized CHO 
DTT/formaldehyde vesicles, with the goal of comparing differences due to vesiculation 
method and differences due to cell type.   
6.2. Materials and Methods 
6.2.1. Cell culture and vesiculation. Chinese hamster ovary (CHO) and A431 cells were 
cultured in T75 flasks.  These cells were vesiculated at 70% confluency using a 
DTT/formaldehyde buffer (129) or a chloride salt osmotic buffer (33).  
6.2.2. Vesicle lipid pelleting. Centrifugation was performed at 125xg, 4 ˚C to pellet the 
cell debris. A second centrifugation was performed at 25000xg for 45 minutes at 4 ˚C to 
pellet the vesicles. The supernatant was discarded.  
6.2.3. Liquid chromatography mass spectrometric (LC-MS) analysis of lipids and 
cholesterol. Three independent samples were prepared for each vesicle type.  After 
pelleting, lipids and cholesterol were extracted as described previously using a modified 
Bligh/Dyer procedure, spiked with appropriate internal standards (17), and analyzed 
using a 6490 Triple Quadrupole LC-MS system (Agilent Technologies, Santa Clara, CA). 
Glycerophospholipids and sphingolipids were separated with normal-phase HPLC as 
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described before (17), with a few changes. An Agilent Zorbax Rx-Sil column (inner 
diameter 2.1 x 100 mm) was used under the following conditions: mobile phase A 
(chloroform:methanol:1 M ammonium hydroxide, 89.9:10:0.1, v/v) and mobile phase B 
(chloroform:methanol:water:ammonium hydroxide, 55:39.9:5:0.1, v/v); 95% A for 2 min, 
linear gradient to 30% A over 18 min and held for 3 min, and linear gradient to 95% A 
over 2 min and held for 6 min. Sterols and glycerolipids were separated with reverse-
phase HPLC using an isocratic mobile phase as before (17) except with an Agilent 
Zorbax Eclipse XDB-C18 column (4.6 x 100 mm).  
Quantification of lipid species was accomplished using multiple reaction monitoring 
(MRM) transitions (17) in conjunction with referencing of appropriate internal standards: 
PA 14:0/14:0, PC 14:0/14:0, PE 14:0/14:0, PG 15:0/15:0, PI 16:0/16:0, PS 14:0/14:0, 
BMP 14:0/14:0, APG 14:0/14:0, LPC 17:0, LPE 14:0, LPI 13:0, Cer d18:1/17:0, SM 
d18:1/12:0, dhSM d18:0/12:0, GalCer d18:1/12:0, GluCer d18:1/12:0, LacCer 
d18:1/12:0, D7-cholesterol, CE 17:0, MG 17:0, 4ME 16:0 diether DG, D5-TG 
16:0/18:0/16:0 (Avanti Polar Lipids, Alabaster, AL).  
6.2.4. Thin layer chromatography. The pelleted plasma membrane vesicles were 
resuspended in distilled water. The solution was dried in a rotory evaporator and the 
lipids were extracted using the Folch method with chloroform:methanol:distilled water 
(2:1:1 (v/v)) at room temperature (43). The extracts were dried under a stream of N2 gas 
and resuspended in a chloroform: methanol mixture (2:1 (v/v)). One dimensional thin 
layer chromatography (TLC) was used to analyze the lipid content.  Whatman flexible 
silica gel G plates were spotted with solutions containing the extracted lipids, as well as 
the following lipid standards: 1-palmitoyl-2-deoyl-sn-glycerol-3-phosphocholine 
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(POPC), 1-palmitoyl-2-deoyl-sn-glycerol-3-phospho-L-Serine (POPS), 1-palmitoyl-2-
deoyl-sn-glycerol-3-phosphoethanolamine (POPE), Sphingomyelin (from Porcine brain), 
and cholesterol (Avanti Polar Lipids Inc). The plates were then placed in a chamber with 
a chloroform: methanol:7-N NH4OH (65:27:5 (v/v)) solution to separate the different 




P NMR phospholipid  analysis. Vesicle pellets were resuspended in distilled 
water. The solution was dried in a rotory evaporator and the lipids were extracted using 
the Folch method with chloroform:methanol:distilled water (2:1:1 (v/v)) at room 
temperature (43). The extracts were dried under a stream of N2 gas and resuspended in a 
chloroform: methanol mixture (2:1 (v/v)). 20-30 mg of lipid extracts from each vesicle 
type was sent to Avanti Polar Lipids Analytical Services for 
31
P NMR analysis.  A Bruker 
Avance™ III 400 mHz with a 5 mm BBFO Probe NMR spectrometer was used to 
characterize the phospholipid composition of the samples dissolved in 1 mL of detergent.  
6.2.6. Annexin V binding to plasma membrane derived vesicles. Vesicles were 
incubated for 1 hour with fluorescein-conjugated Annexin V using the LI2004 Annexin V 
detection kit (Molecular Probes).  Images were recorded in a Nikon confocal microscope. 
6.2.7. Plasmids for vesicle content leakage assays. The wild type human fibroblast 
growth factor receptor 2 (FGFR2) plasmid was a gift from Dr. Moosa Mohammadi 
(NYU). The FGFR2-mCherry plasmid was constructed by fusing mCherry to the C-
terminus of full length FGFR2. The plasmid encoding 1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase delta-1-GFP (Plcδ1-PH-GFP) was obtained from Dr. 
Tamas Balla (NIH). The plasmids encoding Intersectin II-GFP, 1-phosphatidylinositol 
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4,5-bisphosphate phosphodiesterase gamma-1-GFP (Plcɣ-GFP) and Protein kinase C 
theta-GFP (PKCӨ-GFP)  were a kind gift from Dr. Christoph Wuelfing (University of 
Bristol). The Growth factor receptor-bound protein 2-Venus (Grb2-Venus) plasmid was a 
gift from Dr. Jin Zhang (Johns Hopkins). The VVVVVV (Venus x 6) plasmid was 
purchased from Addgene (courtesy of Dr. Steven Vogel, NIH). 
6.2.8. Western blot analysis of EGFR in A431 vesicles. The vesicle pellets were lysed 
with lysis buffer (25 mM Tris-HCl, 0.5% Triton X-100, 20mM NaCl, 2 mM EDTA, 
phosphatase inhibitor and protease inhibitor, Roche Applied Science). The lysates were 
loaded onto 3–8% NuPAGE®Novex®Tris–Acetatemini gels (Invitrogen, CA). The 
proteins were transferred onto a nitrocellulose membrane, and blocked using 5% milk in 
TBS. EGFR was detected with anti-EGFR receptor antibodies (2232s, Cell Signaling 
Technology USA), followed by anti-rabbit HRP conjugated antibodies (W4011, 
Promega). The proteins were visualized with the Amersham ECL detection system (GE 
Healthcare) as described previously (53, 54).  
6.2.9. EGF-Rhodamine binding to EGFR in A431 vesicles. Vesicles were incubated 
with 1ug/mL of Epidermal Growth Factor - Tetramethylrhodamine Conjugate (E3481, 
Molecular Probes) for 1h, and were then imaged in the confocal microscope. 
6.3. Results  
6.3.1. Different methods of vesicle production lead to small, but statistically 
significant differences in cholesterol and lipid composition. We first compared the 
lipid and cholesterol content of the three types of vesicles used in this study: A431 
chloride salt vesicles, A431 DTT/formaldehyde vesicles, and CHO DTT/formaldehyde 
158 
 
vesicles using liquid chromatography-mass spectrometry (LC-MS).  Three independent 
samples were prepared for each type of vesicle preparation. The vesicles were pelleted 
and the lipids were extracted as described in Materials and Methods. The LC-MS results, 
shown in Figure 1, report on the relative abundance of cholesterol and lipids in the three 
vesicle preparations. We found that the three types of vesicles contain significant 
amounts of free cholesterol (FC), phosphatidylcholine (PC), sphingomyelin (SM), 
phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinositol (PI). 
Other substantial lipids are dhSM, PCe, PEp and LPC in A431 DTT/formaldehyde 
vesicles, Cer, dhSM, PCe, PEp and LPC in A431 chloride salt vesicles, DG, GM3, dhSM, 
PCe, PEp and LPC in CHO DTT/formaldehyde vesicles (see abbreviations in Figures 1).  
The mole % of free cholesterol in the three vesicle preparations is 33.5 ± 0.1,   30.0 ± 1.4, 
and 22.5 ± 2 for A431 chloride salt, A431 DTT/formaldehyde, and CHO 
DTT/formaldehyde vesicles, respectively. There is no statistically significant difference 
between the free cholesterol mole% in A431 chloride salt and A431 DTT/formaldehyde 
vesicles (p = 0.092), based on a two-tailed t-test. However, there is a statistically 
significant difference between A431 DTT/formaldehyde vesicles and CHO 
DTT/formaldehyde vesicles (p = 0.023).  
Figure 2 compares the lipid content of the three vesicle preparations. As expected, the 
major lipid component in the three vesicle preparations is PC. There is a statistically 
significant difference between PC mole % in A431 chloride salt vesicles (43.8 ± 0.8 mole 
%) and A431 DTT/formaldehyde vesicles (51.0 ± 1.4 mole %) (p = 0.014).  On the other 
hand, the PC levels in A431 DTT/ formaldehyde vesicles are not different from CHO 
DTT/ formaldehyde levels (55.5 ± 3.1mole %) (p =0.34).  
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The SM content in the A431 chloride salt vesicles, A431 DTT/formaldehyde vesicles, 
and CHO DTT/formaldehyde vesicles is 7.2 ± 0.6 mole %, 7.7 ± 0.6 mole %, and 9.6 ± 
0.5 mole % respectively. No statistical differences are observed between SM mole % in 
A431 chloride salt and A431 DTT/ formaldehyde vesicles (p = 0.25), or between A431 
DTT/formaldehyde and CHO DTT/formaldehyde vesicles (p = 0.6). Similarly, PI mole % 
is not significantly different in the three vesicle types.  
PS content was 5.9 ± 0.6 mole % in A431 chloride salt vesicles, 6.5 ± 0.4 mole % in 
A431 DTT/formaldehyde vesicles, and 3.5 ± 0.1 mole % in CHO DTT/ formaldehyde 
vesicles. The PS content was different in A431 DTT/ formaldehyde and in CHO DTT/ 
formaldehyde vesicles (p = 0.0009) but not in A431 DTT/ formaldehyde and A431 
chloride salt vesicles. Similarly, the PE content was similar in the two types of A431 
vesicles, but different in the A431 and CHO vesicles. 
Monosialodihexosylganglioside 3 (GM3) levels were not statistically different in A431 
chloride salt vesicles (0.3 mole %) and in A431 DTT/formaldehyde vesicles (0.3 mole %) 
(p=0.15), but were significantly different when comparing A431 DTT/formaldehyde (0.3 
mole %) and CHO DTT/formaldehyde (2.0 mole %) vesicles. This difference was most 
likely due to differences in cellular membrane composition, as GM3 has been previously 
reported in the plasma membranes of intact CHO cells (156), but not in A431 cells (112).  
Overall, the LC-MS results (see Fig S1 for complete results) demonstrated that all vesicle 
preparations contain all the major lipids known to exist in plasma membranes of intact 
cells. While there were some statistically significant differences between lipids in A431 
chloride salt vesicles and A431 DTT/formaldehyde vesicles, these differences appeared 
only in two lipid components, namely PC and plasmalogen phosphatidylethanolamine 
160 
 
(PEp). On the other hand, significant differences were observed between free cholesterol, 
CE, GM3, dhSM, PE, PEp and PS levels when comparing A431 DTT/formaldehyde and 
CHO DTT/formaldehyde vesicles, due to differences in cell type.  
The lipid composition of the three types of vesicles was further studied using Thin Layer 
Chromatography (TLC) and
 31
P NMR. The TLC results, presented in Figure S2, show 
that cholesterol, PC, SM, PE, PS and PI are present in all vesicle types. We also used the 
Avanti analytical services to characterize the lipid composition of A431 chloride salt 
vesicles and A431 DTT/formaldehyde vesicles with 
31
P NMR (spectra shown in Figure 
S3). The analysis identified PC, PE, PI, PS, SM and LPE as the major species in the 
A431 chloride salt vesicles, and PC, PE, PI, PS, SM, LPE and LPC in the A431 
DTT/formaldehyde vesicles (Fig 3).  
Overall, 
31
 P NMR and TLC results are in agreement with the LC-MS results, since they 
identified the same major lipids as the LC-MS experiments. They further confirmed that 
PC is the major phospholipid component in all vesicle preparations. 
6.3.2. Vesicles bind annexin V, independent of production method. It is known that 
plasma membrane vesicles form as a result of cell stress which induces an apoptotic 
response (130, 131). Under stress, the cellular membrane loses some of its asymmetry, as 
PS, which is found in the cytoplasmic leaflet of intact cells, becomes exposed on the cell 
surface. As a result, the plasma membrane derived-vesicles are expected to have PS on 
their outer surfaces. Annexin V, which binds specifically to PS, is therefore expected to 
bind to the vesicles (101). Here we asked whether we can detect differences in Annexin 
V binding to the A431 chloride salt vesicles, A431 DTT/formaldehyde vesicles, and 
CHO DTT/formaldehyde vesicles. We thus incubated the vesicles with fluorescently 
161 
 
labeled Annexin V.  Fluorescence images, captured in the confocal microscope, are 
shown in Figure 4. We did not detect obvious differences in Annexin V binding, based on 
recorded pixel intensities.  Thus, it appears that there are no measurable differences in PS 
exposure to Annexin V due to production method.  In these experiments, no Annexin V 
binding was observed to intact, non-apoptotic, un-vesiculated cells, which served as 
control. 
6.3.3. Cytoplasmic proteins are not retained in vesicles produced via osmotic 
vesiculation. In our prior work, we have shown that soluble fluorescent proteins, 
expressed in CHO cells, fill the DTT/formaldehyde vesicles (81).  In the course of the 
current work we noticed, however, that the fluorescent proteins are not retained within 
chloride salt vesicles.  To further investigate this phenomenon, we studied the retention 
of several soluble cytoplasmic proteins of different molecular weight, within the vesicles. 
We labeled the membranes of cells and vesicles using Fibroblast Growth Factor 
Receptor-(FGFR2)-mCherry, a fluorescently tagged membrane protein.   
Figure 5 shows the results for Grb2-Venus (molecular weight ~60 kDa).  In these 
experiments, CHO cells were co-transfected with plasmids encoding for FGFR2-mCherry 
and Grb2-Venus.  After expression, FGFR2-mCherry was located on the membane, while 
Grb2 filled the cytoplasm. After vesiculation, Grb2-Venus (molecular weight ~60 kDa) 
was not found inside CHO chloride salt vesicles, but was found inside the CHO 
DTT/formaldehyde vesicles.  We next performed experiments with proteins of higher 
molecular weight, PKCӨ-GFP (MW~120 kDa), Venusx6 (MW~160 kDa), Intersectin II-
GFP (MW~170 kDa), and PLCɣ-GFP (MW~210 kDa). These are all soluble proteins that 
reside in the cytoplasm of intact cells (Figure S4, B-F).  As shown in Figures S6-S8 and 
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Figure 6, none of these proteins were found inside the vesicles produced with the osmotic 
stress method.  
In Figure 6, we see that PLCɣ-GFP (MW~210 kDa) associates with the plasma 
membrane in cells when FGFR2-mCherry is present because it specifically interacts with 
it.  Despite binding to FGFR2 in cells, however, PLCɣ-GFP was not found in the 
choloride salt vesicles (Figure 6). This likely occurs because, upon vesiculation, PLCɣ-
GFP reaches a new equilibrium with the aqueous sample volume which is effectively 
infinite.   
To confirm that transient interactions with the membrane do not lead to soluble protein 
retention in the chloride salt vesicles, we also worked with -PH domain-GFP 
(MW~45 kDa), which is known to bind to PIP2 in cells. As seen in Figure S6, -PH 
domain-GFP is not retained inside the chloride salt vesicles, either. All above 
experiments lead us to conclude that the chloride salt vesicles, unlike the 
DTT/formaldehyde vesicles, are ghost vesicles that lack cytoplasmic content. 
6.3.4. EGFR incorporates very efficiently in chloride salt vesicles, but not in 
DTT/formaldehyde vesicles. Vesicles are derived from the plasma membranes of cells, 
and are thus expected to contain membrane proteins, not only lipids. However, it is not 
known if the incorporation of membrane proteins in the vesicles in affected by the 
method of vesicle production. Since A431 cells are known to express the epidermal 
growth factor receptor (EGFR) endogenously at high levels (15, 16, 52), we sought to 
compare the amount of EGFR in the A431 vesicles produced with the two methods using 
Western blotting.  
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After vesiculation, we loaded identical amounts of total protein on the gel, and we 
visualized EGFR using anti-EGFR antibodies as described in Materials and Methods. The 
results are shown in Figure 7. While we see intense anti-EGFR bands in vesicles 
produces with the osmotic stress method, we see very weak anti-EGFR staining in the 
vesicles produces with the DTT/formaldehyde method. This finding suggests that EGFR 
is not efficiently incorporated in the vesicles during DTT/formaldehyde vesiculation, but 
is efficiently incorporated during osmotic vesiculation.  
To assess the functionality of EGFR in the two types of vesicles, we investigated if the 
incorporated EGFR is capable of binding its ligand, EGF.   The vesicles were therefore 
incubated with fluorescently labeled EGF (EGF-Rhodamine), see Figure 8. We observed 
that a large fraction (~50-90%) of the A431/chloride salt vesicles was labeled. On the 
other hand, only a small fraction of the A431 DTT/formaldehyde vesicles (~5%) bind 
EGF-Rhodamine. This finding is consistent with the observation that EGFR is not 
incorporated efficiently in the DTT/formaldehyde vesicles. Yet, EGF-Rhodamine binding 
in Figure 8 suggests that the receptors in the two types of vesicles are capable of ligand 
binding.  
6.4. Discussion 
Here we characterized and compared A431 vesicles produced by two different methods: 
osmotic vesiculation with chloride salts and chemical vesiculation using DTT and 
formaldehyde. We also characterized CHO DTT/formaldehyde vesicles. The goal of 
these experiments was to understand how differences due to production method compare 
with differences due to cell type.  
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Here we uncovered small but statistically significant differences in lipid composition, 
particularly in PC and PEp content, due to production method. On the other hand, 
statistically significant differences in FC, CE, dhSM, GM3, PE, PEp and PS were 
observed in A431 and CHO vesicles produced with the same chemical vesiculation 
method. Thus, differences in cholesterol and lipid content due to production method are 
quite modest, and smaller than differences due to cell type. 
We further demonstrated that the vesiculation method affects the efficiency of 
incorporation of the membrane protein EGFR into the vesicles.  In particular, EGFR 
incorporates easily into A431 chloride salt vesicles but is much less efficiently 
incorporated into DTT/formaldehyde vesicles.  Yet, prior work has demonstrated that 
other membrane proteins such as GPA, Neu, and FGFR3 readily incorporate in 
DTT/formaldehyde vesicles (22, 23, 113, 114, 122). Thus, the incorporation efficiency of 
a membrane protein into the vesicles depends both on the production method and on the 
identity of the membrane protein itself. 
The most striking difference between chloride salt and DTT/formaldehyde vesicles is in 
the degree of retention of soluble proteins inside the vesicles. While soluble proteins are 
retained within the DTT/formaldehyde vesicles, soluble proteins of molecular weight up 
to 210 kDa are not found inside the chloride salt vesicles. An explanation of this finding 
may be that formaldehyde cross-links cellular components and thus helps with the 
retention of soluble proteins in the cytoplasm. 
Overall, we find that plasma membrane-derived vesicles produced by osmotic and 
chemical vesiculation are not identical models of the cellular membrane. We therefore 
propose that parallel biophysical characterization of membrane proteins in the two types 
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of vesicles may be highly advantageous in some cases. Thus far, the interactions between 
TM helices have been characterized in the two types of vesicles and have been shown to 
be similar (33, 123). Soluble proteins, however, may interact with full-length membrane 
proteins and modulate their behavior.  While such effects are difficult to quantify in live 
cells, they could be assessed by quantifying differences in membrane protein interactions 













Figure 6-1. Cholesterol and lipid composition of A431 chloride salt vesicles, A431 
DTT/formaldehyde vesicles, and CHO DTT/formaldehyde vesicles, determined by LC-
MS. Three independent samples were analyzed for each vesicle preparation. FC: free 
cholesterol; SM: sphingomyelin; PC: phosphatidylcholine; PCe: ether 
phosphatidylcholine; PE:  phosphatidylethanolamine; PEp: plasmalogen 
phosphatidylethanolamine; PI: phosphatidylinositol ; PS: phosphatidylserine; CE: 
cholesteryl ester; DG: diacylglycerol, Cer: ceramide; GM3: 
monosialodihexosylganglioside 3; dhSM: dihydrosphingomyelin; PA: phosphatidic acid; 
LPC: lysophosphatidylcholine. Cholesterol is significantly different between A431 and 





Figure 6-2. Lipid composition of A431 chloride salt vesicles, A431 DTT/formaldehyde 
vesicles, and CHO DTT/formaldehyde vesicles, calculated by re-scaling the LC-MS data 
shown in Figure 1. The major lipid component is PC, and there is a statistically 
significant difference between PC abundance in A431 vesicles produced with the two 
methods (DTT/formaldehyde and chloride salt).  There are also significant differences in 
PEp abundance. Comparing A431 DTT/formaldehyde and CHO DTT/formaldehyde 
samples, statistically significant differences are observed between PE, PS, GM3, dhSM, 






Figure 6-3. Phospholipid content of the vesicles, from 
31
P NMR experiments performed 
by Avanti Polar Lipids Analytical Services (see Figure S2 for spectra). Single samples 
were analyzed for each vesicle preparation. Qualitatively, the results are in agreement 




   
 
Figure 6-4. Annexin V binding to (A) A431 chloride salt vesicles, (B) A431 
DTT/formaldehyde vesicles, and (C) CHO DTT/formaldehyde vesicles. No statistical 

























Figure 6-5. Top panel: Chinese Hamster Ovary (CHO) expressing Grb2-Venus (MW ~ 
60 kDa) and FGFR2-mCherry. Middle panel: Grb2-Venus (MW ~ 60 kDa) is not retained 











Figure 6-6. Top panel:  CHO cells expressing Plcɣ-GFP and FGFR2-mCherry. Bottom 






Figure 6-7. Western blots staining for endogenous Epidermal Growth Factor Receptor 
(EGFR) in A431 vesicles.  After vesicle lysis, identical amounts of total protein were 
loaded on the gel, and EGFR bands were visualized using anti-EGFR antibodies as 
described in Materials and Methods.  Lane 1: A431 chloride salt vesicles. Lane 2: A431 
DTT/formaldehyde vesicles.  
 
 
Figure 6-8. EGF-Rhodamine binding to A431 vesicles. Left: A341 chloride salt vesicles; 
Right: A431 DTT/formaldehyde vesicles. 
171 kDa






























































































































Figure S1(6-9). High Performance Liquid Chromatography Mass Spectrometry (LC-MS) 
results for A431 chloride salt vesicles, A431 DTT/formaldehyde vesicles, and CHO 
DTT/formaldehyde vesicles. (A) Cholesterol and lipids.  (B) Lipids only. FC: free 
cholesterol; SM: sphingomyelin; PC: phosphatylcholine; PCe: ether phosphatidylcholine; 
PE:  phosphatidylethanolamine; Pep: plasmalogen phosphatidylethanolamine; PI: 
phosphatidylinositol ; PS: phosphatidylserine; CE: cholesteryl ester; DG: diacylglycerol, 
Cer: ceramide; GM3: Monosialodihexosylganglioside 3; dhSM: dihydrosphingomyelin; 








Figure S2(6-10). Thin-layer chromatogram of lipid extracts from different vesicle 
preparations.  Lane 1: CHO, DTT/formaldehyde method. Lane 3: A431, 
DTT/formaldehyde method. Lane 5:  Sphingomyelin (SM1 and SM2).  Lane 6: 
Phoshatidylcholine (PC), Lane 7: Phoshatidylethanolamine (PE). Lane 8: 
Phoshatidylserine (PS). Lane 9: Cholesterol (CL).  Lane 10: A431, chloride salt osmotic 
method.  Lane 12:  Sphingomyelin (SM1 and SM2).  Lane 13: Phoshatidylcholine (PC), 
Lane 14: Phoshatidylethanolamine (PE). Lane 15: Phoshatidylserine (PS). Lane 16: 
Cholesterol (CL). Thin layer chromatography results for lipid extracts from the 
three types of vesicles. Qualitatively, the results support the MS-LC data, as the TLC 
















































P NMR spectra (acquired by Avanti Polar Lipids Analytical Services) 





Figure S4(6-12). CHO cells expressing the soluble cytoplasmic proteins used in the 
leakage assays: (A) Plcδ1-PH-GFP (MW~45 kDa), (B) Grb2-Venus (MW~60 kDa), (C) 
PKCӨ-GFP (MW~120kDa), (D) Venusx6 (MW~160 kDa), (E) Intersectin II-GFP 








Figure S5(6-13). Top panel: Chinese Hamster Ovary (CHO) cells co-expressing FGFR2-
mCherry and Plcδ1-PH-GFP. Bottom panel: Plcd1-PH-GFP (MW~45 kDa) in not 














Figure S6(6-14). Top panel: CHO cells co-expressing PKCӨ-GFP and FGFR2-mCherry. 










Figure S7(6-15). Top panel: Chinese Hamster Ovary (CHO) co-expressing VVVVVV 
(Venus x 6) and FGFR2-mCherry. Bottom panel: Venus x 6 (MW~ 160kDa) is not 

















Figure S8(6-16). Top panel: CHO cells co-expressing Intersectin II-GFP and FGFR2-
mCherry. Bottom panel: Intersectin II-GFP (MW~ 170kDa) is not retained inside CHO 












Here we introduce a fast, cost-effective, and highly efficient method for production of 
soluble fluorescent proteins from bacteria. The method does not require optimization, and 
does not utilize IPTG induction. The method relies on un-induced expression in the 
BL21-gold (DE3) strain of E.coli and yields large amounts (up to 0.4 µmoles) of protein 
from a 250 mL culture.  This method is much simpler than published methods, and can be 
used to produce any fluorescent protein that is needed in biomedical research.  
Keywords: Fluorescent protein, gene expression, protein production, high-yield, FRET, 
His-Tag, E. coli. 
 
Fluorescent proteins are widely used as reporters of molecular localization and molecular 
interactions in cells or in model systems. Quantitative fluorescence spectroscopic 
techniques, including Fӧrster Resonance Energy Transfer (FRET)-based methods, often 
rely on calibrations that utilize purified solutions of soluble fluorescent proteins of known 
concentrations (22, 25, 45, 81, 138). The production of such proteins from E.coli has 
traditionally relied on extensive and time consuming optimization of bacterial cultures, 
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followed by optimization of Isopropyl β-D-1-thiogalactopyranoside (IPTG) induction of 
protein expression (111).  These production methods, however, are never guaranteed to 
work, even after many laborious optimization steps.  Fluorescent proteins from 
commercial sources are very expensive, and an efficient and cost-effective method of 
fluorescent protein production will be of great utility to the researchers in the field. Here 
we report on such a method, which can be used for the production of any soluble 
fluorescent protein.  The method is based on the un-induced expression of fluorescent 
proteins in a strain of E.coli, BL21-Gold (DE3).  It does not require optimization, and 
does not utilize IPTG. The yield of the method matches or surpasses the best optimized 
scenarios for IPTG-induced protein yields. 
We have expressed and purified four different fluorescent proteins using this new 
method. The genes encoding for these fluorescent proteins were cloned into a commonly 
used and commercially available bacterial vector (pRSETB). The pRSETB-mCherry 
plasmid was a gift from Dr. R. Tsien (University of California, San Diego, CA), and was 
used without further manipulation. The yellow fluorescent protein (YFP) plasmid was a 
gift from Dr. M. Edidin (Johns Hopkins University, Baltimore, MD). The GFP2 gene was 
received from Dr. V. Raicu (University of Wisconsin, Milwaukee, WI) and the 
mTurquoise gene was a gift from Dr. P. Park (Case Western Reserve University, 
Cleveland, OH).  The cDNA for all four proteins encoded a start codon, an N-terminal 
His-tag (6xHistidine) sequence, and the gene for the fluorescent protein. To produce 
pRSETB-YFP, pRSETB-GFP2, and pRSETB-mTurquoise, the fluorescent protein cDNA 
was inserted between the BamHI and Hind III sites within the multiple cloning site of the 
pRSETB vector (which encodes for the PT7 promoter, pUC origin and Ampicillin 
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resistance genes, and a stop codon at the 3’ end). All the plasmids were sequenced using 
the T7 forward and T7-term primers by Genewiz, Inc., and were subsequently used for E. 
coli transformation. 
In commonly used procedures, small cultures of bacteria are first optimized for protein 
expression before moving to large cultures (89, 111). To do so, small cultures of LB 
media (~ 5mL) are inoculated with a bacterial glycerol stock from a previous culture, or 
with a freshly transformed E. coli colony. These cultures are then incubated at 37˚C for 
different time periods to yield different optical densities (as measured in a UV-Vis 
spectrometer). The bacterial expression of fluorescent proteins is then induced by adding 
various amounts of IPTG.  The expression time is varied to find the optimal conditions 
that ensure the highest yield of fluorescent proteins (usually assessed by SDS-PAGE).   
Once the optimum conditions are identified for the small culture, a large culture (100mL  
to 1L) is initiated and protein expression is induced with IPTG at the optimum optical 
density (Figure 1). Over the past few years we have attempted to use this procedure to 
produce large quantities of fluorescent proteins. Although we were successful several 
times, we also encountered many challenges.  The optimization procedure was time-
consuming and the yields were often very low, despite many optimization steps.  
Furthermore, the optimization did not always translate from small to large culture, and 
the reproducibility was low. In addition, the optimal optical density and IPTG 
concentration were different for each type of fluorescent protein and thus separate 
optimization procedures were required for each protein. Lastly, the E.coli glycerol stocks 




We discovered, however, that fluorescent proteins are produced in BL21-Gold (DE3) 
cells without IPTG induction via un-induced expression that does not require 
optimization. BL21-Gold (DE3) Competent Cells (Agilent Technologies) are integral to 
this method of production, as other strains of E. coli did not prove suitable for high levels 
of un-induced expression.  The E.coli cells were transformed with YFP, mCherry, GFP2, 
and mTurquoise-encoding plasmid DNA according to the manufacturer’s protocol. The 
bacteria were grown in LB growth media containing 100 μg/mL Ampicillin salt (Sigma 
Aldrich). We inoculated 250-300mL of LB media with a freshly transformed bacterial 
colony and cultured it for 18-22 hours at 37˚C.  To our amazement, we found that at the 
end of this long period of time visibly large quantities of the fluorescent proteins were 
produced without any IPTG addition. This was obvious from the change in the color of 
the LB media into the color of the fluorescent protein. The exact harvesting time within 
the 18-22 hour time window was not critical, unlike the stringent time requirements of 
common protocols.  
To purify the fluorescent proteins, the intact cells were pelleted using a Beckman Coulter 
centrifuge at 9000 rpm, 14 minutes, 4˚C. The pellet was visibly colored (intense purple 
for mCherry (Figure 2B) and bright yellow to bright green for YFP, mTurquoise and 
GFP2). The intense color was an indication of successful fluorescent protein production 
and very high protein yields which we have never observed using the established 
protocols. The pellets could be stored at -20C or immediately lysed using Bugbuster® 
Master Mix (Invitrogen) with added protease inhibitor cocktail (complete mini EDTA-
free tabs, Roche Applied Science). The lysate was gently agitated for 20 minutes at room 
temperature before centrifugation.  Centrifugation was performed at 13000 rpm, at a 
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temperature of 4˚C, for 20 minutes. The supernatant of the bacterial lysate, which 
contained the fluorescent proteins, was collected and the fluorescent proteins were 
purified by nickel affinity chromatography. The column was filled with 2 mL of nickel-
NTA Agarose resin (5Prime), which was pre-equilibrated in 50 mM NaH2PO4 and 0.5 M 
NaCl at pH 8.0. The lysate was added to the column in portions and equilibrated for 30-
60 minutes after each lysate addition. A wash buffer (50 mM NaH2PO4,0.5 M NaCl, pH 
8.0 with 20 mM Imidazole PH 6.0) was applied to the column three times, followed by an 
elution buffer (50 mM NaH2PO4, 0.5 M NaCl, pH 8.0 with 250 mM Imidazole PH 6.0) to 
collect the purified fluorescent protein fractions. Upon the completion of elution, the 
collected protein solution was passed through a 0.22 μm filter and the stock solutions 
(Figure 3) were stored at 4 C. The concentration was measured by collecting the 
absorption spectra using a UV-Vis spectrometer (Cary 50, Varian). The yields measured 
for the different fluorescent proteins ranged from 0.02 µmoles to 0.4 µmoles, purified 
from a 250 mL culture. The fluorescent proteins produced from a single trial were 
sufficient to use in tens of imaging experiments for calibration purposes.  
While we do not understand the exact mechanism behind this un-induced mass protein 
production, the critical step in the protocol is the long, 18-22h incubation time. The 
phenomenon that we observe here is likely similar to the so-called “auto-induction” 
reported previously (51, 144). It has been suggested that this auto-induction is caused by 
small amounts of lactose (usually present in yeast extract), and can be inhibited by the 
presence of glucose (144). To test if glucose inhibits fluorescent protein production, we 
prepared three cultures from freshly transformed colonies and added 1mg/mL glucose 
after 6h and 12h of shaking. In addition, we prepared a culture where we added 500 
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mg/mL of glucose after 1h of shaking. In all these cases, after 22h we still observed high 
levels of fluorescent protein expression (Figure 2). Therefore, the glucose did not 
suppress significantly the production of fluorescent proteins in the absence of IPTG.  
The spectral properties of the purified fluorescent proteins were recorded in a 
fluorometer. Figure 4 shows the excitation and emission spectra of each of the four 
fluorescent proteins that were produced and purified as described above. The resulting 
excitation and emission spectra were identical to the ones reported in the literature (81, 
133). Therefore, this method provides a quick, high-yield production route for any 





Figure 7-1. Protocols for fluorescent protein expression in E. coli.  The commonly used 
method is on the left.  Our new method is on the right.  
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Figure 7-2. The mCherry pellet.  (A) IPTG-induced culture; (B) un-induced culture; (C) 
un-induced culture, 1 mg/mL glucose added after 6h; (D) un-induced culture, 1mg/mL 
glucose added after 12h; (E) un-induced culture, 500 mg/mL glucose added after 1h. 
 
 
Figure 7-3. Purified stocks of fluorescent proteins in phosphate saline buffer. From left 
to right: mCherry, mTurquoise, YFP and GFP2 solutions. 




Figure 7-4. Excitation and emission spectra of the produced fluorescent proteins: EYFP, 
mCherry, GFP2 and mTurquoise. The emission and excitation maxima (in nm) are also 
shown. Spectra are identical to the ones reported in the literature (133). 









































































































One of the objectives of this thesis was to understand ligand-independent FGFR and 
VEGFR2 dimerization. In Chapter 1, the QI-FRET methodology was utilized as a direct 
dimerization assay to quantify FGFR1, FGFR2 and FGFR3 interactions in plasma 
membrane-derived vesicles. In this work, the vesicles were produced from mammalian 
cells expressing FGFRs tagged with YFP or mCherry as a FRET pair. 500-1000 vesicles 
were imaged for each receptor and analyzed. By fitting the data to a dimerization model, 
the free energy of dimerization (ΔG) and the intrinsic FRET (I-FRET), which depends on 
the distance between the fluorescent proteins in the dimers, were calculated. The results 
demonstrated that although the three receptors belong to the same RTK family, they 
possess different propensities for ligand-independent dimerization. The extrapolation of 
the dimerization curves to concentrations below 100 rec/μm
2
 revealed that FGFR2 and 
FGFR3 form dimers even at low physiological concentrations. Similarly, the results 
presented in Chapter 2 demonstrated that VEGFR2 has a strong propensity for 
dimerization in the absence of ligands even at low physiological concentrations.  
A second goal for this thesis was to investigate the effect of bound ligand on FGFR and 
VEGFR2 dimerization and dimer structure. Our measurements demonstrated that both 
FGF and VEGF receptors form constitutive dimers when treated with high concentrations 
of fgfs and vegfs, respectively. Next, we monitored the effect of ligand binding on the 
structure of the transmembrane domain dimers of the receptors, using truncated versions 
in which the fluorescent proteins were attached to the TM domains. The results in 
Chapter 1 demonstrated that fgf1-bound and fgf2-bound FGFR dimers have different 
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structures. The fgf1-bound structure is characterized by larger distance between the C-
termini of the TM domains. In the fgf2-bound structure, the C-termini of the TM domains 
are closer together. We further showed that the phosphorylation of FGFR1 and FGFR3 is 
higher in the fgf2-bound state than in the fgf1 state, thus establishing the biological 
significance of these new structural findings.   
In Chapter 2 we also investigated if different VEGFs (VEGFA121, VEGFA165, VEGF C 
and VEGF) induce structural changes upon binding to VEGFR2 dimers. We found that 
all four ligands induce structural changes, but there were no measurable differences 
between the ligand-bound structures. Furthermore,  while fgf2 binding to FGFR dimers 
brought the C-termini of FGFR TM domains closer together, VEGF binding to VEGFR2 
pushed the C-termini of VEGFR2 TM domains further apart. Thus, the ligand induced a 
structural change for all studied receptors, but the nature of the change was different for 
the two receptor families.  
In Chapter 3 of the thesis we investigated the role of the juxtamembrane domain of 
FGFR3 in unliganded dimerization. We demonstrated that the JMD stabilizes FGFR3 
unliganded dimers. We further demonstrated that the TMD and the JMD work 
synergistically in dimer stabilization. Indeed, merely anchoring the JMD to the plasma 
membrane via a different TM sequence (the one of GpA) did not increase GpA dimer 
stability. 
In Chapter 4, we investigated the role of three cysteine pathogenic mutations in the 
extracellular domains of the FGF receptors, on receptor dimerization and function. The 
FGFR1 C178S mutation is in domain D1, and is linked to Kallman syndrome. The 
FGFR2 C342R mutation is in domain D3, and is linked to Crouzon and Pffiefer 
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syndromes.  The  FGFR3 C228R mutation is in domain D2 and in found in colorectal 
cancer. Our results demonstrated that all three mutations stabilized FGFR dimers to 
varying degrees, with C342R FGFR2 and C228 FGFR3 forming the strongest dimers. 
Using non-reducing and reducing SDS PAGE, we demonstrated that inter-molecular 
disulfide bonds play a role in the stabilization of C178S FGFR1, C342R FGFR2 and 
C228R FGFR3 dimers. 
In Chapter 5, we characterized the plasma membrane derived vesicles used in the 
dissertation. A range of analytical techniques demonstrated the existence of key 
phospholipid components of mammalian plasma membranes in CHO and A431 vesicles. 
We showed that the different vesiculation methods have a small but statistically 
significant effect on lipid composition. We further showed that soluble cytoplasmic 
proteins leak out of the vesicles used in our studies.  
Finally, in Chapter 6, we describe a fast and effective method for purification of 
fluorescent proteins from bacteria. These proteins are necessary for calibration purposes 
in the QI-FRET methodology and in other quantitative imaging techniques used in 
biophysical research.   
The dissertation sheds new light on the molecular mechanism of FGFR and VEGFR 
signal transduction across the plasma membrane. Unlike many traditional biophysical and 
biochemical methods, the QI-FRET methodology provides a direct quantitative assay for 
studies of receptor dimerization in the plasma membrane. The method enables us to 
directly obtain the following four parameters over a range of RTK concentrations: (i) 
concentrations of RTK dimers, (ii) concentrations of RTK monomers, (iii) total RTK 
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concentrations and (iv) FRET efficiencies. These parameters are then sufficient to 
calculate dimerization propensities in quantitative terms.  
The QI-FRET method was used here in conjunction with plasma membrane-derived 
vesicles. These vesicles are a simple homogeneous model of the plasma membrane, 
allowing us to focus on the physical interactions between the receptors. Now that the 
plasma membrane-derived vesicles are characterized, they will likely continue to be a 
useful model system in biomembrane research. They offer a major advantage over other 
model systems because diverse membrane proteins can be studied without the need for 
their purification and reconstitution.  
Overall, our results demonstrate the power of quantitative methods in RTK research. 
They provide new knowledge about RTK signal transduction across the plasma 
membrane, and establish the biological significance of unliganded RTK dimers. As 
unliganded dimers are implicated in cancers arising due to RTK overexpression, we hope 
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